<html xmlns="http://www.w3.org/1999/xhtml" lang="en"><head id="head1"><title>
	Tentative Rulings - Online Services - LA Court
</title><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link rel="icon" type="image/png" href="../commonv4/images/favicon-16x16.png" sizes="16x16"><link rel="icon" type="image/png" href="../commonv4/images/favicon-32x32.png" sizes="32x32">

<!-- Stylesheet -->
<link id="Link5" rel="stylesheet" type="text/css" href="../commonv4/styles/sitemaster.css" media="all"><link id="Link4" rel="stylesheet" type="text/css" href="../commonv4/styles/fonts.css" media="all"><link id="Link3" rel="stylesheet" type="text/css" href="../commonv4/styles/common.css" media="all"><link id="Link10" rel="stylesheet" type="text/css" href="../commonv4/styles/home.css" media="all"><link id="Link6" rel="stylesheet" type="text/css" href="../commonv4/styles/wrapper.css" media="all"><link id="Link7" rel="stylesheet" type="text/css" href="../commonv4/styles/breadcrumb.css" media="all"><link id="Link8" rel="stylesheet" type="text/css" href="../commonv4/styles/screen.css" media="all"><link id="Link9" rel="stylesheet" type="text/css" href="../commonv4/styles/pending.css" media="all"><link rel="stylesheet" type="text/css" href="../commonv4/styles/styles3.css" media="all"><link rel="stylesheet" type="text/css" href="../commonv4/styles/template.css" media="all"><link href="../commonv4/styles/jquery-ui.css" rel="stylesheet"><link href="../commonv4/styles/jquery-ui-smoothness.css" rel="stylesheet"><link id="Link1" rel="stylesheet" type="text/css" href="../commonv4/styles/tooltip.css" media="all"><link id="Link2" rel="stylesheet" type="text/css" href="../commonv4/styles/global508.css" media="all">
    
    <script async="" src="//www.google-analytics.com/analytics.js"></script><script type="text/javascript" language="javascript" src="../commonv4/scripts/text2speech.js"></script>
    <style type="text/css">
        HR { COLOR: #447cbd }
	    @media Print { .noPrint { DISPLAY: none }
	    .Print { FONT-SIZE: 1.58em }}
	</style>
    <script type="text/javascript">
        
    </script>


</head>


<body> 
    <!--JQuery-->
    <script src="/tentativerulingnet/commonv4/scripts/jquery-1.11.1.min.js" type="text/javascript"></script>
 

    <div id="mainContainer">

        <div id="headerWrap">
            <!-- Start Translate -->
            <style>
    div[id^="pmTranslate"].popMessage {
        background-color: rgb(255, 251, 226);
        color: #BD3911;
        top: 100px;
    }

    div[id^="pmTranslate"].popMessage .textbox {
        background-color: #F7F6F0;
    }
</style>

<div class="translate">
    <a onclick="return showPopMessage('pmTranslateEspanol', this)" id="espanol" href="https://translate.google.com/translate?hl=en&amp;sl=en&amp;tl=es&amp;u=http://www.lacourt.org/" style="font-size:11px">Español </a>&nbsp;&nbsp;&nbsp;&nbsp;
    <a onclick="return showPopMessage('pmTranslateVietnamese', this)" id="vietnamese" href="https://translate.google.com/translate?hl=en&amp;sl=en&amp;tl=vi&amp;u=http://www.lacourt.org/" style="font-size:11px">Tiếng Việt</a> &nbsp;&nbsp;&nbsp;&nbsp;
    <a onclick="return showPopMessage('pmTranslateKorean', this)" id="korean" href="https://translate.google.com/translate?hl=en&amp;sl=en&amp;tl=ko&amp;u=http://www.lacourt.org/" style="font-size:12px">한국어</a> &nbsp;&nbsp;&nbsp;&nbsp;
    <a onclick="return showPopMessage('pmTranslateChinese', this)" id="chinese" href="https://translate.google.com/translate?hl=en&amp;sl=en&amp;tl=zh-CH&amp;u=http://www.lacourt.org/" style="font-size:13px">中文</a> &nbsp;&nbsp;&nbsp;&nbsp;
    <a onclick="return showPopMessage('pmTranslateArmenian', this)" id="armenian" href="https://translate.google.com/translate?hl=en&amp;sl=en&amp;tl=hy&amp;u=http://www.lacourt.org/" style="font-size:12px">հայերեն</a>
</div>

<div id="pmTranslate" class="popMessage">
    <div class="title"><span class="icon2 icon-info"></span>&nbsp;LANGUAGE TRANSLATION DISCLAIMER</div>
    <div class="close"><a onclick="hidePopMessage('pmTranslate')" href="#">X</a></div>
    <div class="textbox">
        <p>The official language used for the content of the Los Angeles Superior Court public website is English. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Computerized translations are only an approximation of the website's original content. The translation should not be considered exact and in some cases may include incorrect or offensive language.</p>

        <p>The Los Angeles Superior Court does not warrant the accuracy, reliability or timeliness of any information translated by Google™ Translate or any other translation system. In addition, some applications, files or items cannot be translated including graphs, photos or some portable document formats (pdfs).</p>
        <p>Please be aware that when a translation is requested, you will be leaving the Los Angeles Superior Court website. The Los Angeles Superior Court does not endorse the use of Google™ Translate. Other translation services may be used to view our site. Any person or entity that relies on information obtained from any translation system does so at their own risk. When a translation is complete, you assume the risk of any inaccuracies, errors or other problems encountered. The Los Angeles Superior Court is not responsible for any damage or issues that may possibly result from using Google™ Translate or any other translation system.</p>

        <p>If you have any questions about Google™ Translate, please click the following link: <a href="https://support.google.com/translate/?hl=en#topic=7011755" target="_blank">Google™ Translate FAQs</a>.</p>
    </div>
    <div class="button">
        <a class="url" href="#">Translate</a>
    </div>
</div>

<div id="pmTranslateEspanol" class="popMessage">
    <div class="title"><span class="icon2 icon-info"></span>&nbsp;RENUNCIA LEGAL SOBRE LOS PROGRAMAS DE TRADUCCIÓN</div>
    <div class="close"><a onclick="hidePopMessage('pmTranslateEspanol')" href="#">X</a></div>
    <div class="textbox">
        <p>El idioma oficial utilizado para el material del sitio web público de la Corte Superior de Los Ángeles es el inglés. Google™ Translate es un servicio gratis en línea de traducción de idiomas que puede traducir texto y páginas web en distintos idiomas. Las traducciones por computadora son solo una aproximación del contenido original del sitio web. La traducción no se debe considerar exacta y en algunos casos podría incluir lenguaje incorrecto u ofensivo.</p>

        <p>La Corte Superior de Los Ángeles no garantiza la exactitud, confiabilidad o autenticidad de cualquier información traducida por Google™ Translate u otro sistema de traducción. Además, algunas aplicaciones, archivos o elementos no se pueden traducir (como gráficas, fotos o algunos formatos portátiles de documentos [pdf]).</p>
        <p>Tenga en cuenta que al solicitar una traducción estará dejando el sitio web de la Corte Superior de Los Ángeles. La Corte Superior de Los Ángeles no endosa el uso de Google™ Translate. Usted puede usar otros servicios de traducción para ver nuestro sitio web. Toda persona o entidad que dependa de la información obtenida de cualquier sistema de traducción lo hará bajo su propio riesgo. Cuando se haga una traducción, usted asumirá el riesgo por todas las inexactitudes, errores u otros problemas que encuentre. La Corte Superior de Los Ángeles no se hace responsable por daños o problemas que puedan surgir por el uso de Google™ Translate o cualquier otro sistema de traducción.</p>

        <p>Si tiene alguna pregunta sobre Google™ Translate, haga clic en el siguiente enlace: <a href="https://support.google.com/translate/?hl=es#topic=7011755" target="_blank">Preguntas frecuentes de Google Translate™</a>.</p>
    </div>
    <div class="button">
        <a class="url" href="#">Traducir</a>
    </div>
</div>

<div id="pmTranslateVietnamese" class="popMessage">
    <div class="title"><span class="icon2 icon-info"></span>&nbsp;KHÔNG CHỊU TRÁCH NHIỆM VỀ KẾT QUẢ PHIÊN DỊCH NGÔN NGỮ</div>
    <div class="close"><a onclick="hidePopMessage('pmTranslateVietnamese')" href="#">X</a></div>
    <div class="textbox">
        <p>Ngôn ngữ chính thức sử dụng cho nội dung của website công cộng của Tòa Thượng Thẩm Los Angeles là Anh Ngữ. Google™ Translate là dịch vụ phiên dịch ngôn ngữ miễn phí trên mạng có thể phiên dịch văn bản và những trang web sang nhiều ngôn ngữ khác nhau. Phiên dịch bằng máy điện toán chỉ có kết quả xấp xỉ gần giống nội dung nguyên thủy của website này. Không nên xem bản dịch là chính xác và trong một số trường hợp bản dịch có thể sử dụng ngôn ngữ sai hoặc xúc phạm.</p>

        <p>Tòa Thượng Thẩm Los Angeles không bảo đảm mức chính xác, đáng tin hoặc nhanh chóng của bất cứ tin tức nào do Google™ Translate hoặc bất cứ hệ thống phiên dịch nào khác thực hiện. Ngoài ra, không thể phiên dịch được một số ứng dụng, hồ sơ hoặc loại khác gồm cả biểu đồ, hình ảnh hoặc một số dạng văn kiện lưu động (pdfs).</p>
        <p>Xin lưu ý là khi yêu cầu phiên dịch là quý vị rời khỏi website của Tòa Thượng Thẩm Los Angeles. Tòa Thượng Thẩm Los Angeles không ủng hộ việc sử dụng Google™ Translate. Có thể sử dụng các dịch vụ phiên dịch khác để xem website của chúng tôi. Bất cứ người hoặc thực thể nào dựa vào tin tức thu thập từ bất cứ hệ thống phiên dịch nào đều phải tự chịu rủi ro. Khi phiên dịch xong, quý vị tự chịu bất cứ rủi ro nảo về những chỗ không chính xác, sai lầm hoặc những vấn đề khác gặp phải. Tòa Thượng Thẩm Los Angeles không chịu trách nhiệm về bất cứ thiệt hại hoặc vấn đề nào có thể phát xuất từ việc sử dụng Google™ Translate hoặc bất cứ hệ thống phiên dịch nào khác.</p>

        <p>Nếu quý vị có bất cứ thắc mắc nào về Google™ Translate, xin bấm vào đường nối sau đây: <a href="https://support.google.com/translate/?hl=vi#topic=7011755" target="_blank">Google™ Translate FAQs</a>.</p>
    </div>
    <div class="button">
        <a class="url" href="#">Phiên Dịch</a>
    </div>
</div>

<div id="pmTranslateKorean" class="popMessage">
    <div class="title"><span class="icon2 icon-info"></span>&nbsp;언어 번역 면책 조항</div>
    <div class="close"><a onclick="hidePopMessage('pmTranslateKorean')" href="#">X</a></div>
    <div class="textbox">
        <p>로스앤젤레스 상급법원 공개 웹사이트의 내용에 사용되는 공식 언어는 영어입니다. Google™ Translate(번역)는 텍스트와 웹페이지를 다른 언어로 번역할 수 있는 무료 온라인 언어 번역 서비스입니다. 컴퓨터화된 번역은 단지 웹사이트의 원래 내용과 비슷할 뿐입니다. 이 번역은 정확하다고 생각해서는 안되고, 어떤 경우에는 부정확하거나 모욕적인 언어가 포함될 수도 있습니다.</p>

        <p>로스앤젤레스 상급법원은 Google™ Translate 또는 다른 번역 시스템으로 번역된 정보의 정확성, 신뢰성 또는 적시성을 보증하지 않습니다. 또한, 그래프, 사진 또는 이동 가능 문서 형식(pdf)을 포함하는 어떤 애플리케이션, 파일 또는 항목을 번역할 수 없습니다.</p>
        <p>번역이 요청되면, 로스앤젤레스 상급법원 웹사이트를 떠난다는 것을 확인해 주십시오. 로스앤젤레스상급법원은 Google™ Translate의 사용을 보증하지 않습니다. 저희 웹사이트를 보시려면 다른 번역 서비스를 이용할 수도 있습니다. 번역 시스템에서 얻은 정보에 의존하는 개인이나 단체는 위험을 무릅쓰고 그렇게 합니다. 번역이 완료되면, 부정확성, 오류 또는 다른 문제가 발생할 위험을 감수합니다. 로스앤젤레스 상급법원은 Google™ Translate 또는 다른 번역 시스템을 사용함으로써 발생 가능한 손해 또는 문제에 대해 책임을 지지 않습니다.</p>

        <p>Google™ Translate에 대한 질문이 있는 경우, 다음의 링크를 클릭해 주십시오:<a href="https://support.google.com/translate/?hl=ko#topic=7011755" target="_blank"> Google™ Translate FAQs</a>.</p>
    </div>
    <div class="button">
        <a class="url" href="#">번역하십시오</a>
    </div>
</div>

<div id="pmTranslateChinese" class="popMessage">
    <div class="title"><span class="icon2 icon-info"></span>&nbsp;语言翻译免责声明</div>
    <div class="close"><a onclick="hidePopMessage('pmTranslateChinese')" href="#">X</a></div>
    <div class="textbox">
        <p>洛杉矶高等法院公共网站内容使用的官方语言是英语。Google™ Translate（谷歌翻译）是免费的在线语言翻译服务，可将文本和网页翻译成不同语言。计算机翻译只能近似网站的原始内容。这种翻译不应视为准确，一些情况下可能包含错误或冒犯性语言。</p>

        <p>洛杉矶高等法院不保证Google™ Translate或其他翻译系统翻译的任何信息准确、可靠或及时。此外，有些应用软件、文件或项目无法翻译，包括图片、照片或一些便携文件格式（pdf)。</p>
        <p>请注意，提出翻译请求时，您将离开洛杉矶高等法院网站。洛杉矶高等法院不认可使用Google™ Translate。可用其他翻译服务浏览我们的网站。任何个人或实体依赖翻译系统获得信息，需自行承担风险。翻译完成后，您需承担任何不准确、错误或其他问题的风险。洛杉矶高等法院不就使用Google™ Translate或其他翻译系统可能导致的任何损害或问题承担责任。</p>

        <p>如果您有关于Google™ Translate的疑问，请点击下面的链接：<a href="https://support.google.com/translate/?hl=zh#topic=7011755" target="_blank">Google™ Translate常见问题。</a></p>
    </div>
    <div class="button">
        <a class="url" href="#">翻译</a>
    </div>
</div>

<div id="pmTranslateArmenian" class="popMessage">
    <div class="title"><span class="icon2 icon-info"></span>&nbsp;ԼԵԶՎԱԿԱՆ ԹԱՐԳՄԱՆՈՒԹՅԱՆ ՎԵՐԱԲԵՐՅԱԼ ՎԵՐԱՊԱՀԱԿԱՆ ՀԱՅՏԱՐԱՐՈՒԹՅՈՒՆ</div>
    <div class="close"><a onclick="hidePopMessage('pmTranslateArmenian')" href="#">X</a></div>
    <div class="textbox">
        <p>Լոս Անջելեսի Առաջին ատյանի դատարանի հանրային կայքի պաշտոնական լեզուն անգլերենն է։ Google™ Translate-ն անվճար լեզվական թարգմանչական ծառայություն է, որի միջոցով տեքստ ու կայքեր կարելի է թարգմանել զանազան լեզուներով։ Համակարգչային թարգմանությունը կայքի բնօրինակի սոսկ մոտավոր ներկայացումն է։ Թարգմանությունը չպետք է դիտվի իբրև ճշգրիտ, և երբեմն կարող է ներառել ոչ ճիշտ, կամ վիրավորական արտահայտություններ։</p>

        <p>Լոս Անջելեսի Առաջին ատյանի դատարանը չի երաշխավորում Google™ Translate-ի, կամ մեկ այլ թարգմանչական համակարգի կողմից թարգմանված որևէ տեղեկատվության ճշգրտությունը, վստահելիությունն ու արդիականությունը։ Բացի այդ, որոշ ծրագրեր, ֆայլեր կամ պարագաներ, օրինակ՝ գրաֆիկներ, լուսանկարներ, կամ որոշ փոխադրելի փաստաթղթային ձևաչափեր (pdf), թարգմանվել չեն կարող։</p>
        <p>Խնդրում ենք նկատի ունենալ, որ թարգմանության խնդրանք ներկայացնելիս Դուք Լոս Անջելեսի Առաջին ատյանի դատարանի կայքից դուրս կտեղափոխվեք։ Լոս Անջելեսի Առաջին ատյանի դատարանը չի քաջալերում Google™ Translate-ի օգտագործումը։ Մեր կայքը կարելի է դիտել այլ թարգմանչական ծառայություններով ևս։ Ցանկացած անձ, կամ կազմակերպություն, ով հենվում է որևէ թարգմանչական համակարգից ստացված որևէ տեղեկատվության վրա, այդպես է վարվում սեփական ռիսկի հաշվին։ Թարգմանության ավարտին, Դուք հանձն եք առնում ցանկացած անճշտության, սխալի, կամ հայտնաբերված այլ խնդրի ռիսկը։ Լոս Անջելեսի Առաջին ատյանի դատարանը պատասխանատու չէ որևէ այնպիսի վնասի կամ խնդրի համար, որը թերևս կարող է առաջանալ Google™ Translate-ի, կամ թարգմանչական մեկ այլ համակարգի օգտագործման արդյունքում։</p>

        <p>Եթե Google™ Translate-ի վերաբերյալ որևէ հարց ունեք, ապա խնդրում ենք սեղմել հետևյալ հղումը․ <a href="https://support.google.com/translate/?hl=hy#topic=7011755" target="_blank">Google™ Translate FAQs</a>.</p>
    </div>
    <div class="button">
        <a class="url" href="#">Թարգմանել</a>
    </div>
</div>

            <!-- End Translate -->

            
            

            <!-- Font Size -->
            

            <!-- Start Logo -->
            <div class="logo">
                <a href="/page/HO0000" onclick="return processLink(this)"><img src="../commonv4/images/logo.gif" id="Img1" alt="Banner Image - The Superior Court of California County of Los Angeles "></a>
            </div>
            <!-- End Logo -->

   	        <!-- Start Search -->
            <div class="searchWrap" role="search">
            <form name="searchForm" method="get" onsubmit="doSearch(); return false;">
    
    	        <div id="searchfieldWrap">
    		        <input aria-label="Enter Search Criteria" id="searchfield" type="text" name="search" value="Search" onclick="selectSearchText()" onkeydown="">
    	        </div>
        
            <div id="btngoWrap">
                    <a id="searchLink" href="#" onclick="return doSearch(this)"><img src="../commonv4/images/blank.gif" id="Img2" style="margin-left:1px;margin-top:1px" alt="Start Site Search" width="33" height="33"></a>
            </div>
        
            </form>
	        </div> 
            
            <!-- Survey -->
              
        </div>

        <!-- Start MainMenu -->
        <script>
    function keyClick(event, linkObj) {
        if (event.key == 'Enter') processLink(linkObj);
    }

    var baseUrl = window.location.pathname;

    if (baseUrl.search(/lascweb/i) == 1) {
        baseUrl = "/lascweb/";
    }
    else {
        baseUrl = "/";
    }

</script>
<style>
    .btnHRS
    {
        display: block;
        width: 202px;
        height: 33px;
        text-align: left;
        padding: 12px 0 0 10px;
        font-size: 16px;
        text-decoration: none;
        line-height: 18px;
        color: #e5e5e5;
        background-color:#012362;
         }
        .btnHRS a {
            /*background: url(img/btn-HomeColor.gif) no-repeat left top;*/
            
            font-family: verdana,Arial, sans-serif;
            font-size: 13px;
        }

            .btnHRS a:hover {
                /*background: url(img/btn-HomeColorOver.png) no-repeat left top;*/
            }


    .btnHRS {
        margin-bottom: 6px;
    }

    .btnHRS a {
        display: block;
        width: 202px;
        height: 33px;
        text-align: left;
        padding: 12px 0 0 10px;
        font-size: 16px;
        text-decoration: none;
        line-height: 18px;
        color: #e5e5e5;
    }

        .btnHRS a:hover {
            text-decoration: none;
            line-height: 18px;
        }

</style>
<div class="container clearfix">
    <div class="left" style="position: relative;">
        <div class="navBar clear Main" tabindex="-1" aria-label="Main Site Navigation Menu" role="navigation">
            <div class="navBarWrap" tabindex="-1">
                <div class="left tabContainer" tabindex="-1" onmouseover="try{navigationMenu.SelectTabNoSubNav($('.navBarTab', this));}catch(e){}" onmouseout="try{navigationMenu.DeSelectTab($('.navBarTab', this));}catch(e){}" onfocus="return false;">
                    <div class="navBarTab navTab" id="navBarTab1" style="width:60px" tabindex="0" onclick="return processLink($('a.nav', $(this)));" onkeydown="return keyClick(event,$('a.nav', $(this)));">
                        <div class="nav clickable" id="nav1"><a class="nav" tabindex="-1" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" href="/page/HO0001">Home<br><span></span></a></div>
                    </div>
                    <div class="navBorderRight"></div>
                </div>
                        
                <div class="left tabContainer" aria-haspopup="true" tabindex="-1" onmouseover="try{navigationMenu.SelectTabNoSubNav($('.navBarTab', this));}catch(e){}" onmouseout="try{navigationMenu.DeSelectTab($('.navBarTab', this));}catch(e){}" onfocus="return false;">
                    <div class="navBorderLeft"></div>
                    <div class="navBarTab navTab navWhiteBox selectedTab" id="navBarTab2" style="width:138px" tabindex="0" onclick="return processLink($('a.nav', $(this)));" onkeydown="return keyClick(event,$('a.nav', $(this)));">
                        <div class="nav clickable" id="nav2">
                            <a class="nav" tabindex="-1" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" href="/page/ON0001" data-flexmenu="flexmenu2">Online&nbsp;Services</a><br><span class="nav2">Pay Fines, Search Records...</span>
                        </div>

                        <!-- Drop Down menu begins here -->
                        <div class="flexdropdownmenu container" id="flexmenu2">
                            <div class="column">
                                <div class="columntitle" tabindex="-1">
                                    <a class="globalMenuLink" tabindex="0" href="https://www.lacourt.org/lacc" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };ga('send','event','LACourtConnect','Global Nav','Online Services');return processLink(this);" onkeydown="return keyClick(event,this);">
                                        <script>document.write("<img style=\"width:200px;border-color:#f3c727;border-style:solid;border-width:2px\" alt=\"LA Court Connect\" src=\"" + baseUrl + "commonv4/images/LACCButton.png" + "\">")</script><img style="width:200px;border-color:#f3c727;border-style:solid;border-width:2px" alt="LA Court Connect" src="/commonv4/images/LACCButton.png">
                                    </a>
                                </div>
                                <div class="columntitle" tabindex="-1">
                                    <a class="globalMenuLink" tabindex="0" href="https://my.lacourt.org/attorney" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };ga('send','event','AttorneyPortal','Global Nav','Online Services');return processLink(this);" onkeydown="return keyClick(event,this);">
                                        <script>document.write("<img style=\"width:200px;border-color:#f3c727;border-style:solid;border-width:2px\" alt=\"Attorney Portal\" src=\"" + baseUrl + "commonv4/images/LAAPLOGO.png" + "\">")</script><img style="width:200px;border-color:#f3c727;border-style:solid;border-width:2px" alt="Attorney Portal" src="/commonv4/images/LAAPLOGO.png">
                                    </a>
                                </div>
                                <div class="columntitle" tabindex="-1">
                                    <a style="background-color:rgb(33, 106, 190);height:25px;color:#e3e3e3;padding:5px 5px 5px 5px;border-radius:5px" tabindex="0" href="/page/EXGV178" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Hearing Reminder Service</a>
                                </div>
                                <div class="columntitle" tabindex="-1">
                                    <a style="background-color:rgb(33, 106, 190);height:25px;color:#e3e3e3;padding:5px 5px 15px 5px;border-radius:5px" tabindex="0" target="dd" href="/newsmedia/digitaldivide/" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };" onkeydown="return keyClick(event,this);">Internet Access Options for Court Users</a>
                                </div>

                                <div class="columntitle" tabindex="-1">
                                    <a class="globalMenuLink" tabindex="0" href="/page/HO0201" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Appellate Division and Appeals Division</a>
                                </div>
                                <div class="listx" id="DIV23">
                                    <div class="listitem" tabindex="-1">
                                        <a class="globalMenuLink" tabindex="0" href="/page/AP0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Access</span>
                                        </a>
                                    </div>
                                    <div class="listitem" tabindex="-1">
                                        <a class="globalMenuLink" tabindex="0" href="/page/AP0101" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Tentative Rulings</span>
                                        </a>
                                    </div>

                                </div>
                                <br><br>
                                <div class="columntitle"><a class="globalMenuLink" tabindex="0" href="/page/HO0202" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Civil</a></div>
                                <div class="listx" id="flexmenu25">
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/HO0209" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Civil efiling</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0104" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Access</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">

                                            <span class="globalMenuSpan">Case Document Images</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0103" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Calendar</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem">
            <a class="globalMenuLink" tabindex="0"
               href="/page/EXGV178" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                <span class="globalMenuSpan">Hearing Reminder Service</span>
            </a>
        </div>-->
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/EXGV162" onclick="ga('send', 'event', 'FamilyLaw', 'ODR-Modria', 'GlobalMenu'); try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Court Reservation System (CRS)</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0105" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Courtroom Information</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0106" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Filing Court Locator</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0110" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Interpreter Request</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0101" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Search for Case Number by Name</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem ">
            <a class="globalMenuLink" tabindex="0"
               href="/page/CI0107" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                <span class="globalMenuSpan">Tentative Rulings</span>
            </a>
        </div>-->
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/ON0053" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Tentative Rulings</span>
                                        </a>
                                    </div>
                                </div>
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 320px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle"><a class="globalMenuLink" tabindex="0" href="/page/HO0203" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Criminal</a></div>
                                <div class="listx" id="flexmenu27">
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/ON0041" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Government Agency Criminal Record<br> Online Request</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CR0101" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Criminal Calendar Search</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem">
                                        <a class="globalMenuLink" tabindex="0"
                                           href="/page/EXGV178" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Hearing Reminder Service</span>
                                        </a>
                                    </div>-->
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CR0104" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Criminal Case Summary</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CR0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Search for Case by Defendant Name</span>
                                        </a>
                                    </div>
                                </div>
                                <br><br>
                                <div class="columntitle"><a class="globalMenuLink" tabindex="0" href="/page/HO0204" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Family Law</a></div>
                                <div class="listx" id="flexmenu26">
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PDF0051" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Request for Order Dates</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/FL0101" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this); " onkeydown="return keyClick(event, this); ">
                                            <span class="globalMenuSpan">Case Calendar</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem">
                                        <a class="globalMenuLink" tabindex="0"
                                           href="/page/EXGV178" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Hearing Reminder Service</span>
                                        </a>
                                    </div>-->
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/FL0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Access</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">

                                            <span class="globalMenuSpan">Case Document Images</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/FL0104" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Divorce Judgment Documents</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/FL0105" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Filing Court Locator</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem "
       ><a class="globalMenuLink" tabindex="0"
        href="/page/FL0106" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);"><span
        class="globalMenuSpan">Child Custody Mediation Appt.</span></a>
    </div>-->
                                    <!--<div class="listitem "
       ><a class="globalMenuLink" tabindex="0"
        href="/page/FL0107" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);"><span
        class="globalMenuSpan">Counselor & Evaluator Directory</span></a>
    </div>-->
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/FL0130" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Interpreter Request</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/EXGV163" onclick="ga('send', 'event', 'FamilyLaw', 'ODR-Modria', 'GlobalMenu');try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">On-line Dispute Resolution</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/FL0102" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Our Children First</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/FL0127" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Search for Case Number by Name</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/FL0131" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Tentative Rulings</span>
                                        </a>
                                    </div>
                                </div>
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 320px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle"><a class="globalMenuLink" tabindex="0" href="/page/HO0205" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Probate</a></div>
                                <div class="listx" id="DIV24">
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PR0108" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Probate efiling</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PR0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Access</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Document Images</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PR0101" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Calendar</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem">
                                        <a class="globalMenuLink" tabindex="0"
                                           href="/page/EXGV178" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Hearing Reminder Service</span>
                                        </a>
                                    </div>-->
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PR0102" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Filing Court Locator</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PR0106" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Interpreter Request</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PR0103" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Probate Notes</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PR0105" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Search for Case Number by Name</span>
                                        </a>
                                    </div>
                                </div>
                                <br><br>
                                <div class="columntitle"><a class="globalMenuLink" tabindex="0" href="/page/HO0206" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Small Claims</a></div>
                                <div class="listx" id="DIV25">
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Access</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Document Images</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0102" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Case Calendar</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem">
                                        <a class="globalMenuLink" tabindex="0"
                                           href="/page/EXGV178" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Hearing Reminder Service</span>
                                        </a>
                                    </div>-->
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0113" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Courtroom Information</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0103" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Filing Court Locator</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0105" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Interpreter Request</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0104" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Search for Case Number by Name</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/DV0029" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Small Claims efiling</span>
                                        </a>
                                    </div>
                                </div>
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 320px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle"><a class="globalMenuLink" tabindex="0" href="/page/HO0207" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Traffic</a></div>
                                <div class="listx" id="flexmenu24">
                                    <!--<div class="listitem">
                                        <a class="globalMenuLink" tabindex="0"
                                           href="/page/EXGV178" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Hearing Reminder Service</span>
                                        </a>
                                    </div>-->
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0204" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Find Your Ticket by Drivers License</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0205" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Find Your Ticket by Ticket Number</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0206" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Búsqueda por licencia de manejar</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0207" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Búsqueda por número de multa</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_IRTR" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Interpreter Request</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem">
        <a class="globalMenuLink" tabindex="0" href="https://mycourtservices.lacourt.org/Appointment/Intro?anonyAppt=1&serviceModuleId=6AEB6FD9-F13E-E611-80DA-005056A3454C" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
            <span class="globalMenuSpan">Schedule Traffic Clerk Appointment</span>
        </a>
    </div>-->
                                    <!--							<div class="listitem ">
        <a class="globalMenuLink" tabindex="0" href="/page/TR0100"  onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
        <span class="globalMenuSpan">Pay your Ticket Online</span>
        </a>
    </div>
    <div class="listitem ">
        <a class="globalMenuLink" tabindex="0" href="/page/TR0104"  onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
        <span class="globalMenuSpan">Find your Ticket By Driver's License</span>
        </a>
    </div>
    <div class="listitem ">
        <a class="globalMenuLink" tabindex="0" href="/page/TR0105" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
        <span class="globalMenuSpan">Find your Ticket By Citation Number</span></a>
    </div>
    <div class="listitem ">
        <a class="globalMenuLink" tabindex="0" href="/page/TR0101" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
        <span class="globalMenuSpan">Request an Extension</span></a>
    </div>
    <div class="listitem ">
        <a class="globalMenuLink" tabindex="0" href="/page/TR0102" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
        <span class="globalMenuSpan">Request Traffic School</span>
            </a>
    </div>
    <div class="listitem ">
        <a class="globalMenuLink" tabindex="0" href="/page/TR0103" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">

            <span class="globalMenuSpan">Reserve Court Date</span>
            </a>
    </div>-->
                                </div>


                                <br><br>
                                <div class="columntitle"><a class="globalMenuLink" tabindex="0" href="/page/HO0208" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Other</a></div>
                                <div class="listx" id="flexmenu28">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/ON0038" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Court Date Calculator</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/EXGV149" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Access to Electronic Records</span>
                                        </a>
                                    </div>
                                </div>
                            </div>


                        </div>
                    </div>
                    <div class="navBorderRight"></div>
                </div>
                <!-- END DROP DOWN MENU -->
                <div class="left tabContainer" aria-haspopup="true" tabindex="-1" onmouseover="try{navigationMenu.SelectTabNoSubNav($('.navBarTab', this));}catch(e){}" onmouseout="try{navigationMenu.DeSelectTab($('.navBarTab', this));}catch(e){}" onfocus="return false;">
                    <div class="navBorderLeft"></div>
                    <div class="navBarTab navTab" id="navBarTab3" style="width:156px" tabindex="0" onclick="return processLink($('a.nav', $(this)));" onkeydown="return keyClick(event,$('a.nav', $(this)));">
                        <div class="nav clickable" id="nav3">
                            <a class="nav" tabindex="-1" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);" href="/page/FO0001" data-flexmenu="flexmenu3">Forms,&nbsp;Filings&nbsp;&amp;&nbsp;Files</a><br><span class="nav2">Forms, Filing Fees...</span>
                        </div>

                        <!-- Drop Down menu begins here -->
                        <div class="flexdropdownmenu container" id="flexmenu3">
                            <div class="column" style="width:200px">
                                <div class="columntitle"><a href="/page/EXGV021" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">State Judicial Council <br>Approved Forms</a></div>
                                <p>Judicial Council forms can be used in every Superior Court in California. You will need to use these forms when you file your case.</p> <p> Statewide approved forms are available for Adoptions, Appellate, Civil, Conservatorships, Criminal, Guardianships, Family Law, Juvenile, Name Change, Probate, Small Claims, and Traffic.</p> <p style="font-size:11px;font-weight:bold">(When you click this link, you will be taken to the California Courts website)</p>
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 200px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle"><a href="/page/FO0002" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Locally Approved Forms</a></div>
                                <p>In addition to forms approved by the State Judicial Council, the Superior Court of Los Angeles has approved a variety of local forms that you may need to use as your case continues.</p>
                                <!--						        <div class="listitem ">
            <a class="globalMenuLink" tabindex="0" href="/page/TR0048" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
            <span class="globalMenuSpan">Electronic Filing (e-Filing)</span></a>
        </div>
        <div class="listitem ">
            <a class="globalMenuLink" tabindex="0" href="/page/CI0017" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                <span class="globalMenuSpan">How Can I File by Fax?</span></a>
        </div>-->
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 200px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column" style="width:170px">
                                <div class="columntitle"><a href="/page/HO0002" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Locate Your Filing Courthouse</a></div>
                                <p>Locate the courthouse where your case belongs.</p>
                                <p><br></p>
                                <div class="columntitle"><a href="/page/FO0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Filing Fees</a></div>
                                <p>Filing fee information for Civil Limited, Civil Unlimited, Family Law, Small Claims and Probate cases.</p>

                            </div>

                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 200px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle"><a href="/page/FO0002" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Files</a></div>
                                <p>The Los Angeles Superior Court is transitioning to electronic "paperless" case files.</p>

                                <div class="listx" id="DIV26">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/EXGV149" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Access to Electronic Records</span>
                                        </a>
                                    </div>
                                </div>
                            </div>
                        </div>
                        </div>
                    <div class="navBorderRight"></div>
                </div>
                <div class="left tabContainer" aria-haspopup="true" tabindex="=-1" onmouseover="try{navigationMenu.SelectTabNoSubNav($('.navBarTab', this));}catch(e){}" onmouseout="try{navigationMenu.DeSelectTab($('.navBarTab', this));}catch(e){}" onfocus="return false;">
                    <div class="navBorderLeft"></div>
                    <div class="navBarTab navTab" id="navBarTab4" style="width:137px" tabindex="0" onclick="return processLink($('a.nav', $(this)));" onkeydown="return keyClick(event,$('a.nav', $(this)));">
                        <div class="nav clickable" id="nav4" tabindex="-1">
                            <a class="nav" tabindex="-1" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" href="page/EXGVSH001" onkeydown="return keyClick(event,this);" data-flexmenu="flexmenu4">Self-Help</a>
                            <br>
                            <span class="nav2">For persons without attorneys</span>
                        </div>

                          <div class="flexdropdownmenu container" id="flexmenu4">
                              <div class="column">
                                  <div class="columntitle" tabindex="-1">
                                      <a class="globalMenuLink" tabindex="0" href="https://www.lacourt.org/lacc" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };ga('send','event','LACourtConnect','Global Nav','Self-Help');return processLink(this);" onkeydown="return keyClick(event,this);">
                                          <script>document.write("<img style=\"width:200px;border-color:#f3c727;border-style:solid;border-width:2px\" alt=\"LA Court Connect\" src=\"" + baseUrl + "commonv4/images/LACCButton.png" + "\">")</script><img style="width:200px;border-color:#f3c727;border-style:solid;border-width:2px" alt="LA Court Connect" src="/commonv4/images/LACCButton.png">
                                      </a>
                                  </div>

                                  <div class="columntitle">Where Can I Get Help?</div>
                                  <div class="listx" id="DIV20">
                                      <!--<div class="listitem ">
            <a class="globalMenuLink" tabindex="0"
               href="/page/SH_RA001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                <span class="globalMenuSpan">Where Can I Get Help in Person?</span>
            </a>
        </div>-->
                                      <div class="listitem ">
                                          <a class="globalMenuLink" tabindex="0" href="/page/SH_RA001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                              <span class=""><span style="color:red">NEW</span> - Self-Help resources are changing under the Court's new AccessLACourt | Your Way program. Learn about new online workshops and appointments and the court's new Service Catalog.<br></span>
                                              <!--<span class="globalMenuSpan">How Can I Get Help Online<br />to Fill Out Court Forms or<br />to File at Home?</span>-->
                                          </a>

                                      </div>
                                  </div>
                                  <br><br>
                                  <div class="columntitle">Self-Help Service Catalog</div>
                                  <div class="listx" id="flexmenu44">
                                      <div class="listitem">
                                          <a class="" href="https://selfhelp.lacourt.org/" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                              <span class=""><span style="color:red">NEW</span> - Browse workshops, guided interviews, one-on-one appointments, and court information, in areas such as Divorce, Child Custody and Visitation, Evictions, Guardianship, and more.<br></span>

                                          </a>
                                      </div>
                                  </div>
                              </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 305px; margin-right: 20px; float: left;">&nbsp;</div>

                            <div class="column">
                                <div class="columntitle">Abuse &amp; Harassment</div>
                                <div class="listx" id="DIV3">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_AH001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Restraining Orders</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_AH002" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Domestic Violence</span>
                                        </a>
                                    </div>
                                </div>
                                <br><br>
                                <div class="columntitle">Divorce and Separation</div>
                                <div class="listx" id="DIV13">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_DS001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Divorce or Legal Separation</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_DS002" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Summary Dissolution</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_DS003" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Annulment</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_DS004" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Spousal Support</span>
                                        </a>
                                    </div>
                                </div>
                                <br><br>
                                <div class="columntitle">Families &amp; Children</div>
                                <div class="listx" id="flexmenu44">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_FM001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Adoption</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_FM002" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Child Custody and Visitation</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_FM003" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Child Support</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_FM004" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Establish Paternity</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_FM006" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Guardianship of Children</span>
                                        </a>
                                    </div>
                                </div>
                                

                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 305px; margin-right: 20px; float: left;">&nbsp;</div>

                            <div class="column">
                                <div class="columntitle">Evictions, Landlords &amp; Tenants</div>
                                <div class="listx" id="DIV8">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0031" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Unlawful Detainer</span>
                                        </a>
                                    </div>
                                </div>
                                <br><br>
                                <div class="columntitle">Traffic Violators</div>
                                <div class="listx" id="DIV14">
                                    <!--							        <div class="listitem "
           ><a class="globalMenuLink" tabindex="0"
            href="/page/TR0100" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);"><span
            class="globalMenuSpan">Pay Ticket Online</span></a>
        </div>
        <div class="listitem "
           ><a class="globalMenuLink" tabindex="0"
            href="/page/TR0102" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);"><span
            class="globalMenuSpan">Request Traffic School</span></a>
        </div>
        <div class="listitem "
           ><a class="globalMenuLink" tabindex="0"
            href="/page/TR0101" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);"><span
            class="globalMenuSpan">Request an Extension</span></a>
        </div>-->
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0204" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Find Your Ticket by Driver's License</span>
                                        </a>
                                    </div>

                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0205" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Find Your Ticket by Ticket Number</span>
                                        </a>
                                    </div>


                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0206" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Búsqueda por licencia de manejar</span>
                                        </a>
                                    </div>

                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0207" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Búsqueda por número de multa</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0009" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">How do I Pay My Ticket</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0023" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Failure to Appear in Court</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/TR0033" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Failure to Pay a Court-Ordered Fine</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PDF0036" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Petition for Ability to Pay/Vacate<br>Civ. Assessment</span>
                                        </a>
                                    </div>
                                </div>
                                

                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 305px; margin-right: 20px; float: left;">&nbsp;</div>

                            <div class="column">
                                <div class="columntitle">Wills, Estates &amp; Trusts</div>
                                <div class="listx" id="DIV16">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SH_WT001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Wills, Estates &amp; Trusts</span>
                                        </a>
                                    </div>
                                </div>
                                <br><br>
                                <div class="columntitle">Small Claims</div>
                                <div class="listx" id="DIV9">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0010" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">What is Small Claims Court?</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0014" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Thinking About Filing a Small<br>Claims Case?</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0019" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Filing My Case</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0025" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Service Notice of My Case to<br>the Defendant</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/SC0028" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Responding to a Small Claims<br>Case as a Defendant</span>
                                        </a>
                                    </div>

                                </div>
                                <br><br>
                                <div class="columntitle">Help Resources &amp; Assistance</div>
                                <div class="listx" id="DIV18">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/PDF0001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Courtspeak</span>
                                        </a>
                                    </div>
                                </div>
                                <div class="listx" id="DIV19">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/EXGV081" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">California Courts Self Help Website</span>
                                        </a>
                                    </div>
                                </div>
                                <div class="listx" id="DIV21">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/EXGV082" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Law Library</span>
                                        </a>
                                    </div>
                                </div>
                                <div class="listx" id="DIV22">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/EXGV109" onclick="ga('send', 'event', 'SelfHelp', 'CaCourtsImmigration', 'GlobalMenu'); try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="ga('send', 'event', 'SelfHelp', 'CaCourtsImmigration', 'GlobalMenu'); return keyClick(event,this);">
                                            <span class="globalMenuSpan">California Courts Immigration Resources</span>
                                        </a>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="navBorderRight"></div>
                </div>

                <div class="left tabContainer" aria-haspopup="true" tabindex="-1" onmouseover="try{navigationMenu.SelectTabNoSubNav($('.navBarTab', this));}catch(e){}" onmouseout="try{navigationMenu.DeSelectTab($('.navBarTab', this));}catch(e){}" onfocus="return false;">
                    <div class="navBorderLeft"></div>
                    <div class="navBarTab navTab" id="navBarTab5" style="width:123px" tabindex="0" onclick="return processLink($('a.nav', $(this)));" onkeydown="return keyClick(event,$('a.nav', $(this)));">

                        <div class="nav clickable" id="nav5" tabindex="-1">
                            <a class="nav" tabindex="-1" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" href="/page/DV0001" data-flexmenu="flexmenu5">Divisions</a>
                            <br>
                            <span class="nav2">Civil, Criminal, Family...</span>
                        </div>
                        <div class="flexdropdownmenu container" id="flexmenu5">
                            <div class="column">
                                <div class="columntitle">
                                    LA Court Divisions
                                </div>
                                <p>Legal matters are handled in one of LA Court's 9 divisions.</p> <!--<p>If you want to know which division applies to your case, please visit <a href="/page/SH0001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" style="display:inline">Self Help</a> to learn more about your case type.</p>-->
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 112px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle">
                                    <a href="/page/DV0002" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                        Appellate and Appeals
                                    </a>
                                </div>
                                <div class="columntitle">
                                    <a href="/page/DV0003" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                        Civil
                                    </a>
                                </div>
                                <div class="columntitle">
                                    <a href="/page/DV0004" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                        Criminal
                                    </a>
                                </div>
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 112px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle">
                                    <a href="/page/DV0005" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                        Family Law
                                    </a>
                                </div>
                                <div class="columntitle">
                                    <a href="/page/DV0006" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                        Juvenile
                                    </a>
                                </div>
                                <div class="columntitle">
                                    <a href="/page/DV0007" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                        Mental Health
                                    </a>
                                </div>
                            </div>

                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 112px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle">
                                    <a href="/page/DV0008" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                        Probate
                                    </a>
                                </div>
                                <div class="columntitle">
                                    <a href="/page/DV0009" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                        Small Claims
                                    </a>
                                </div>
                                <div class="columntitle">
                                    <a href="/page/DV0010" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                        Traffic
                                    </a>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="navBorderRight"></div>
                </div>


                <div class="left tabContainer" aria-haspopup="true" tabindex="-1" onmouseover="try{navigationMenu.SelectTabNoSubNav($('.navBarTab', this));}catch(e){}" onmouseout="try{navigationMenu.DeSelectTab($('.navBarTab', this));}catch(e){}" onfocus="return false;">
                    <div class="navBorderLeft"></div>
                    <div class="navBarTab navTab" id="navBarTab6" style="width:116px" tabindex="0" onclick="return processLink($('a.nav', $(this)));" onkeydown="return keyClick(event,$('a.nav', $(this)));">
                        <div class="nav clickable" id="nav6" tabindex="-1">
                            <a class="nav" tabindex="-1" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" href="/page/JR0000" data-flexmenu="flexmenu6">Jury</a><br>
                            <span class="nav2">Jury Duty Portal, Q&amp;A...</span>
                        </div>
                        <div class="flexdropdownmenu container" id="flexmenu6" style="text-align: left">
                            <div class="column">
                                <div class="columntitle">
                                    <a class="globalMenuLink" tabindex="0" href="/page/JR0001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">Jury Home</a>
                                </div>
                                <p>This juror site provides basic juror information on preparing for jury service and what to expect while serving.</p>
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 160px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle"><a class="globalMenuLink" tabindex="0" href="/page/JR0300" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">My Jury Duty Portal</a></div>
                                <p>With My Jury Duty Portal you can register for jury service, request an excuse, postponement or new court location, and complete your online orientation.</p>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="navBorderRight"></div>


                <div class="left tabContainer" aria-haspopup="true" tabindex="-1" onmouseover="try{navigationMenu.SelectTabNoSubNav($('.navBarTab', this));}catch(e){}" onmouseout="try{navigationMenu.DeSelectTab($('.navBarTab', this));}catch(e){}" onfocus="return false;">
                    <div class="navBorderLeft"></div>

                    <div class="navBarTab navTab" id="navBarTab7" style="width:146px" tabindex="0" onclick="return processLink($('a.nav', $(this)));" onkeydown="return keyClick(event,$('a.nav', $(this)));">
                        <div class="nav clickable" id="DIV2" tabindex="-1">
                            <a class="nav" tabindex="-1" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" href="/page/GI0000" data-flexmenu="flexmenu7">General&nbsp;Info</a>
                            <br>
                            <span class="nav2">Courthouses, ADA ...</span>
                        </div>
                        <div class="flexdropdownmenu container" id="flexmenu7">
                            <div class="column">
                                <div class="columntitle">Contacts and Locations</div>
                                <div class="listx" id="DIV4">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_COURTHOUSES" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Courthouses</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI0072" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Judicial Officers</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI0074" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Courtrooms</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_AD050" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">ADA</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_CC001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Contact the Court</span>
                                        </a>
                                    </div>-->
                                </div>
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 265px; margin-right: 20px; float: left;">&nbsp;</div>

                            <div class="column">
                                <div class="columntitle">News and Media</div>
                                <div class="listx" id="DIV5">
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_ACYW" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">AccessLACourt | Your Way</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_NC001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">LASC News Center</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="newsmedia/UI/media.aspx" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Information for the Media</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_NEWSRELEASE" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">News Releases</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_ATTORNEYNOTICE" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Notice to Attorneys</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_PUBLICNOTICES" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Public Notices</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_ANNUALREPORT" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Publications</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/EXGV149" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Access to Electronic Records</span>
                                        </a>
                                    </div>
                                </div>
                            </div>
                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 265px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle">Court Resources</div>
                                <div class="listx" id="DIV6">
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/Page/GI0060" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Local Court Rules</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/Page/GI_OB001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Obtaining Copies of Court Records</span>
                                        </a>
                                    </div>
                                    <div class="listitem">
                                        <a class="globalMenuLink" tabindex="0" href="/page/EXLA030" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Alternative Dispute Resolution </span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_RE001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Official Reporting Services</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_IN001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Court Interpreters</span>
                                        </a>
                                    </div>
                                    <!--  <div class="listitem ">
          <a class="globalMenuLink" tabindex="0"
             href="/page/PDF0008" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
              <span class="globalMenuSpan">Surplus Property Donation Program</span>
          </a>
      </div>-->
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_BS001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Bids &amp; Solicitations</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_AR001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Archives and Exhibits</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem "
        >
        <a class="globalMenuLink" tabindex="0"
           href="/page/PDF0008" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
            <span class="globalMenuSpan">LASC Donation Program</span>
        </a>
    </div>-->
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="https://paceportal.lacourt.org/" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">PACE</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/CI0112" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Digital Evidence Presentation System (DEPS) Information for Attorneys</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_SB001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">California Values Act</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem ">
        <a class="globalMenuLink" tabindex="0"
           href="/page/GI_PARP001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
            <span class="globalMenuSpan">What is PARP?</span>
        </a>
    </div>-->
                                </div>
                            </div>

                            <div class="column" style="background: rgb(185, 181, 181); width: 1px; height: 265px; margin-right: 20px; float: left;">&nbsp;</div>
                            <div class="column">
                                <div class="columntitle">Community Focus</div>
                                <div class="listx" id="DIV7">
                                    <!--<div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_DI006" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Diversity and Inclusion</span>
                                        </a>
                                    </div>-->
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_CO020" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Judicial Mentor Program</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_CO001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Community Outreach</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_DI001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Diversity Outreach</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_CO025" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">The Good We Do</span>
                                        </a>
                                    </div>-->
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_VP001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Volunteers, Interns, Externs</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_EM001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Employment</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_TJ001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Temporary Judge Program</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_AC001" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">About the Court</span>
                                        </a>
                                    </div>
                                    <div class="listitem ">
                                        <a class="globalMenuLink" tabindex="0" href="/page/GI_PNHOME" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                                            <span class="globalMenuSpan">Public Notice &amp; Inquiry</span>
                                        </a>
                                    </div>
                                    <!--<div class="listitem ">
            <a class="globalMenuLink" tabindex="0"
               href="/page/GI_NC003" onclick="try { navigationMenu.CancelBubble(event); } catch (e) { };return processLink(this);" onkeydown="return keyClick(event,this);">
                <span class="globalMenuSpan">Information Regarding Courtroom Access</span>
            </a>
        </div>
    </div>-->
                                </div>
                        </div>
                    </div>

                </div>
            </div>
        </div>
    </div>
</div>



        <!-- End MainMenu -->

        <form method="post" action="./Result.aspx?Referer=Index" id="lascwebform">
<div class="aspNetHidden">
</div>

<div class="aspNetHidden">

	<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAJ7yz38fyZyp5eB/7SmLpub1IlAGoPR5IElWZPVAGsVJNIEdKLaQ3ilzkT4M41L+HlLXGQCyI5K6WqkK5DUuk2X">
</div>
            <h1><span style="display:none" role="heading">Main Content</span></h1>
            <div class="pageWrap">
                
    
    <div id="siteMasterHolder_breadcrumbHolder_breadcrumb_breadcrumbBarContainer" class="breadcrumbBarContainer" display="none" style="display:none;">
    <div id="siteMasterHolder_breadcrumbHolder_breadcrumb_enabledLink" display="none" class="breadcrumbBar">
        <a href="#" class="topBreadcrumb" onclick="return processLink(this)"><span class="glyphicon glyphicon-menu-right"></span></a>
    </div>    
    <div id="siteMasterHolder_breadcrumbHolder_breadcrumb_disabledLink" class="breadcrumbBar">
        <div class="topBreadcrumb"><span class="glyphicon glyphicon-menu-right"></span></div>
    </div>
</div>
<div style="height:30px">
    <div id="siteMasterHolder_breadcrumbHolder_breadcrumb_returnLinkContainer" style="text-align:right; display:none">
        <a type="button" class="btn btn-default btn-sm" href="#" onclick="return processLink(this);">
            <span class="glyphicon glyphicon-screenshot"></span>  Home </a>
    </div>
</div>

<script type="text/javascript">$("#navBarTab2").addClass("navWhiteBox selectedTab");</script>
                
            


    
    <div class="mainContentWrap" id="divMainContent">
        <div class="basicWrap">
            <div class="contentCategory" style="padding-top: 28px; padding-bottom: 10px;">
                
    Online Services

            </div>
            <div class="contentTitle">
                
    Tentative Rulings

            </div>
            <div class="contentText">
                

					<!-- begin content -->
                <div class="synthesisControlPanel">
                    <div class="noPrint" align="right" valign="top"><input name="ctl00$ctl00$siteMasterHolder$basicBodyHolder$printbutton" type="button" id="siteMasterHolder_basicBodyHolder_printbutton" class="button printButton" onclick="window.open('ResultPopup.aspx', 'offworld', 'width=630,height=500,directories=yes,resizable=yes,status=yes,menubar=yes,location=yes,scrollbars=yes'); return false;" value="Print"></div>
                    <fieldset class="synthesisControlPanelContainer" style="width: 160px; border: black 1px solid; padding: 10px; border-radius: 8px;">
                        <legend style="color:black; font-weight:bold;">Text-to-Speech</legend>
                        <button type="button" class="synthesisButtonPlay" onclick="toggleSpeech()">Play</button>
                        <button type="button" class="synthesisButtonStop" onclick="stopSpeech()">Reset</button>
                    </fieldset>
                </div>
					<br>

                    
					<!--- begin text table--->									
                    <style>
                        .Print {
                            width: 100% !important;
                        }
                        font.fontChange {
                            font-family: open_sansregular !important;
                        }
                        .fontChange {
                            font-family: open_sansregular !important;
                            font-size: 14px !important;
                        }
                        p.MsoListParagraphCxSpFirst {
                            padding-left: 35px;
                        }
                        p.MsoListParagraph {
                            padding-left: 50px;
                        }
                        button.synthesisButton {
                            color: #fff;
                            background-color: #007bff;
                            border-color: #007bff;
                            display: inline-block;
                            font-weight: 400;
                            text-align: center;
                            white-space: nowrap;
                            vertical-align: middle;
                            -webkit-user-select: none;
                            -moz-user-select: none;
                            -ms-user-select: none;
                            user-select: none;
                            border: 1px solid transparent;
                            padding: 0.375rem 0.75rem;
                            font-size: 1rem;
                            line-height: 1.5;
                            border-radius: 0.25rem;
                            transition: color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;
                        }
                        button.synthesisButton:hover {
                            background-color: #004997;
                            border-color: #004997;
                        }
                        button.synthesisButtonPlay {
                            color: #fff;
                            background-color: #007bff;
                            border-color: #007bff;
                            display: inline-block;
                            font-weight: 400;
                            text-align: center;
                            white-space: nowrap;
                            vertical-align: middle;
                            -webkit-user-select: none;
                            -moz-user-select: none;
                            -ms-user-select: none;
                            user-select: none;
                            border: 1px solid transparent;
                            padding: 0.375rem 0.75rem;
                            font-size: 1rem;
                            line-height: 1.5;
                            border-radius: 0.25rem;
                            transition: color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;
                        }
                        button.synthesisButtonPlay:hover {
                            background-color: #004997;
                            border-color: #004997;
                        }
                        button.synthesisButtonStop {
                            color: #fff;
                            background-color: #007bff;
                            border-color: #007bff;
                            display: inline-block;
                            font-weight: 400;
                            text-align: center;
                            white-space: nowrap;
                            vertical-align: middle;
                            -webkit-user-select: none;
                            -moz-user-select: none;
                            -ms-user-select: none;
                            user-select: none;
                            border: 1px solid transparent;
                            padding: 0.375rem 0.75rem;
                            font-size: 1rem;
                            line-height: 1.5;
                            border-radius: 0.25rem;
                            transition: color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;
                        }
                        button.synthesisButtonStop:hover {
                            background-color: #004997;
                            border-color: #004997;
                        }
                        .synthesisControlPanelContainer {
                            border: black 1px solid;
                            padding: 10px;
                            border-radius: 8px;
                        }
                        .printButton {
                            color: #fff;
                            background-color: #007bff;
                            border-color: #007bff;
                            display: inline-block;
                            font-weight: 400;
                            text-align: center;
                            white-space: nowrap;
                            vertical-align: middle;
                            -webkit-user-select: none;
                            -moz-user-select: none;
                            -ms-user-select: none;
                            user-select: none;
                            border: 1px solid transparent;
                            padding: 0.375rem 0.75rem;
                            font-size: 1rem;
                            line-height: 1.5;
                            border-radius: 0.25rem;
                            transition: color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;
                        }
                        .printButton:hover {
                            background-color: #004997;
                            border-color: #004997;
                        }
                        .noPrint {
                            width: 200px;
                            float: right;
                            padding-top: 30px;
                            padding-right: 20px;
                        }
                        #play-resume-button {
                          position: relative;
                        }

                        #play-resume-button-image {
                          position: absolute;
                          top: 0;
                          left: 0;
                        }

                        #stop-button {
                          margin-left: 10px;
                        }
                    </style>
                   
                    
					<table class="resultsTable" style="font-size: 14px; font-family: open_sansregular !important;" cellspacing="0" cellpadding="0" width="98%" border="0">
					<tbody><tr>
						<td><div id="speechSynthesis" class="Print"><b> DEPARTMENT 11 LAW AND MOTION RULINGS </b><p><br></p><hr size="4" noshade=""> <p><b> Case Number: </b> 21STCV21284&nbsp;&nbsp;&nbsp;<b> Hearing Date: </b>  June 18, 2024&nbsp;&nbsp;&nbsp;<b> Dept: </b> 11</p><p> </p><p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:
normal"><u><br>Does v. City of Los Angeles</u> (23STCV21284)<o:p></o:p></b></p>

<p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:
normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:
normal"><u>Doe 1 v. Los Angeles Police Department</u> (23STCV21995)<o:p></o:p></b></p>

<p class="MsoNormal"><b style="mso-bidi-font-weight:normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:
normal">Tentative Ruling Re: Anti-SLAPP Motions to Strike<o:p></o:p></b></p>

<p class="MsoNormal"><b style="mso-bidi-font-weight:normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal">Date:<span style="mso-tab-count:3" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>6/18/24<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal">Time:<span style="mso-tab-count:3" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>3:00
pm<o:p></o:p></b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b style="mso-bidi-font-weight:normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b style="mso-bidi-font-weight:normal">Moving Party:<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Cross-Defendants Ben Camacho and Stop
LAPD Spying Coalition (“Coalition”)<o:p></o:p></b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b style="mso-bidi-font-weight:normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b style="mso-bidi-font-weight:normal">Opposing Party:<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Cross-Complainants City of Los Angeles,
et al. (collectively “City”)<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal">Department: <span style="mso-tab-count:2" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>11<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal">Judge: <span style="mso-tab-count:2" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>David
S. Cunningham III<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal">________________________________________________________________________<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal"><b style="mso-bidi-font-weight:normal">TENTATIVE RULING<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">Camacho’s and Coalition’s anti-SLAPP motions to strike are
granted.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal"><b style="mso-bidi-font-weight:normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal">BACKGROUND<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="text-align:justify">In October 2021, journalist Ben
Camacho filed a Public Records Act request for a roster and photos of all
police officers employed by the Los Angeles Police Department (“LAPD”).<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>City refused to produce the roster and
photos, so Camacho filed a lawsuit to compel production.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">In September 2022, City settled
the lawsuit.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>City agreed to “produc[e]
pictures of all full-time, active duty” LAPD officers, “except for officers
then working in an undercover capacity as of July 2022.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(City’s Anti-SLAPP Motion, p. 5.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>During the production, though, City
“inadvertently included” the names and pictures of some undercover officers.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>Camacho then published the names and pictures online.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">“Six months later, in March
2023,” Coalition “republished” the names and pictures “on a website it had
created, watchthewatchers.net.”<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(Coaltion’s Anti-SLAPP Motion, p. 2.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">“In September 2023, over 800
anonymous individuals filed the present pair of damages actions.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Id. at p. 3.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“[P]laintiffs claim they are current and
retired LAPD officers whose identities had been secret until the City made them
public.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">In January 2024, City filed a
cross-complaint against Camacho and Coalition for equitable indemnity and
contribution.<o:p></o:p></p>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">On February 29, 2024, Camacho and
Coalition moved under the anti-SLAPP statute to strike City’s cross-claims.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">On March 22, 2024, the Court
heard the motions but ended up continuing the hearing.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">Here, the Court considers whether
the motions should be granted.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><b>LAW<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="text-align:justify">“<span style="color:#3D3D3D;
background:white" class="fontChange">The Legislature has authorized a special motion to strike
that may be filed against ‘SLAPP’ suits (Strategic Lawsuits Against Public
Participation).”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Edmon &amp; Karnow,
Cal. Practice Guide: Civ. Procedure Before Trial (The Rutter Group June 2023
Update) ¶ 7:500.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“The anti-SLAPP motion
is a procedural remedy, designed to quickly identify and dispose of lawsuits
brought to chill the valid exercise of a party's constitutional right of
petition or free speech.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">“Courts use a two-step process for determining whether an action
or a claim is a SLAPP suit subject to a special motion to strike.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.) <span style="mso-spacerun:yes" class="fontChange">&nbsp;</span>“Plaintiff’s claim must (1) arise out of
defendant’s protected speech or petitioning;&nbsp;</span><em><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:major-fareast;
color:#3D3D3D;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0in;
padding:0in;background:white" class="fontChange">and</span></em><span style="color:#3D3D3D;
background:white" class="fontChange">&nbsp;(2) lack even minimal merit.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid., emphasis in original.)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">“Commonly, the court first determines whether plaintiff’s
claims arise out of protected activity – i.e., whether the claim against
defendant is predicated on defendant's exercise of a constitutional right of
free speech or petition.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.) <span style="mso-spacerun:yes" class="fontChange">&nbsp;</span>“It is defendant’s burden to show the claim
arises out of protected activity.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>If
that burden is not met, the motion will be denied.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">“If defendant meets the first prong burden, the burden shifts
to plaintiff to show the probability that plaintiff will succeed on the merits
of the claim.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.) <span style="mso-spacerun:yes" class="fontChange">&nbsp;</span>“In other words, even if the conduct for which
defendant is being sued implicates defendant’s free speech or petition rights,
the lawsuit may proceed if plaintiff makes a prima facie showing that the claim
has merit.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.)</span><b><o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>DISCUSSION<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b><o:p>&nbsp;</o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b><i>Camacho and Coalition<o:p></o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">Comacho and Coalition contend
their motions should be granted because:<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* City’s cross-claims “arise[]
from protected activity” (Camacho’s Anti-SLAPP Motion, p. 4; see also
Coalition’s Anti-SLAPP Motion, p. 5 [asserting that the cross-claims arise from
“either requesting public records . . . or publishing public records”]); <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* Camacho’s conduct and
Coalition’s conduct “address[ed] an issue of public interest in a public forum”
(Camacho’s Anti-SLAPP Motion, p. 6, emphasis deleted; see also Coalition’s
Anti-SLAPP Motion, pp. 5-7 [claiming the conduct “implicated a public issue”
and “connected to conversation about the public issue”], emphasis deleted); and
<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* “City cannot show a probability
of success” (Camacho’s Anti-SLAPP Motion, p. 8, emphasis deleted; see also
Coalition’s Anti-SLAPP Motion, pp. 7-15 [claiming the contribution cross-claim
is unripe and the cross-claim for equitable indemnity fails because Plaintiffs’
underlying causes of action are “[un]likely to succeed against [] Coalition”
since (1) the First Amendment “bars any liability[,]” (2) Plaintiffs cannot
satisfy the elements of their claims, (3) “Coalition does not know who the over
800” Plaintiffs “are[,]” and (4) Plaintiffs’ claims “are meritless against []
City”], emphasis deleted.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><b><i>City<o:p></o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">City disagrees.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>City contends the motion should be denied
because:<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* it “violates” the Court’s stay
order (Opposition, p. 3, emphasis deleted);<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* Camacho and Coalition “cannot
file an anti-SLAPP motion based on the act of filing a cross-complaint iself”
(ibid.; see also id. at p. 4); and <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* the cross-claims do not arise
out of protected conduct (see id. at p. 4 [asserting that requesting and
publishing photos of undercover cops “are not ‘protected activities’”]).<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">Alternatively, City contends
Plaintiffs’ underlying claims should be dismissed if Coalition’s motion is
granted because the cross-claims constitute derivative claims and “are . . .
based on the adequacy of” Plaintiffs’ claims.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(Id. at p. 4.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><b><i>Joint Reply<o:p></o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">In reply, Camacho and Coalition
assert:<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* City failed to serve the
opposition brief (see Joint Reply, p. 2);<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* the stay order does not cover
Camacho and Coalition (see id. at pp. 3-5);<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* “[d]efeating indemnification or
contribution claims does not extinguish the liability of the party seeking
indemnification” (id. at p. 5, emphasis deleted);<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* the anti-SLAPP statute applies
to City’s cross-claims (see id. at pp. 6-7); and<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* putting Camacho’s and
Coalition’s motions on hold until Plaintiffs’ underlying claims are resolved
via summary judgment or trial would be improper (see id. at pp. 7-9).<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><b><i>Analysis<o:p></o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify"><b><i><o:p>&nbsp;</o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify">The first two issues – whether
Camacho and Coalition filed their motions in violation of the stay order and
whether City’s opposition should be stricken for lack of service – have been
resolved.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Court addressed these
issues in the March 22<sup>nd</sup> ruling.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(See 3/22/24 Ruling Re: Anti-SLAPP Motions to Strike, pp. 3-5.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The third issue – whether Camacho
and Coalition are prohibited from “fil[ing] an anti-SLAPP motion based on the
act of filing a cross-complaint” (Opposition, p. 3) – weighs in Camacho’s and
Coalition’s favor.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Their motions target
the substance of City’s cross-claims, not the fact that City filed a
pleading.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Anti-SLAPP motions can be used
for this purpose.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Joint Reply, p.
6.) <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The next issue is whether City’s
causes of action arise out of Camacho’s and Coalition’s “<span style="color:#3D3D3D;background:white" class="fontChange">protected speech or petitioning[.]”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Edmon &amp; Karnow, supra, at ¶ 7:500.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>City’s cross-complaint contains two causes of
action – equitable indemnity and contribution.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>The premise of the causes of action is that Camacho and Coalition are
partly or totally responsible for Plaintiffs’ alleged injuries because they are
the ones who published the names and pictures.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(See, e.g., Cross-Complaint, ¶¶ 15, 21-22, 24-25.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>As noted above, City claims </span>requesting
and publishing names and photos of undercover officers “are not ‘protected
activities’.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Opposition, p. 4.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The Court disagrees.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Camacho is a journalist.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>He requested the names and pictures pursuant
to the Public Records Act.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>When City
refused to produce them, he filed a lawsuit to compel compliance with the
statute.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Then the case settled, and he
published the names and photos that City produced to him through the
settlement.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Then Coalition republished
them on its website, the same names and photos that were already available to
the public due to Camacho’s publication.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>All of these acts involved protected speech and petitioning, especially
given the broad right of the press to publish confidential matters, even police
personnel files, when they relate to issues of public interest – e.g., police
accountability.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See, e.g., <u>Association
for Los Angeles Deputy Sheriffs v. Los Angeles Times Communications LLC</u>
(2015) 239 Cal.App.4<sup>th</sup> 808, 815-821; see also Camacho’s Anti-SLAPP
Motion, pp. 4-8 [discussing cases]; Coalition’s Anti-SLAPP Motion, pp. 4-7
[similar].)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">City’s suggestion – that Camacho
breached the settlement by publishing inadvertently produced names and pictures
(see Opposition, p. 4 [stating that the settlement parties “agreed to exclude”
undercover officers “from the settlement”]) – does not change the result.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“Speech or petitioning activity that is
‘illegal as a matter of law’ is not constitutionally protected and falls
outside the protection of the anti-SLAPP statute.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Burke, Anti-SLAPP Litigation (The Rutter
Group October 2023 Update) ¶ 6:46.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“‘Illegal’
means criminal behavior[.]”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Id. at ¶
6:48, emphasis deleted.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“The mere
showing of an alleged statutory or common-law violation” is not enough.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.; see also, e.g., <u>Bergstein v.
Stroock &amp; Stroock &amp; Lavan LLP</u> (2015) 236 Cal.App.4<sup>th</sup>
793.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>City fails to show that the
purported breach constitutes a crime or that another exception applies.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Opposition, pp. 3-4.)<a style="mso-footnote-id:ftn1" href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/does%20v%20city%20of%20la%206-18-24%20tentative%20ruling%20re%20camacho%20and%20coalition%20anti-SLAPP%20mtns%20to%20strike%20(23stcv21284)%20FINAL.docx#_ftn1" name="_ftnref1" title=""><span class="MsoFootnoteReference fontChange"><span style="mso-special-character:footnote" class="fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[1]</span></span><!--[endif]--></span></span></a><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp; </span><o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The first prong is satisfied.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The final issue is whether City
shows a probability of success.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See <span style="color:#3D3D3D;background:white" class="fontChange">Edmon &amp; Karnow, supra, at ¶
7:500.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>City bears the burden of proof
(see ibid.), yet it did not submit evidence, and it fails to discuss the
merits.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Opposition, pp. 2-5.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Instead, City contends: <o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">* the Court should not decide Camacho’s and Coalition’s
motions until City’s anti-SLAPP motion is resolved (see Opposition, p. 4); or,<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">* if “the Court is inclined to grant” Camacho’s and
Coalition’s motions, Plaintiffs’ claims against City must also be dismissed now
because the cross-claims are derivate (id. at p. 3; see also id. at pp. 4-5).<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">Both points fail.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The
Court determined at a prior status conference that it will hear Camacho’s and
Coalition’s motions first.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Moreover,
“[w]hether a defendant should </span>be indemnified by a third party does not dictate
whether the defendant is liable to the plaintiffs.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Joint Reply, p. 5.)<span style="color:#3D3D3D;
background:white" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>City’s cases do not
hold otherwise.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See <u>Prince v.
Pacific Gas &amp; Electric Co.</u> (2009) 45 Cal.4<sup>th</sup> 1151, 1155
[granting <i>summary judgment</i>, finding that the power company’s statutory
immunity from direct liability for the minor’s injury precluded the property
owner’s indemnity cross-claim against the power company]; see also <u>Leko v.
Cornerstone Building Inspection Service</u> (2001) 86 Cal.App.4<sup>th</sup>
1109, 1115 [reversing <i>judgment on the pleadings</i> and <i>summary judgment</i>,
finding that “public policy does not preclude a realtor from seeking equitable
indemnity against a home inspection company in an appropriate case”].)<a style="mso-footnote-id:ftn2" href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/does%20v%20city%20of%20la%206-18-24%20tentative%20ruling%20re%20camacho%20and%20coalition%20anti-SLAPP%20mtns%20to%20strike%20(23stcv21284)%20FINAL.docx#_ftn2" name="_ftnref2" title=""><span class="MsoFootnoteReference fontChange"><span style="mso-special-character:footnote" class="fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;color:#3D3D3D;background:white;
mso-font-kerning:0pt;mso-ligatures:none;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA" class="fontChange">[2]</span></span><!--[endif]--></span></span></a><o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">Also, as explained in the tentative ruling on City’s motion
to compel anti-SLAPP discovery,<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">[t]he Court agrees
[with City] that the First Amendment is not absolute, but the alleged threats
[] do not appear to change the result.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>City highlights a series of purported Twitter (now X) postings by a
person named Steven William Sutcliffe.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>[Citation.]<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Twitter is a separate
website.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>There is no allegation of a
connection, then or now, between Sutcliffe and Camacho or Coalition.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>[Citations.]<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>At most, the pleadings indicate that an unconnected third party included
a link to Coalition’s website in some of his posts, a website, it is worth
repeating, where Coalition republished names and photos that a journalist had
already published to the public.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>City
does not cite a case with similar facts that extends indemnity and contribution
this far.<o:p></o:p></p>

<p class="MsoNormal" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">Nor does City
explain how the requested discovery could overcome Camacho’s and Coalition’s
non-First Amendment legal arguments.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>Indeed, City does not even respond to those arguments.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>[Citations.]<o:p></o:p></p>

<p class="MsoNormal" style="margin-right:.5in;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="margin-right:.5in;text-align:justify">(6/18/24
Tentative Ruling Re: Motion to Compel Anti-SLAPP Discovery, p. 4.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">The second prong is unsatisfied.<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D;
background:white" class="fontChange">Accordingly, on the current record, the Court finds that Camacho’s
and Coalition’s motions should be granted.<o:p></o:p></span></p>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p>

<div style="mso-element:footnote-list"><!--[if !supportFootnotes]--><br clear="all">

<hr align="left" size="1" width="33%">

<!--[endif]-->

<div style="mso-element:footnote" id="ftn1">

<p class="MsoFootnoteText" style="text-align:justify"><a style="mso-footnote-id:
ftn1" href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/does%20v%20city%20of%20la%206-18-24%20tentative%20ruling%20re%20camacho%20and%20coalition%20anti-SLAPP%20mtns%20to%20strike%20(23stcv21284)%20FINAL.docx#_ftnref1" name="_ftn1" title=""><span class="MsoFootnoteReference fontChange"><span style="mso-special-character:footnote" class="fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[1]</span></span><!--[endif]--></span></span></a>
Coalition is not bound by the settlement and simply republished information
that had previously been published to the public by a member of the press.<o:p></o:p></p>

</div>

<div style="mso-element:footnote" id="ftn2">

<p class="MsoFootnoteText" style="text-align:justify"><a style="mso-footnote-id:
ftn2" href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/does%20v%20city%20of%20la%206-18-24%20tentative%20ruling%20re%20camacho%20and%20coalition%20anti-SLAPP%20mtns%20to%20strike%20(23stcv21284)%20FINAL.docx#_ftnref2" name="_ftn2" title=""><span class="MsoFootnoteReference fontChange"><span style="mso-special-character:footnote" class="fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[2]</span></span><!--[endif]--></span></span></a>
City additionally cites <u>Aetna Inc. v. Whatley Kallas, LLP</u>, 2020 WL
4012597.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The decision is unpublished, so
the Court declines to consider it. <o:p></o:p></p>

</div>

</div>******************************************************************************************************************************************<br><br><p class="MsoNormal" align="center" style="text-align:center"><b><u>Does v. City of Los Angeles</u> (23STCV21284)<o:p></o:p></b></p>

<p class="MsoNormal" align="center" style="text-align:center"><b>&nbsp;</b></p>

<p class="MsoNormal" align="center" style="text-align:center"><b><u>Doe 1 v. Los Angeles Police Department</u> (23STCV21995)<o:p></o:p></b></p>

<p class="MsoNormal"><b>&nbsp;</b></p>

<p class="MsoNormal" align="center" style="text-align:center"><b>Tentative Ruling Re: Anti-SLAPP Motions to Strike<o:p></o:p></b></p>

<p class="MsoNormal"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6/18/24<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b>Time:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3:00
pm<o:p></o:p></b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>&nbsp;</b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>Moving Party:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cross-Defendants Ben Camacho and Stop
LAPD Spying Coalition (“Coalition”)<o:p></o:p></b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>&nbsp;</b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>Opposing Party:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cross-Complainants City of Los Angeles,
et al. (collectively “City”)<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b>Department: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b>Judge: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; David
S. Cunningham III<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>________________________________________________________________________<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal"><b>TENTATIVE RULING<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Camacho’s and Coalition’s anti-SLAPP motions to strike are
granted.&nbsp; <o:p></o:p></span></p>

<p class="MsoNormal"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b>BACKGROUND<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify">In October 2021, journalist Ben
Camacho filed a Public Records Act request for a roster and photos of all
police officers employed by the Los Angeles Police Department (“LAPD”).&nbsp; City refused to produce the roster and
photos, so Camacho filed a lawsuit to compel production.&nbsp; <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">In September 2022, City settled
the lawsuit.&nbsp; City agreed to “produc[e]
pictures of all full-time, active duty” LAPD officers, “except for officers
then working in an undercover capacity as of July 2022.”&nbsp; (City’s Anti-SLAPP Motion, p. 5.)&nbsp; During the production, though, City
“inadvertently included” the names and pictures of some undercover officers.&nbsp; (Ibid.)&nbsp;
Camacho then published the names and pictures online.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">“Six months later, in March
2023,” Coalition “republished” the names and pictures “on a website it had
created, watchthewatchers.net.”&nbsp;
(Coaltion’s Anti-SLAPP Motion, p. 2.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">“In September 2023, over 800
anonymous individuals filed the present pair of damages actions.”&nbsp; (Id. at p. 3.)&nbsp; “[P]laintiffs claim they are current and
retired LAPD officers whose identities had been secret until the City made them
public.”&nbsp; (Ibid.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">In January 2024, City filed a
cross-complaint against Camacho and Coalition for equitable indemnity and
contribution.<o:p></o:p></p>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">On February 29, 2024, Camacho and
Coalition moved under the anti-SLAPP statute to strike City’s cross-claims.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">On March 22, 2024, the Court
heard the motions but ended up continuing the hearing.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">Here, the Court considers whether
the motions should be granted.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><b>LAW<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify">“<span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">The Legislature has authorized a special motion to strike
that may be filed against ‘SLAPP’ suits (Strategic Lawsuits Against Public
Participation).”&nbsp; (Edmon &amp; Karnow,
Cal. Practice Guide: Civ. Procedure Before Trial (The Rutter Group June 2023
Update) ¶ 7:500.)&nbsp; “The anti-SLAPP motion
is a procedural remedy, designed to quickly identify and dispose of lawsuits
brought to chill the valid exercise of a party's constitutional right of
petition or free speech.”&nbsp; (Ibid.)&nbsp; <o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“Courts use a two-step process for determining whether an action
or a claim is a SLAPP suit subject to a special motion to strike.”&nbsp; (Ibid.) &nbsp;“Plaintiff’s claim must (1) arise out of
defendant’s protected speech or petitioning;&nbsp;</span><em><span style="color: rgb(61, 61, 61); border: 1pt none windowtext; padding: 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">and</span></em><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;(2) lack even minimal merit.”&nbsp; (Ibid., emphasis in original.)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“Commonly, the court first determines whether plaintiff’s
claims arise out of protected activity – i.e., whether the claim against
defendant is predicated on defendant's exercise of a constitutional right of
free speech or petition.”&nbsp; (Ibid.) &nbsp;“It is defendant’s burden to show the claim
arises out of protected activity.&nbsp; If
that burden is not met, the motion will be denied.”&nbsp; (Ibid.)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“If defendant meets the first prong burden, the burden shifts
to plaintiff to show the probability that plaintiff will succeed on the merits
of the claim.”&nbsp; (Ibid.) &nbsp;“In other words, even if the conduct for which
defendant is being sued implicates defendant’s free speech or petition rights,
the lawsuit may proceed if plaintiff makes a prima facie showing that the claim
has merit.”&nbsp; (Ibid.)</span><b><o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b>DISCUSSION<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b><i>Camacho and Coalition<o:p></o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">Comacho and Coalition contend
their motions should be granted because:<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* City’s cross-claims “arise[]
from protected activity” (Camacho’s Anti-SLAPP Motion, p. 4; see also
Coalition’s Anti-SLAPP Motion, p. 5 [asserting that the cross-claims arise from
“either requesting public records . . . or publishing public records”]); <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* Camacho’s conduct and
Coalition’s conduct “address[ed] an issue of public interest in a public forum”
(Camacho’s Anti-SLAPP Motion, p. 6, emphasis deleted; see also Coalition’s
Anti-SLAPP Motion, pp. 5-7 [claiming the conduct “implicated a public issue”
and “connected to conversation about the public issue”], emphasis deleted); and
<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* “City cannot show a probability
of success” (Camacho’s Anti-SLAPP Motion, p. 8, emphasis deleted; see also
Coalition’s Anti-SLAPP Motion, pp. 7-15 [claiming the contribution cross-claim
is unripe and the cross-claim for equitable indemnity fails because Plaintiffs’
underlying causes of action are “[un]likely to succeed against [] Coalition”
since (1) the First Amendment “bars any liability[,]” (2) Plaintiffs cannot
satisfy the elements of their claims, (3) “Coalition does not know who the over
800” Plaintiffs “are[,]” and (4) Plaintiffs’ claims “are meritless against []
City”], emphasis deleted.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><b><i>City<o:p></o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">City disagrees.&nbsp; City contends the motion should be denied
because:<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* it “violates” the Court’s stay
order (Opposition, p. 3, emphasis deleted);<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* Camacho and Coalition “cannot
file an anti-SLAPP motion based on the act of filing a cross-complaint iself”
(ibid.; see also id. at p. 4); and <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* the cross-claims do not arise
out of protected conduct (see id. at p. 4 [asserting that requesting and
publishing photos of undercover cops “are not ‘protected activities’”]).<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">Alternatively, City contends
Plaintiffs’ underlying claims should be dismissed if Coalition’s motion is
granted because the cross-claims constitute derivative claims and “are . . .
based on the adequacy of” Plaintiffs’ claims.&nbsp;
(Id. at p. 4.)&nbsp; <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><b><i>Joint Reply<o:p></o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">In reply, Camacho and Coalition
assert:<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* City failed to serve the
opposition brief (see Joint Reply, p. 2);<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* the stay order does not cover
Camacho and Coalition (see id. at pp. 3-5);<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* “[d]efeating indemnification or
contribution claims does not extinguish the liability of the party seeking
indemnification” (id. at p. 5, emphasis deleted);<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* the anti-SLAPP statute applies
to City’s cross-claims (see id. at pp. 6-7); and<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">* putting Camacho’s and
Coalition’s motions on hold until Plaintiffs’ underlying claims are resolved
via summary judgment or trial would be improper (see id. at pp. 7-9).<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><b><i>Analysis<o:p></o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify"><b><i>&nbsp;</i></b></p>

<p class="MsoNormal" style="text-align:justify">The first two issues – whether
Camacho and Coalition filed their motions in violation of the stay order and
whether City’s opposition should be stricken for lack of service – have been
resolved.&nbsp; The Court addressed these
issues in the March 22<sup>nd</sup> ruling.&nbsp;
(See 3/22/24 Ruling Re: Anti-SLAPP Motions to Strike, pp. 3-5.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The third issue – whether Camacho
and Coalition are prohibited from “fil[ing] an anti-SLAPP motion based on the
act of filing a cross-complaint” (Opposition, p. 3) – weighs in Camacho’s and
Coalition’s favor.&nbsp; Their motions target
the substance of City’s cross-claims, not the fact that City filed a
pleading.&nbsp; Anti-SLAPP motions can be used
for this purpose.&nbsp; (See Joint Reply, p.
6.) <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The next issue is whether City’s
causes of action arise out of Camacho’s and Coalition’s “<span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">protected speech or petitioning[.]”&nbsp; (Edmon &amp; Karnow, supra, at ¶ 7:500.)&nbsp; City’s cross-complaint contains two causes of
action – equitable indemnity and contribution.&nbsp;
The premise of the causes of action is that Camacho and Coalition are
partly or totally responsible for Plaintiffs’ alleged injuries because they are
the ones who published the names and pictures.&nbsp;
(See, e.g., Cross-Complaint, ¶¶ 15, 21-22, 24-25.)&nbsp; As noted above, City claims </span>requesting
and publishing names and photos of undercover officers “are not ‘protected
activities’.”&nbsp; (Opposition, p. 4.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The Court disagrees.&nbsp; Camacho is a journalist.&nbsp; He requested the names and pictures pursuant
to the Public Records Act.&nbsp; When City
refused to produce them, he filed a lawsuit to compel compliance with the
statute.&nbsp; Then the case settled, and he
published the names and photos that City produced to him through the
settlement.&nbsp; Then Coalition republished
them on its website, the same names and photos that were already available to
the public due to Camacho’s publication.&nbsp;
All of these acts involved protected speech and petitioning, especially
given the broad right of the press to publish confidential matters, even police
personnel files, when they relate to issues of public interest – e.g., police
accountability.&nbsp; (See, e.g., <u>Association
for Los Angeles Deputy Sheriffs v. Los Angeles Times Communications LLC</u>
(2015) 239 Cal.App.4<sup>th</sup> 808, 815-821; see also Camacho’s Anti-SLAPP
Motion, pp. 4-8 [discussing cases]; Coalition’s Anti-SLAPP Motion, pp. 4-7
[similar].)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">City’s suggestion – that Camacho
breached the settlement by publishing inadvertently produced names and pictures
(see Opposition, p. 4 [stating that the settlement parties “agreed to exclude”
undercover officers “from the settlement”]) – does not change the result.&nbsp; “Speech or petitioning activity that is
‘illegal as a matter of law’ is not constitutionally protected and falls
outside the protection of the anti-SLAPP statute.”&nbsp; (Burke, Anti-SLAPP Litigation (The Rutter
Group October 2023 Update) ¶ 6:46.)&nbsp; “‘Illegal’
means criminal behavior[.]”&nbsp; (Id. at ¶
6:48, emphasis deleted.)&nbsp; “The mere
showing of an alleged statutory or common-law violation” is not enough.&nbsp; (Ibid.; see also, e.g., <u>Bergstein v.
Stroock &amp; Stroock &amp; Lavan LLP</u> (2015) 236 Cal.App.4<sup>th</sup>
793.)&nbsp; City fails to show that the
purported breach constitutes a crime or that another exception applies.&nbsp; (See Opposition, pp. 3-4.)<a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/does%20v%20city%20of%20la%206-18-24%20tentative%20ruling%20re%20camacho%20and%20coalition%20anti-SLAPP%20mtns%20to%20strike%20(23stcv21284)%20FINAL.docx#_ftn1" name="_ftnref1" title=""><span class="MsoFootnoteReference fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[1]</span></span><!--[endif]--></span></a>&nbsp;&nbsp;&nbsp; <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The first prong is satisfied.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The final issue is whether City
shows a probability of success.&nbsp; (See <span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Edmon &amp; Karnow, supra, at ¶
7:500.)&nbsp; City bears the burden of proof
(see ibid.), yet it did not submit evidence, and it fails to discuss the
merits.&nbsp; (See Opposition, pp. 2-5.)&nbsp; Instead, City contends: <o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">* the Court should not decide Camacho’s and Coalition’s
motions until City’s anti-SLAPP motion is resolved (see Opposition, p. 4); or,<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">* if “the Court is inclined to grant” Camacho’s and
Coalition’s motions, Plaintiffs’ claims against City must also be dismissed now
because the cross-claims are derivate (id. at p. 3; see also id. at pp. 4-5).<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Both points fail.&nbsp; The
Court determined at a prior status conference that it will hear Camacho’s and
Coalition’s motions first.&nbsp; Moreover,
“[w]hether a defendant should </span>be indemnified by a third party does not dictate
whether the defendant is liable to the plaintiffs.”&nbsp; (Joint Reply, p. 5.)<span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp; City’s cases do not
hold otherwise.&nbsp; (See <u>Prince v.
Pacific Gas &amp; Electric Co.</u> (2009) 45 Cal.4<sup>th</sup> 1151, 1155
[granting <i>summary judgment</i>, finding that the power company’s statutory
immunity from direct liability for the minor’s injury precluded the property
owner’s indemnity cross-claim against the power company]; see also <u>Leko v.
Cornerstone Building Inspection Service</u> (2001) 86 Cal.App.4<sup>th</sup>
1109, 1115 [reversing <i>judgment on the pleadings</i> and <i>summary judgment</i>,
finding that “public policy does not preclude a realtor from seeking equitable
indemnity against a home inspection company in an appropriate case”].)<a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/does%20v%20city%20of%20la%206-18-24%20tentative%20ruling%20re%20camacho%20and%20coalition%20anti-SLAPP%20mtns%20to%20strike%20(23stcv21284)%20FINAL.docx#_ftn2" name="_ftnref2" title=""><span class="MsoFootnoteReference fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size: 12pt; font-family: &quot;Times New Roman&quot;, serif; color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">[2]</span></span><!--[endif]--></span></a><o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Also, as explained in the tentative ruling on City’s motion
to compel anti-SLAPP discovery,&nbsp; <o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">[t]he Court agrees
[with City] that the First Amendment is not absolute, but the alleged threats
[] do not appear to change the result.&nbsp;
City highlights a series of purported Twitter (now X) postings by a
person named Steven William Sutcliffe.&nbsp;
[Citation.]&nbsp; Twitter is a separate
website.&nbsp; There is no allegation of a
connection, then or now, between Sutcliffe and Camacho or Coalition.&nbsp; [Citations.]&nbsp;
At most, the pleadings indicate that an unconnected third party included
a link to Coalition’s website in some of his posts, a website, it is worth
repeating, where Coalition republished names and photos that a journalist had
already published to the public.&nbsp; City
does not cite a case with similar facts that extends indemnity and contribution
this far.<o:p></o:p></p>

<p class="MsoNormal" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">Nor does City
explain how the requested discovery could overcome Camacho’s and Coalition’s
non-First Amendment legal arguments.&nbsp;
Indeed, City does not even respond to those arguments.&nbsp; [Citations.]<o:p></o:p></p>

<p class="MsoNormal" style="margin-right:.5in;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="margin-right:.5in;text-align:justify">(6/18/24
Tentative Ruling Re: Motion to Compel Anti-SLAPP Discovery, p. 4.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">The second prong is unsatisfied.<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Accordingly, on the current record, the Court finds that Camacho’s
and Coalition’s motions should be granted.<o:p></o:p></span></p>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p>

<div><!--[if !supportFootnotes]--><br clear="all">

<hr align="left" size="1" width="33%">

<!--[endif]-->

<div id="ftn1">

<p class="MsoFootnoteText" style="text-align:justify"><a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/does%20v%20city%20of%20la%206-18-24%20tentative%20ruling%20re%20camacho%20and%20coalition%20anti-SLAPP%20mtns%20to%20strike%20(23stcv21284)%20FINAL.docx#_ftnref1" name="_ftn1" title=""><span class="MsoFootnoteReference fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[1]</span></span><!--[endif]--></span></a>
Coalition is not bound by the settlement and simply republished information
that had previously been published to the public by a member of the press.<o:p></o:p></p>

</div>

<div id="ftn2">

<p class="MsoFootnoteText" style="text-align:justify"><a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/does%20v%20city%20of%20la%206-18-24%20tentative%20ruling%20re%20camacho%20and%20coalition%20anti-SLAPP%20mtns%20to%20strike%20(23stcv21284)%20FINAL.docx#_ftnref2" name="_ftn2" title=""><span class="MsoFootnoteReference fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[2]</span></span><!--[endif]--></span></a>
City additionally cites <u>Aetna Inc. v. Whatley Kallas, LLP</u>, 2020 WL
4012597.&nbsp; The decision is unpublished, so
the Court declines to consider it.&nbsp;<o:p></o:p></p>

</div>

</div>***********************************************************************************************************************************************<br><p class="MsoNormal" align="center" style="text-align:center"><b><u>Does v. City of Los Angeles</u> (23STCV21284)<o:p></o:p></b></p>

<p class="MsoNormal" align="center" style="text-align:center"><b>&nbsp;</b></p>

<p class="MsoNormal" align="center" style="text-align:center"><b><u>Doe 1 v. Los Angeles Police Department</u> (23STCV21995)<o:p></o:p></b></p>

<p class="MsoNormal"><b>&nbsp;</b></p>

<p class="MsoNormal" align="center" style="text-align:center"><b>Tentative Ruling Re: Motion to Seal Confidential Matrix<o:p></o:p></b></p>

<p class="MsoNormal"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6/18/24<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>Time:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3:00
pm<o:p></o:p></b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>Moving Party:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; John Doe 1, et al. (collectively “Plaintiffs”)<o:p></o:p></b></p>

<p class="MsoNormal" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>Opposing Party:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ben Camacho and Stop LAPD Spying
Coalition (“Coalition”)<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>Department: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>Judge: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; David
S. Cunningham III<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>________________________________________________________________________<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal"><b>TENTATIVE RULING<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The hearing on Plaintiffs’ motion
to seal is continued.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">The Court grants Plaintiffs leave
to file a motion to use pseudonyms.&nbsp; <o:p></o:p></p>

<p class="MsoNormal"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b>BACKGROUND<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify">In October 2021, journalist Ben
Camacho filed a Public Records Act request for a roster and photos of all
police officers employed by the Los Angeles Police Department (“LAPD”).&nbsp; The City of Los Angeles (“City”) refused to
produce the roster and photos, so Camacho filed a lawsuit to compel
production.&nbsp; <o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">In September 2022, City settled
the lawsuit.&nbsp; City agreed to “produc[e]
pictures of all full-time, active duty” LAPD officers, “except for officers
then working in an undercover capacity as of July 2022.”&nbsp; (City’s Anti-SLAPP Motion, p. 5.)&nbsp; During the production, though, City
“inadvertently included” the names and pictures of some undercover officers.&nbsp; (Ibid.)&nbsp;
Camacho then published the names and pictures online.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">“Six months later, in March
2023,” Coalition “republished” the names and pictures “on a website it had
created, watchthewatchers.net.”&nbsp;
(Coaltion’s Anti-SLAPP Motion, p. 2.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">“In September 2023, over 800
anonymous individuals filed the present pair of damages actions.”&nbsp; (Id. at p. 3.)&nbsp; “[P]laintiffs claim they are current and
retired LAPD officers whose identities had been secret until the City made them
public.”&nbsp; (Ibid.)<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">In January 2024, City filed a
cross-complaint against Camacho and Coalition for equitable indemnity and
contribution.<o:p></o:p></p>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">On February 29, 2024, Camacho and
Coalition moved under the anti-SLAPP statute to strike City’s cross-claims.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify">On March 22, 2024, the Court
heard the motions but ended up continuing the hearing.<o:p></o:p></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal">Here, Plaintiffs move to seal a Confidential Matrix, which
contains each Plaintiff’s first and last names and other personal information.<o:p></o:p></p>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><b>LAW<o:p></o:p></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify"><b><i>Sealing<o:p></o:p></i></b></p>

<p class="MsoNormal" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">The court may order that a record be filed under seal only if
it expressly finds facts that establish: <o:p></o:p></p>

<p class="MsoNormal" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoListParagraphCxSpFirst" style="margin-top:0in;margin-right:.5in;
margin-bottom:0in;margin-left:.75in;margin-bottom:.0001pt;mso-add-space:auto;
text-align:justify;text-indent:-.25in;mso-list:l0 level1 lfo1"><!--[if !supportLists]-->(1)<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;" class="fontChange">&nbsp;&nbsp;
</span><!--[endif]-->There exists an
overriding interest that overcomes the right of public access to the record;<o:p></o:p></p>

<p class="MsoListParagraphCxSpMiddle" style="margin-top:0in;margin-right:.5in;
margin-bottom:0in;margin-left:.75in;margin-bottom:.0001pt;mso-add-space:auto;
text-align:justify">&nbsp;<o:p></o:p></p>

<p class="MsoListParagraphCxSpLast" style="margin-top:0in;margin-right:.5in;
margin-bottom:0in;margin-left:.75in;margin-bottom:.0001pt;mso-add-space:auto;
text-align:justify;text-indent:-.25in;mso-list:l0 level1 lfo1"><!--[if !supportLists]-->(2)<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;" class="fontChange">&nbsp;&nbsp;
</span><!--[endif]-->The overriding
interest supports sealing the record; <o:p></o:p></p>

<p class="MsoNormal" style="margin-right:.5in;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoListParagraph" style="margin-top:0in;margin-right:.5in;margin-bottom:
0in;margin-left:.75in;margin-bottom:.0001pt;mso-add-space:auto;text-align:justify;
text-indent:-.25in;mso-list:l0 level1 lfo1"><!--[if !supportLists]-->(3)<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;" class="fontChange">&nbsp;&nbsp;
</span><!--[endif]-->A substantial
probability exists that the overriding interest will be prejudiced if the
record is not sealed; <o:p></o:p></p>

<p class="MsoNormal" style="margin-right:.5in;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoListParagraph" style="margin-top:0in;margin-right:.5in;margin-bottom:
0in;margin-left:.75in;margin-bottom:.0001pt;mso-add-space:auto;text-align:justify;
text-indent:-.25in;mso-list:l0 level1 lfo1"><!--[if !supportLists]-->(4)<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;" class="fontChange">&nbsp;&nbsp;
</span><!--[endif]-->The proposed sealing
is narrowly tailored; and <o:p></o:p></p>

<p class="MsoNormal" style="margin-right:.5in;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoListParagraph" style="margin-top:0in;margin-right:.5in;margin-bottom:
0in;margin-left:.75in;margin-bottom:.0001pt;mso-add-space:auto;text-align:justify;
text-indent:-.25in;mso-list:l0 level1 lfo1"><!--[if !supportLists]-->(5)<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;" class="fontChange">&nbsp;&nbsp;
</span><!--[endif]-->No less restrictive
means exist to achieve the overriding interest.<o:p></o:p></p>

<p class="MsoNormal"><b>&nbsp;</b></p>

<p class="MsoNormal" style="text-align:justify">(Cal. Rules of Court, rule
2.550(d).) “These findings embody <em><span style="color: rgb(61, 61, 61); border: 1pt none windowtext; padding: 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">constitutional</span></em><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;requirements for a request to seal court records,
protecting the First Amendment right of public access to civil trials.&nbsp; (</span><span style="color:#3D3D3D" class="fontChange">Edmon
&amp; Karnow, Cal. Practice Guide: Civ. Procedure Before Trial (The Rutter
Group June 2023 Update) ¶ 9:418, emphasis in original.)<span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;<o:p></o:p></span></span></p>

<p class="MsoNormal" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
parties’ agreement to seal documents is not enough to support a motion to
seal.&nbsp; (Id. at ¶ 9:417.1 [“Parties
sometimes operate under an informal arrangement pursuant to which documents are
‘deemed filed under seal’ unless an objection is made. Such an arrangement ‘is
entirely inconsistent with the mandatory requirements of rules 2.550 and 2.551
and the constitutional values informing those requirements.’”].)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">“Only
the specific words of documents that constitute the sensitive material should
be sealed; generally, it is not permissible to seal the entire document.”&nbsp; (Id. at ¶ 9:418.5.)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><b><i><span style="color:#3D3D3D" class="fontChange">Pseudonyms<o:p></o:p></span></i></b></p>

<p class="MsoNormal" style="text-align:justify"><b><i><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></i></b></p>

<p class="MsoNormal" style="text-align:justify"><strong><span style="color: rgb(61, 61, 61); border: 1pt none windowtext; padding: 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“F</span></strong><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">iling
a complaint as a ‘Doe’ impairs the public’s right of access to court records [citations].&nbsp; It also violates the statutory requirement
that a complaint include ‘names of all the parties’ [citation]. &nbsp;Therefore, plaintiffs are not permitted to use
fictitious names (e.g., ‘John Doe’ or ‘Jane Doe’) absent ‘exceptional
circumstances.’&nbsp; [Citations.]”&nbsp; (Id. at ¶ 2:136.5.)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“</span><span style="color:#3D3D3D" class="fontChange">A court may permit [a] plaintiff
to proceed under a fictitious name when&nbsp;</span><em><span style="mso-fareast-font-family:
&quot;Times New Roman&quot;;mso-fareast-theme-font:major-fareast;color:#3D3D3D;
border:none windowtext 1.0pt;mso-border-alt:none windowtext 0in;padding:0in" class="fontChange">exceptional
circumstances</span></em><span style="color:#3D3D3D" class="fontChange">&nbsp;justify protecting [the]
plaintiff's true identity[.]”&nbsp; (Id. at ¶
2:136.6, emphasis in original.)&nbsp; Examples
of exceptional circumstances include:<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">* “matters
of a highly sensitive and personal nature (e.g., prior criminal history,
HIV-positive status, victim of sexual assault) [citation]” (ibid.); or<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">* “a
real danger of physical or mental harm to plaintiff or others” (ibid.); or<span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange"><o:p></o:p></span></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">* “</span><span style="color:#3D3D3D" class="fontChange">where the injury sought
to be avoided by the complaint (e.g., invasion of plaintiff’s privacy) would be
incurred by disclosure of plaintiff’s identity. [Citation.]”&nbsp; (Ibid.)<span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange"><o:p></o:p></span></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“The test for whether a party can be permitted to use a pseudonym
has also been termed the ‘overriding interest test’ – the same used for sealing
requests[.]”&nbsp; (Ibid.).&nbsp; “A party’s request for anonymity should be
granted only if the court finds that an overriding interest will likely be
prejudiced without use of a pseudonym, and that it is not feasible to protect
the interest with less impact on the constitutional right of access.”&nbsp; (<u>Department of Fair Employment and Housing
v. Superior Court</u> (2022) 82 Cal.App.5<sup>th</sup> 105, 111 (“<u>DFEH</u>”).)&nbsp; <o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“In deciding the issue the court must bear in mind the
critical importance of the public’s right to access judicial proceedings.
Outside of cases where anonymity is expressly permitted by
statute,&nbsp;litigating by pseudonym should occur ‘only in the rarest of
circumstances.’”&nbsp; (Id. at 111-112.)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><b><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">DISCUSSION<o:p></o:p></span></b></p>

<p class="MsoNormal" style="text-align:justify"><b><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></b></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Camacho and Coalition contend the motion to seal should be
denied or the hearing should be continued because, first, Plaintiffs need to
file a motion to use pseudonyms.&nbsp; (See
Joint Opposition to Motion to Seal, pp. 3-5.)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Plaintiffs claim the sealing and pseudonyms issues involve
the same standard and can be heard at the same time.&nbsp; They contend the motion to seal subsumes the
pseudonyms issue.&nbsp; (See Reply to Motion
to Seal, p. 7.)&nbsp; <o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“Procedurally, because a hearing is required, a party who
wants to proceed anonymously will file the initial complaint or petition&nbsp;</span><em><span style="color: rgb(61, 61, 61); border: 1pt none windowtext; padding: 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">conditionally</span></em><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;under a pseudonym and then move for an order granting
permission to proceed that way.”&nbsp; (<u>DFEH</u>,
supra, 82 Cal.App.5<sup>th</sup> at 111 n.1, emphasis in original.)&nbsp; “If the request is granted, the initial
pleading can remain. &nbsp;If pseudonym use is
denied, the pleading must be amended to state the party's true name.”&nbsp; (Ibid.)<o:p></o:p></span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Given these rules, the Court finds that the hearing should be
continued.&nbsp; Plaintiffs filed the lead
case in early September 2023.&nbsp; Two
related cases have been filed since then.&nbsp;
In all three complaints, Plaintiffs use pseudonyms in place of their
real names, but they have never moved for an order to “proceed
pseudonymously.”&nbsp; (Joint Opposition to
Motion to Seal, p. 5.)&nbsp; Even the moving
brief for the motion to seal fails to address the pseudonyms issue (Plaintiffs
discuss it for the first time in the reply brief).&nbsp; (See Motion to Seal, pp. 12-14; see also
Reply to Motion to Seal, p. 7.)&nbsp; As a
result, the motion to seal is out of procedural order and puts the cart before
the horse.&nbsp; Continuing the hearing to
give Plaintiffs a chance to file an appropriate pseudonyms motion will cure
this procedural defect.<o:p></o:p></span></p>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p><br><span name="wp"><hr><p class="fontChange"><b> Case Number: </b> 23STCV00719&nbsp;&nbsp;&nbsp;<b> Hearing Date: </b>  June 18, 2024&nbsp;&nbsp;&nbsp;<b> Dept: </b> 11</p><p class="fontChange"> </p><p class="MsoNormal fontChange" align="center" style="text-align:center;mso-pagination:none;
tab-stops:center 3.25in;mso-layout-grid-align:none;text-autospace:none"><b><span style="font-size:14.0pt" class="fontChange">Case Number: </span></b><b style="mso-bidi-font-weight:
normal"><span style="font-size:14.0pt" class="fontChange">23STCV00719<span style="mso-bidi-font-weight:
bold" class="fontChange"><o:p></o:p></span></span></b></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center;mso-pagination:none;
mso-layout-grid-align:none;text-autospace:none"><b><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></b></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center;mso-pagination:none;
mso-layout-grid-align:none;text-autospace:none"><u><span style="font-size:14.0pt" class="fontChange">People
of the State of California vs Eli Lilly and Company, et al<o:p></o:p></span></u></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center"><a name="_Hlk169448188"><span style="font-size:14.0pt;mso-bidi-font-weight:bold" class="fontChange">Tentative
Ruling Re: Manufacturer Defendants’ Demurrer<o:p></o:p></span></a></p>

<span style="mso-bookmark:_Hlk169448188"></span>

<p class="MsoNormal fontChange" align="center" style="text-align:center;mso-pagination:none;
mso-layout-grid-align:none;text-autospace:none"><span style="font-size:14.0pt" class="fontChange">(CCP
§632; CRC 3.1590)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center;mso-pagination:none;
mso-layout-grid-align:none;text-autospace:none"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center;mso-pagination:none;
mso-layout-grid-align:none;text-autospace:none"><span style="font-size:14.0pt" class="fontChange">Dated:<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>June 18, 2024<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-pagination:none;tab-stops:192.1pt;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(1)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>This decision
is the Court’s Tentative Ruling regarding the Manufacturer Defendants’ Demurrer
to the Original Complaint.<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(2)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>Plaintiff, the
People of the State of California, by and through Rob Bonta, Attorney General
of the State of California, filed a complaint (the “Complaint”) against three
manufacturers (Eli Lilly, Novo Nordisk, and Sanofi) (the "Manufacturer
Defendants") and three pharmacy companies (CVS Caremark, Express Scripts
and OptumRX (the "PBM Defendants" or "PBMs") and a holding
company (CVS Health Corporation) alleging a price gouging conspiracy to
artificially inflate the price of insulin. The Complaint contains two causes of
action: (1) violation of Business and Professions Code section 17200, the
Unfair Competition Law (“UCL”); and (2) unjust enrichment.<b><o:p></o:p></b></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(3)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>The California Attorney General alleges that Manufacturer
Defendants have significantly increased the list prices of insulin over the
last two decades. These increases allegedly have far outpaced inflation and are
not justified by improvements to the drug or manufacturing costs.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Plaintiff alleges that the insulin market is
deceptive because insulin Manufacturer Defendants provide significant secret
rebates to pharmacy benefit managers (PBMs). These rebates are reportedly as
high as 70% of the list price of insulin.</span><o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(4)<span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp; </span>The Complaint alleges that while the public
is aware of general insulin rebating practices, the actual terms of the rebates
are unknown to the public. The Complaint alleges that PBMs create obstacles
that prevent payers from knowing the amount of rebates PBMs are securing and
from being able to audit the rebate information</span>.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(5)</span><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-size:14.0pt" class="fontChange">The
Complaint further alleges the Manufacturer Defendants made misleading
statements that support their efforts to profit from their pricing conduct. For
example, the manufacturers claim that the net price of insulin was decreasing,
but these statements obscure the allegation that list price competition has
been undercut, resulting in alleged larger out-of-pocket costs for many
consumers.<span style="color:red" class="fontChange"><o:p></o:p></span></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(6)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>Plaintiff alleges that PBMs act as intermediaries in the
pharmaceutical payment system. They negotiate with manufacturers on behalf of insurers
to determine which drugs are included in formularies (lists of covered drugs)
and at what cost. The Attorney General alleges that the PBM market is dominated
by three entities – CVS Caremark, Express Scripts, and OptumRx – giving them
significant negotiating power. Allegedly, PBMs leverage their market power to
secure substantial rebates from manufacturers in exchange for favorable
formulary placement for their drugs. <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(7)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>The Attorney General contends the system creates an incentive
for manufacturers to increase list prices to offset the rebates paid to PBMs.</span>
<span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;</span>The
Complaint alleges that insulin affordability is a significant concern,
particularly for uninsured or underinsured individuals who are exposed to the
full list price without the benefit of rebates. The California Attorney
General's lawsuit alleges that the current pricing practices in the insulin
market harm consumers by artificially inflating prices.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(8)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>The Manufacturer Defendants argue that a safe harbor protects
the alleged conduct because federal and state law expressly permit or require
the conduct in question. Specifically, the Manufacturer Defendants argue that
federal law contemplates and sometimes requires rebates from manufacturers and
the publication of list prices that do not include rebates. The Defendants
argue that state law allows manufacturers to make voluntary pricing decisions,
including price increases, and expresses an intent to permit PBMs to negotiate
discounts and rebates.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(9)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>The Manufacturer Defendants </span><span style="font-size:16.0pt" class="fontChange">argue
</span><span style="font-size:14.0pt" class="fontChange">the Attorney General’s claims are barred
by the statute of limitations, as the complaint and judicially noticeable
materials demonstrate the Attorney General’s awareness of the pricing system in
question years before the statute of limitations cutoff.</span><span style="font-size:16.0pt" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(10)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp; </span>The issues
before the Court in the demurrer are the following:<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(a)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>Whether
the applicable statute of limitations bars the alleged causes of action?<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(b)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>Whether
any <a name="_Hlk169446395">equitable exceptions toll any applicable statute of
limitations defense at the pleading stage</a>?<br style="mso-special-character:
line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(c)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Whether
the <a name="_Hlk169447623">UCL's safe harbor provision protects the
Manufacturer Defendants from liability as a matter of law</a>?<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(d)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>Whether
price inflation as alleged in the Complaint constitutes an unfair business
practice under the UCL?<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(e)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Whether
allegations of "secret rebates" and inflated list prices as alleged
in the Complaint constitute unfair conduct under the UCL?<br style="mso-special-character:
line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(f)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Whether
the Complaint sufficiently alleges reliance on misleading statements from the Manufacturer
Defendants to state a claim under the UCL?<br style="mso-special-character:
line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>(g)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>Whether
the Complaint states a claim for unjust enrichment?<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="page-break-after:avoid"><b><span style="font-size:
14.0pt" class="fontChange">I.<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>RELEVANT FACTUAL AND
PROCEDURAL BACKGROUND<o:p></o:p></span></b></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center;page-break-after:avoid;
tab-stops:.25in;mso-layout-grid-align:none;text-autospace:none"><b><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></b></p>

<p class="MsoListParagraphCxSpFirst fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;text-indent:-.25in;line-height:normal;mso-pagination:none;page-break-after:
avoid;mso-list:l25 level1 lfo17;tab-stops:.25in;mso-layout-grid-align:none;
text-autospace:none"><!--[if !supportLists]--><b><i style="mso-bidi-font-style:
normal"><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">A.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp; </span></span></span></i></b><!--[endif]--><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Complaint<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--></span></i></b><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif" class="fontChange"><o:p></o:p></span></i></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">(11)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp; </span>At its core, this is a price-gouging
case.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Complaint alleges:<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“1. Millions of
Californians suffer from diabetes. For many diagnosed with this condition,
access to insulin to regulate their blood sugar levels is a matter of life and
death. Yet, the excessive price of insulin undermines their access to this
century-old, life-sustaining drug. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“2.
Inexplicably, list prices for insulin have risen several hundred percent over
the last two decades. Today, California diabetics who require insulin to
survive and who are exposed to insulin’s full price, such as uninsured
consumers and consumers with high deductible insurance plans, pay thousands of
dollars per year for insulin. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“3. The
excessive price of insulin disproportionately harms low-income communities who
must choose between paying for insulin or everyday necessities, such as housing
and food. To stretch dollars and insulin supplies, many Californians have
turned to the dangerous practice of rationing insulin or skipping doses despite
the severe risks of loss of sight, limbs, or death. These harms are further
compounded for Black, Hispanic, and low-income communities in California as
they are more likely to be diagnosed with diabetes and to be uninsured or
underinsured. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“4. The United
States insulin market is an oligopoly. The defendants include three insulin
manufacturers (Manufacturer Defendants)—Eli Lilly, Novo Nordisk, and Sanofi—who
make nearly all of the insulin sold in the United States. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“5. Also named
as defendants are the three pharmacy benefit managers (PBM Defendants) that
dominate the PBM market—CVS Caremark, Express Scripts, and OptumRx. PBMs are
entities that administer prescription drug programs, which are a part of the
essential benefits that health insurance plans must cover. One aspect of the
PBM’s role is determining the prescription drugs a given health insurance plan
covers (known as a formulary). Another aspect of the PBM’s role is negotiating
confidential contracts that provide for post-sale discounts (rebates) that a
drug manufacturer will provide to the PBM, not the consumer, if a consumer
fills a prescription for the manufacturer’s drug.<o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“6. The conduct
at issue in this Complaint has two main components. First, the Manufacturer
Defendants aggressively raise the list price of insulin in lockstep with each
other to artificial levels. The inflated and artificial insulin price increases
have significantly exceeded inflation and are not justified by advances in the
efficacy of the drugs or the cost of manufacturing. Insulin costs less than $10
a month to manufacture and its development costs have long been recouped. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“7. Second, PBM
Defendants obtain significant secret rebates, which are a percentage of the
inflated and artificial list price, from the Manufacturer Defendants in
exchange for favorable placement on the PBM’s standard formularies. This
rebating strategy incentivizes the Manufacturer Defendants to raise their list
prices high and higher. The result is that the PBM Defendants’ standard
formularies promote the Manufacturer Defendants’ high list-price insulin
products over lower list-price insulins in California and nationwide. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“8. The
Manufacturer Defendants participate in this conduct because being listed on a
PBM Defendant’s standard national formulary is a financial boon. Like the
insulin market in the United States, the PBM market in the United States is
also oligopolistic. The PBM Defendants capture over 75% of the market. Being
included on a PBM Defendant’s standard national formulary drives higher sales
volume and revenue. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“9. The PBM
Defendants participate in this conduct because their revenue is related to the
size of the secret rebates they negotiate. Larger list prices support larger
secret rebates because rebates are calculated as a percentage of the list
price. Also, the PBM Defendants have a perverse incentive for ever-growing list
prices. The PBM Defendants claim they can extract higher rebates due to their
market power. If drug list prices grow, demand for their rebate negotiation
services increases. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“10. In
addition to participating in conduct raising list prices, Defendants made
misrepresentations about insulin prices and their actions in relation to
insulin prices. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“11. By
increasing the list price of insulin, Defendants harm diabetic Californians who
require insulin. They are exposed to insulin’s unaffordable list price and do
not benefit from the secret rebates.<o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;mso-pagination:none;page-break-after:avoid;tab-stops:.25in;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">“12. Defendants
are liable for the harms caused by their conduct under theories that protect
consumers and competition. Defendants’ conduct harms diabetic Californians who
require insulin without a sufficient counterweighing benefit to them.
Additionally, Defendants’ conduct runs against several principles of honesty
and fair dealing with competitors and consumers, including (a) prohibition on
false discounts and prohibition on misleading statements made in furtherance of
the false discounts, (b) prohibition on members of oligopolies abusing their
market power in order to raise their product prices to unconscionable levels,
(c) prohibition on middlemen in product distribution chains with large market
share leveraging their market power to obtain secret rebates from manufacturers
that are not granted to their smaller middlemen competitors, and (d)
prohibition on members of oligopolies adopting practices that facilitate the
coordination of price increases. <o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;line-height:normal;mso-pagination:none;page-break-after:avoid;tab-stops:
.25in;mso-layout-grid-align:none;text-autospace:none"><span style="font-size:
14.0pt;font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-style:italic" class="fontChange">(Complaint,
¶¶ 1-12.)”<o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;line-height:normal;mso-pagination:none;page-break-after:avoid;tab-stops:
.25in;mso-layout-grid-align:none;text-autospace:none"><i style="mso-bidi-font-style:
normal"><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif" class="fontChange"><o:p>&nbsp;</o:p></span></i></p>

<p class="MsoListParagraphCxSpLast fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;text-indent:-.25in;line-height:normal;mso-pagination:none;page-break-after:
avoid;mso-list:l25 level1 lfo17;tab-stops:.25in;mso-layout-grid-align:none;
text-autospace:none"><!--[if !supportLists]--><b><i style="mso-bidi-font-style:
normal"><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">B.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp; </span></span></span></i></b><!--[endif]--><b><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;font-family:
&quot;Times New Roman&quot;,serif" class="fontChange">Allegations Regarding Insulin Pricing Dynamics<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt;mso-pagination:none;page-break-after:
avoid;tab-stops:.25in;mso-layout-grid-align:none;text-autospace:none"><span style="font-size:14.0pt;mso-bidi-font-style:italic" class="fontChange"><span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(12)</span><span style="font-size:16.0pt;mso-bidi-font-style:italic" class="fontChange"><span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp; </span></span><span style="font-size:14.0pt" class="fontChange">Manufacturer Defendants are
pharmaceutical companies that research, develop, manufacture, and sell
prescription drugs, including analog insulin. Compl. ¶¶ 77, 83-86, 90, 191. Manufacturer
Defendants do not sell insulin directly to patients. Id. ¶¶ 101, 103. Rather,
they sell their medications to wholesalers at a publicly reported list price
known as the Wholesale Acquisition Cost (“WAC”). Id. ¶¶ 101, 103, 104. Federal
law sets forth how manufacturers must calculate the WAC price. According to
Title 42 of the United States Code, which is excerpted in the complaint at
paragraph 104, “[t]he term ‘wholesale acquisition cost’ means, with respect to
a drug or biological, the manufacturer’s list price for the drug or biological
to wholesalers or direct purchasers in the United States, not including prompt
pay or other discounts, rebates or reductions in price . . . .” 42 U.S.C. §
1395w-3a(c)(6)(B) (emphasis added). Once set, these “undiscounted list
price[s]” are published in publicly available “databases administered by
third-party entities.” Compl. ¶ 104. After purchasing insulin from the Manufacturer
Defendants at the WAC price, wholesalers resell the medications to pharmacies,
which in turn sell them to consumers. Id. ¶¶ 101, 103, 105-06. </span><o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(13)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp; </span>The payment system for prescription
medications is complex. The price a consumer ultimately pays for a given
medication depends on a variety of factors, such as the terms of the consumer’s
health plan, the consumer’s insurance status, and negotiations between PBMs and
pharmacies. Id. ¶¶ 106, 109-10, 112. This price may also be impacted by
different affordability programs that each Manufacturer Defendants offers. Id.
¶¶ 190, 193. <o:p></o:p></span></p>

<p class="MsoNormal fontChange"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(14)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp; </span>Although PBMs are not involved in the
physical distribution of pharmaceutical drugs, they are at the center of the
pharmaceutical payment chain. Id. ¶¶ 101, 113, 118, 123-24. PBMs contract with
insurers and other payors to provide prescription drug benefits. Id. ¶ 113. An
important part of these services is the creation of nationwide lists known as
formularies, which dictate the prescription drugs that insurance plans will
cover and the terms of that coverage (including the cost-sharing terms
governing what members pay). Id. ¶¶ 5, 119-22. Maintaining access to these
formularies is essential for Manufacturer Defendants. Because insured consumers
are far more likely to purchase a drug if it is covered by insurance,
“exclusion from a [PBM’s] standard formulary can significantly impact”
patients’ access to Manufacturers’ medicines. Id. ¶ 122. Accordingly, Manufacturer
Defendants compete for formulary access to ensure that patients have affordable
access to their insulins. Id. ¶¶ 151-55, 158. <o:p></o:p></span></p>

<p class="MsoNormal fontChange"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(15)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp; </span>The importance of formularies gives PBMs
enormous leverage over drug prices. Id. ¶¶ 8- 9, 114-27, 151-62, 165. Indeed,
the complaint alleges that the three PBM defendants represent over 250 million
covered lives in the U.S. (as of 2019), reflecting around 74% of the U.S.
population. Id. ¶ 116. PBMs use that leverage to negotiate discounts and
rebates from manufacturers. Id. ¶¶ 5, 8, 9, 122. Because Manufacturer
Defendants face a “risk of backlash from PBMs” if they refuse the PBMs’ rebate
demands, id. ¶¶ 148-50, 152-54, 165, 175, PBMs have been able to “extract
higher rebates due to their market power.” Id. ¶¶ 5, 8, 9, 122; see also Ex. 1,
Cal. Sen. Comm. on Bus., Prof. &amp; Econ. Dev., Background Paper (2017), at 3,
bit.ly/3LNEUTL (“PBMs generally develop a standard, national formulary” that
“incentivizes drug manufacturers to negotiate with PBMs to attain preferred
status”).<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Complaint alleges that the
Manufacturer Defendants were forced to increase the list prices of insulins in
order to pay the “ever growing rebates” demanded by the PBMs “in exchange for
formulary access.” Compl. ¶¶ 151, 165.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(16)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp; </span>The Complaint alleges Defendants engaged, and
continue to engage, in unlawful, unfair, and fraudulent acts and practices in
violation of the UCL, Business and Professions Code § 17200, by artificially
raising the price of analog insulin (insulin). In addition to asserting a claim
under the UCL, the Attorney General asserts a claim for unjust enrichment. <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(17)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp; </span>The Attorney General alleges Manufacturer
Defendants conspired to repeatedly raise the list price of insulin, in
lockstep, to artificially high levels as facilitated by the rebate practices of
the PBMs described below. (Compl., ¶¶ 6-9, 129-167.) For example, the
Manufacturer Defendants raised their insulin prices by over 600% in the past
twenty years. (Id. at ¶ 129.) The Manufacturer Defendants publish these
inflated prices in databases administered by third-party entities. (Id. at ¶
104.) <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange">(18)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp; </span>The Complaint alleges the Manufacturer Defendants
provided substantial secret rebates— eventually representing over 70% of the
list price in some instances—to the PBMs. (Id. at ¶¶ 7, 147-158.) The Attorney
General alleges the Manufacturer Defendants provide secret rebate payments to
the PBMs because access to the PBMs’ market share from off-the-shelf, standard
formularies they provide to, e.g., their commercial health insurance clients drive
higher sales volume and revenue for the Manufacturer Defendants. (Id. at ¶¶ 8,
119-122.) <o:p></o:p></span></p>

<p class="MsoNormal fontChange"><a name="_Hlk169366156"><span style="font-size:14.0pt" class="fontChange">The Complaint
seeks restitution, civil penalties, injunctive relief, and disgorgement, among
other relief.<o:p></o:p></span></a></p>

<span style="mso-bookmark:_Hlk169366156"></span>

<p class="MsoNormal fontChange"><o:p>&nbsp;</o:p></p>

<p class="MsoListParagraph fontChange" style="text-indent:-.25in;mso-pagination:none;
mso-list:l25 level1 lfo17;mso-layout-grid-align:none;text-autospace:none"><!--[if !supportLists]--><b><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;line-height:
107%;font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">C.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;line-height:
107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Manufacturer Defendants’
Arguments Regarding the Statute of Limitations<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.25in"><span style="font-size:14.0pt" class="fontChange">(19)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Manufacturer Defendants argue that the lawsuit is barred
by the statute of limitations. The manufacturers assert that the Attorney
General’s claims are subject to either a three or four-year statute of
limitations. This means that the Attorney General generally must file his
lawsuit within three or four years of the date the alleged wrongdoing occurred.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.25in"><span style="font-size:14.0pt" class="fontChange">(20)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Both the UCL and unjust enrichment claims center on the idea
that insulin prices were “inflated”—and consumers were thereby harmed—because
the list prices that the Manufacturer Defendants charge wholesalers for
diabetes medications did not reflect the rebates that Manufacturers later pay
to the PBM Defendants after consumers fill prescriptions. Compl. ¶¶ 149-51,
155, 173, 207, 230. Manufacturer Defendants argue Plaintiff knew that the
Manufacturer Defendants provide rebates to PBMs to obtain formulary access for
their insulin products, and that federal law requires that the Manufacturers’
list prices exclude those rebates, for at least six years before filing their
complaint.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.25in"><span style="font-size:14.0pt" class="fontChange">(21)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The four-year limit applies to claims made under the UCL, as
stated in the California Business and Professions Code. (Cal. Bus. &amp; Prof.
Code. § 17208.) The statute of limitations for unjust enrichment claims depends
on the underlying wrong. When the underlying wrong is fraud, a three-year
statute of limitations applies. Because the complaint was filed on January 12,
2023, the People need to demonstrate that the UCL claim and the unjust
enrichment claim accrued no earlier than January 12, 2019, and January 12,
2020, respectively.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.25in"><span style="font-size:14.0pt" class="fontChange">(22)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer Defendants point to several events to support
their claim that the statute of limitations bars the Attorney General’s action.
The Manufacturer Defendants argue that the Attorney General’s claims are
untimely because the Attorney General knew about the alleged misconduct at
least six years before filing the Complaint. They base this argument on the
fact that the California Attorney General initiated a civil investigation into
insulin pricing nearly six years prior to filing the Complaint. Furthermore,
the Minnesota Attorney General conducted a simultaneous investigation and filed
a lawsuit in 2018 based on similar allegations. The Manufacturer Defendants
also highlight that other lawsuits raising overlapping claims and making
similar factual allegations were filed as early as February 2017.<b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><o:p></o:p></i></b></span></p>

<p class="MsoListParagraph fontChange" style="text-indent:-.25in;mso-pagination:none;
mso-list:l25 level1 lfo17;mso-layout-grid-align:none;text-autospace:none"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;mso-bidi-font-size:16.0pt;line-height:107%;font-family:
&quot;Times New Roman&quot;,serif;mso-fareast-font-family:&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">D.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b><i><span style="font-size:14.0pt;
line-height:107%;font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:
&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:none" class="fontChange">The </span></i></b><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">Manufacturer
Defendants’ Arguments Regarding the </span></i></b><b><i><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none" class="fontChange">UCL Claim</span></i></b><b><i><span style="font-size:16.0pt;line-height:
107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange"><o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.25in"><span style="font-size:14.0pt" class="fontChange">(23)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Manufacturer Defendants assert that the Plaintiff's UCL
claim, even if not time-barred, is insufficiently substantiated.</span> <span style="font-size:14.0pt" class="fontChange">They argue that their conduct, including rebate
payments and list price reporting, is explicitly authorized by both federal and
state law, thereby falling under the UCL's safe harbor provisions of the UCL.
The Manufacturer Defendants highlight that federal law mandates reporting
requirements without factoring in rebates. They contend that California law
explicitly allows manufacturers to determine drug prices, including increases,
and permits the PBM's to negotiate discounts in rebates. They contend the Attorney
General's argument regarding "artificially inflated" list prices due
to not reflecting rebates cannot satisfy the unfair prong of the UCL considering
the safe harbor provisions.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.25in"><span style="font-size:14.0pt" class="fontChange">(24)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Manufacturer Defendants contend that the Attorney General
fails to demonstrate any specific misrepresentations connected to insulin list
prices or a rebate within the Complaint. They assert the Complaint lacks
allegations of a duty to disclose that would support a fraudulent omission
claim. The Complaint lacks any factual allegations of misrepresentations by the
Manufacturer Defendants regarding the existence, amount, or purpose of rebates
offered to PBMs. They contend there is no "secrecy" or collusion
surrounding pharmaceutical rebates, as Manufacturer Defendants have openly disclosed
the payment of rebates, acknowledging their increasing prevalence overtime. The
Attorney General's reliance on the omissions theory is flawed, as there was no
duty for Manufacturer Defendants to disclose the existence, amount, or purpose
of rebates.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Thus, they contend the
fraudulent prong of the UCL is unsubstantiated.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.25in"><span style="font-size:14.0pt" class="fontChange">(25)<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Attorney General argues that the Manufacturer Defendants
violated the UCL's unlawful prong by violating the California Consumer Legal
Remedies Act (CLRA). They claim that the Manufacturer Defendants made false and
misleading statements about price reductions for insulin, specifically citing
CLRA § 1770(a)(13).</span> <o:p></o:p></p>

<p class="MsoNormal fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-indent:.25in">(26)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-size:14.0pt" class="fontChange">The Manufacturer Defendants contend that the Attorney
General's assertion of a CLRA violation is unfounded because the complaint
lacks any factual basis for misleading statements about insulin prices and
rebates. They emphasize that: (1) the Complaint itself confirms that Manufacturer
Defendants have accurately disclosed their justifiable increases to insulin
list prices; and (2) the Complaint reliance on CLRA subsection (a)(13), which
prohibits false statements regarding price reductions, is misplaced because the
complaint lacks such allegations.<o:p></o:p></span></p>

<p class="MsoListParagraph fontChange" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:
auto;mso-add-space:auto;text-indent:.25in;mso-pagination:none;mso-list:l25 level1 lfo17;
mso-layout-grid-align:none;text-autospace:none"><!--[if !supportLists]--><b><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">E.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp; </span></span></span></b><!--[endif]--><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The
Manufacturer Defendants’ Arguments Regarding Unjust Enrichment</span></i></b><span style="font-size:14.0pt;line-height:107%" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:17.25pt;mso-pagination:none;mso-layout-grid-align:
none;text-autospace:none"><span style="font-size:14.0pt" class="fontChange">(27)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Manufacturer Defendants argue
against the Complaint's unjust enrichment claim, deeming it redundant alongside
the UCL claim. They highlight that unjust enrichment does not constitute an
independent cause of action under California law. They contend the claim is
rooted in the same conduct as the UCL claim, rendering it unnecessary. They
further allege the Attorney General cannot demonstrate a superior equitable
right to any alleged benefits, a requirement for establishing an unjust
enrichment claim. Thus, the Manufacturer Defendants argue that dispute falls
under the purview of existing contracts, which supersedes a quasi-contract
remedy.<br>
<br>
<b>II.<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>DISCUSSION<o:p></o:p></b></span></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center;mso-pagination:none;
mso-layout-grid-align:none;text-autospace:none"><b><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></b></p>

<p class="MsoListParagraph fontChange" style="margin-bottom:10.0pt;mso-add-space:auto;
text-indent:-18.75pt;line-height:normal;mso-list:l14 level1 lfo15"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:
&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">A.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;font-family:
&quot;Times New Roman&quot;,serif" class="fontChange">Standard of Review<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="text-indent:17.25pt"><span style="font-size:14.0pt" class="fontChange">(28)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>When considering demurrers, courts read
the allegations liberally and in context, and “treat the demurrer as admitting
all material facts properly pleaded, but not contentions, deductions or
conclusions of fact or law.” (<i>Serrano v. Priest</i> (1971) 5 Cal.3d 584,
591.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“A demurrer tests the pleadings
alone and not the evidence or other extrinsic matters. Therefore, it lies only
where the defects appear on the face of the pleading or are judicially noticed.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Hahn v. Mirda</i> (2007) 147 Cal.App.4th
740, 747.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>It is error “to sustain a
demurrer without leave to amend if the plaintiff shows there is a reasonable
possibility any defect identified by the defendant can be cured by amendment.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Aubry v. Tri-City Hospital Dist</i>.
(1992) 2 Cal.4th 962, 967.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:17.25pt"><b style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span><o:p></o:p></span></i></b></p>

<p class="MsoListParagraph fontChange" style="margin-bottom:10.0pt;mso-add-space:auto;
text-indent:-18.75pt;line-height:normal;mso-list:l14 level1 lfo15"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:
&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">B.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;font-family:
&quot;Times New Roman&quot;,serif" class="fontChange">The Statute of Limitations Defense</span></i></b><span style="font-size:14.0pt" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><b><i><span style="font-size:14.0pt" class="fontChange">1.<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Request for Judicial Notice (“RJN”<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--></span></i></b><span style="font-size:14.0pt" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(29)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer
Defendants seek judicial notice of legislative records (exhibits 1, 2, 9, 10,
11, 12, and 13), news articles (exhibits 3, 4, 5, 6, 7, 8, 19, 21, 22, 23, 24,
25, 26, and 29), reports filed with the Securities and Exchange Commission
(“SEC”) (exhibits 14, 15, 16, 17, and 27), and court records (exhibits 18, 20,
and 28).<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:17.25pt"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(30)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Court finds that the RJN should be denied because the documents lack
authentication and verification.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See
Yaphe Decl., ¶¶ 1-30 [failing to establish personal knowledge and foundation].)
Even if the Court were inclined to grant the RJN, the Court could only grant it
in part.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Judicial notice would be
appropriate, at most, as to the existence of the legislative records, SEC
reports, and court records, not the truth of their contents.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Court would still need to deny the RJN as
to the news articles.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-indent:.5in"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;text-indent:.5in"><b><i><span style="font-size:14.0pt" class="fontChange">2.<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Applicable
Statutes of Limitations<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i><span style="font-size:
14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(31)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><a name="_Hlk169445934">A four-year limitations period applies to the UCL (see <span style="color:#3D3D3D;background:white" class="fontChange">Stern, Business and Professions Code
Section 17200 Practice (The Rutter Group March 2023 Update) </span><span style="color:#3D3D3D" class="fontChange">¶ 5:290), and either a three-year limitations period or a
four-year limitations period applies to unjust enrichment.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span></span></a><span style="color:#3D3D3D" class="fontChange">(See <i>Federal
Deposit Ins. Corp. v. Dintino</i> (2008) 167 Cal.App.4<sup>th</sup> 333, 347
[finding a three-year limitations period applicable to fraud-based unjust
enrichment]; see also Opposition, p. 33 [arguing that Code of Civil Procedure
section 343’s four-limitations period should apply because the People’s claim
is equity-based].)<o:p></o:p></span></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(32)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer Defendants contend the
demurrer should be sustained because both causes of action accrued more than
four years before the </span><span style="font-size:14.0pt" class="fontChange">Attorney General<span style="color:#3D3D3D" class="fontChange"> filed his complaint.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(See Demurrer, pp. 1-2, 9-11 [claiming Plaintiff knew about the alleged
misconduct at least six years before the filing date].)<o:p></o:p></span></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(33)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
</span><span style="font-size:14.0pt" class="fontChange">Attorney General<span style="color:#3D3D3D" class="fontChange">
claims the allegations satisfy equitable exceptions, namely, the last-overt-act
rule, the continuing-violation doctrine, and the continuous-accrual
doctrine.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Opposition, pp. 28-33.)
Manufacturer Defendants assert that the equitable exceptions do not apply.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Demurrer, pp. 11-14; see also Reply, pp.
1-5.) The Court disagrees with Manufacturer Defendants’ first point.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>To show accrual and the People’s purported
knowledge, Manufacturer Defendants cite the RJN exhibits.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See id. at pp. 4-9, 11.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>As noted above, the RJN is denied.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The exhibits cannot be used to meet the
Manufacturer Defendants’ burden.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></span></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;text-indent:.5in"><b><i><span style="font-size:14.0pt" class="fontChange">3.<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
“Last Overt Act” Doctrine</span></i></b><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(34)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
next issue is twofold.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Do the
allegations show untimeliness independent of the RJN exhibits?<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>If so, do the equitable exceptions apply?<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(35)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Court starts with the last-overt-act rule.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>The Rutter Guide describes it this way:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:12.0pt;margin-right:.8in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange">“A civil conspiracy is not a separate
cause of action. Rather, it is a ground for holding persons liable for a
tortious act committed by another: “The effect of charging . . . conspiratorial
conduct is to implicate all . . . who agree to the plan to commit the wrong as
well as those who actually carry it out.” [Citation.]<o:p></o:p></span></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange">The statute of limitations on an action
for conspiracy to defraud (or other intentional tort) does not begin to run
until the “last overt act” pursuant to the conspiracy has been completed … even
if this occurs more than 3 years after the fraud was discovered: “So long as a
person continues to commit wrongful acts in furtherance of a conspiracy to harm
another, he can neither claim unfair prejudice at the filing of a claim against
him nor disturbance of any justifiable repose built upon the passage of time.”
[Citations.]<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange">(Banke &amp; Segal, Cal. Practice Guide: Civ. Procedure Before
Trial Statutes of Limitations (The Rutter Group February 2024 Update) ¶ 4:1230
[quoting <i>Wyatt v. Union Mortgage Co.</i> (1979) 24 Cal.3d 773], emphasis in
original.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(36)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The </span><span style="font-size:14.0pt" class="fontChange">Attorney
General<span style="color:#3D3D3D" class="fontChange"> claims the rule governs because the Complaint
alleges an ongoing conspiracy and continuing overcharges.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Opposition, p. 29.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></span></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange">Manufacturer Defendants claim the Complaint fails to identify a
specific overcharge within the last four years, the People failed to exercise
reasonable diligence, and the Complaint does not allege a conspiracy.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Reply, pp. 2-4.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(37)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>On
one hand, the demurrer arguably should be overruled.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>While “the date of the commission of the last
overt act in pursuance of the conspiracy” typically must be alleged (<i>Wyatt</i>,
supra, 24 Cal.3d at 789; see also <i>Maheu v. CBS, Inc.</i> (1988) 201
Cal.App.3d 662, 673-674), there is no last overt act when the purported
overcharges are ongoing and/or new.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See
<i>People ex rel. Kennedy v. Beaumont Investment, Ltd.</i> (2003) 111
Cal.App.4th 102, 137 [“Each month's collection of excess rent constitutes an
overt act in furtherance of that conspiracy. [Citation.] Defendants were still
collecting unlawful rent right up through the trial of the <i>People ex rel.
Kennedy</i> case. Thus, when the trial court issued its statement of decision,
defendants had not yet committed the last overt act of their conspiracy and the
statute of limitations had not yet accrued.”]; see also, e.g., Complaint, ¶¶ 62
[alleging that the purported conspiracy “continues to the present”], 206
[alleging that “Defendants’ conduct has harmed, and is continuing to harm, the
People through insulin’s inflated and artificial list price”], 208 [alleging
that “uninsured patients have paid increasingly higher insulin prices for years
on end and continue to do so”], 228 [alleging that Defendants “continue to
engage in acts or practices that are unlawful, unfair, or fraudulent”].)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Moreover, the conspiracy allegations suffice
to meet the notice standard.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See, e.g,
Complaint, ¶¶ 4-9, 62, 133-143, 147-176.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>The efficient approach is to flesh out the facts of the alleged conspiracy
via discovery rather than to hold multiple demurrer rounds.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>These reasons support the Plaintiff’s
position.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(38)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Conversely,
the demurrer arguably should be sustained.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>In reviewing the Complaint, the Court did not see an explicit allegation
that identifies an explicit overcharge that occurred on a date within the last
four years.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>This reason supports
Manufacturer Defendants’ position.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp; </span>(39)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>On
balance, the Court favors sustaining the demurrer because the Attorney
General’s own chart undermines his position.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>The chart appears in paragraph 130 of the Complaint.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Attorney General cites it to demonstrate
that prices rose through 2022 (see Opposition, p. 32), but, instead, it shows
prices flatlining since 2018.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See
Complaint, ¶ 130.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Attorney General
needs to provide amended allegations to address this discrepancy.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp; </span>(40)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>As
a matter of guidance, Manufacturer Defendants’ assertion regarding diligence is
unavailing.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The argument relies on the
RJN exhibits, which cannot be considered, especially as to the truth of the
contents.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(41)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer
Defendants’ reliance on <i>Gabelli v. SEC</i> (2013) 586 U.S. 442 also
fails.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Reply, pp. 3-4.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><i>Gabelli</i> is distinguishable; it
concerns the discovery rule, not the last-over-act rule.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt;color:#3D3D3D" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;text-indent:.5in"><b><i><span style="font-size:14.0pt" class="fontChange">4.<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Continuing Violation Doctrine</span></i></b><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(42)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Court turns to the continuing-violation doctrine.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>It “aggregates a series of wrongs or injuries
for purposes of the statute of limitations, treating the limitations period as
accruing for all of them upon commission or sufferance of the last of
them.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Willis v. City of Carlsbad</i>
(2020) 48 Cal.App.5th 1104, 1124; see also <i>Aryeh v. Canon Business
Solutions, Inc.</i> (2013) 55 Cal.4th 1185, 1192.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>It “allows liability for unlawful . . .
conduct occurring outside the statute of limitations if it is sufficiently
connected to unlawful conduct within the limitations period.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Willis</i>, supra, 48 Cal.App.5th at
1124.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“For the . . . doctrine to apply,
a plaintiff must show the defendant engaged in ‘a pattern of reasonably
frequent and similar acts [that] may, in a given case, justify treating the
acts as an indivisible course of conduct actionable in its entirety,
notwithstanding that the conduct occurred partially outside and partially
inside the limitations period.’”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(43)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Attorney General contends the Court should find the doctrine applicable since
the complaint “allege[s] a continuing pattern and course of conduct as the <span style="color:#3D3D3D" class="fontChange">Manufacturer Defendants</span> consistently and
incrementally raised prices just as the PBMs demanded increasingly greater
rebate percentages.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Opposition, p.
30.)</span> <span style="font-size:14.0pt" class="fontChange">The Attorney General also argues
that the continuing violation doctrine applies because the <span style="color:#3D3D3D" class="fontChange">Manufacturer Defendants’ </span>frequent and similar acts
of increasing prices in tandem with PBM demands for increased rebates
constitute an ongoing pattern of conduct.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>The Attorney General maintains that the continuing-violation doctrine
applies regardless of the Plaintiff’s knowledge of the wrongful conduct before
the limitations period, citing <i>Haddad v. Merck &amp; Co., Inc</i>, (C.D.Cal.</span>
<span style="font-size:14.0pt" class="fontChange">Dec. 9, 2022) 2022 WL 18397392, at *5) a case
concerning failure to warn, to demonstrate its application in similar contexts.<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><a style="mso-comment-reference:DC_1;mso-comment-date:20240616T1658"><span style="font-size:14.0pt;color:black;mso-themecolor:text1" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(44)</span></a><span style="mso-comment-continuation:
1" class="fontChange"><b><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></b></span><span class="MsoCommentReference fontChange"><span style="font-size:8.0pt" class="fontChange"><!--[if !supportAnnotations]--><a class="msocomanchor" id="_anchor_1" href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/Lilly%20DF%20SOD.docx#_msocom_1" language="JavaScript" name="_msoanchor_1">[DC1]</a><!--[endif]--><span style="mso-special-character:comment" class="fontChange">&nbsp;</span></span></span><span style="font-size:14.0pt" class="fontChange">The Attorney General explained that in <i>Haddad</i>,
the court determined that the doctrine applied to a pharmaceutical case where
the manufacturer failed to adequately warn of risks associated with a drug. The
Attorney Geneal also noted that the defendants in <i>Haddad</i>, unlike those
in cases where the courts declined to apply the doctrine, engaged in recurring
wrongful acts, such as ongoing sales and overcharges, within the statutory
period.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(45)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer
Defendants claim the doctrine is inapplicable because the Plaintiff fails to
allege that the “price increases and price reporting are a series of otherwise
nonactionable small harms that became actionable over time.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Reply, p. 5; see also Demurrer, pp. 13-14.)</span>
<span style="font-size:14.0pt" class="fontChange">They further claim the Plaintiff fails to allege
that Manufacturer Defendants “raised prices” during or after 2019.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Reply, p. 5.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(46)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
analysis is the same as the last-overt-act-rule analysis.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Court sustains the demurrer with leave to
amend to show price increases during the limitations period.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;text-indent:.5in"><b><i><span style="font-size:14.0pt" class="fontChange">5.<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Continuous Accrual Doctrine</span></i></b><span style="font-size:14.0pt;
color:#3D3D3D" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(47)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Last
up is the continuous-accrual doctrine. “Where the wrong complained of is
continual or recurring, the cause of action is subject to continuous accrual
for statute of limitations purposes, i.e., a cause of action accrues each time
a wrongful act occurs, triggering a new limitations period.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Banke &amp; Segal, supra, at ¶ 3:70.5,
emphasis in original.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“[E]ach new
breach of such an obligation provides all the elements of a claim – wrongdoing,
harm, and causation.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Ibid</i>.,
emphasis in original.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(48)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>“[U]nder
the theory of continuous accrual, a series of wrongs or injuries may be viewed
as each triggering its own limitations period, such that a suit for relief may
be partially time-barred as to older events but timely as to those within the
applicable limitations period.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Luke
v. Sonoma County</i> (2019) 43 Cal.App.5th 301, 306; see also <i>Aryeh</i>,
supra, 55 Cal.4th at 1199 [“Generally speaking, continuous accrual applies
whenever there is a continuing or recurring obligation: ‘When an obligation or
liability arises on a recurring basis, a cause of action accrues each time a
wrongful act occurs, triggering a new limitations period.’”].) The Plaintiff argues
that the doctrine applies because Manufacturer Defendants’ alleged conduct
“causes ongoing, recurring injury by imposing repeated overcharges.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Opposition, p. 31.)<br>
<br>
<span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(49)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>In
<i>Aryeh</i>, the California Supreme Court determined the application of the
statute of limitations to claims filed under the UCL. (<i>Supra</i>, 55 Cal.4th
1185.) The Supreme Court found that each violation of the UCL triggers a new
statute of limitations. The court determined this by considering the nature of
the obligation breached, rather than how the claim is labeled. In this
particular case, the defendant was obligated to not impose unfair charges in
their monthly bills to the plaintiff. This duty, by its very nature, was
continuous and prone to repeated breaches. As a result, the Court concluded
that each alleged breach should be viewed as starting a new statute of
limitations period. The <i>Aryeh</i> ruling enables the plaintiff to pursue
recovery for charges that fall within the four years before the lawsuit was
filed. The Court also determined that equitable exceptions are relevant when
establishing if a claim was filed on time. (<i>Supra</i>, 55 Cal.4th at
1192-1195.) The Court found it contradictory to believe that while equity
influences available remedies under the UCL, equitable exceptions are
irrelevant when determining the timeliness of a claim. (<i>Ibid</i>.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(50)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer
Defendants assert that the Attorney General fails to allege a “continuing or
recurring obligation[.]” (Reply, p. 4; see also Demurrer, pp. 12-13.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>They contend the obligation to comply with
federal or state law does not qualify as the required obligation.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Reply, pp. 4-5; see also Demurrer, pp.
12-13.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Manufacturer Defendants contend
that the Attorney General’s reliance on <i>Aryeh</i> is misplaced. They argue
that general compliance with the law, such as the UCL, does not constitute a
"continuing obligation". The Manufacturer Defendants argue that
courts have routinely rejected attempts to characterize compliance with the law
as an ongoing obligation. <o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(51) <span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
analysis is the same as the last-overt-act-rule analysis.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The demurrer is sustained with leave amend.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpFirst fontChange" style="margin-bottom:10.0pt;mso-add-space:
auto;text-indent:-18.75pt;line-height:normal;mso-list:l14 level1 lfo15"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:
&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">C.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;font-family:
&quot;Times New Roman&quot;,serif" class="fontChange">The UCL Claims<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--></span></i></b><span style="font-size:14.0pt" class="fontChange"><o:p></o:p></span></p>

<p class="MsoListParagraphCxSpLast fontChange" style="margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:1.0in;mso-add-space:auto;text-indent:-.5in;
line-height:normal;mso-list:l23 level1 lfo31"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:
&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">1.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b><i><span style="font-size:14.0pt;
font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Safe Harbor Provisions<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(52)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
concept of a “safe harbor” acts as a shield against liability under the UCL
when a specific law permits the conduct in question. This means that if the
California legislature has explicitly allowed certain actions, courts cannot
deem those specific actions unfair under the UCL. “If the Legislature has
permitted certain conduct or considered a situation and concluded no action
should lie, courts may not override that determination.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Klein v. Chevron U.S.A., Inc.</i> (2012)
202 Cal.App.4th 1342, 1379 [quoting <i>Cel-Tech Communications, Inc. v. Los
Angeles Cellular Telephone Co</i>. (1999) 20 Cal.4th 163, 182].)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“When specific legislation provides a ‘safe
harbor,’ plaintiffs may not use the general unfair competition law to assault
that harbor.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Ibid</i>.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(53)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>This
rule “does not . . . prohibit an action under the unfair competition law merely
because some other statute on the subject does not . . . prohibit the
challenged conduct.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Ibid</i>.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“To forestall an action under the unfair
competition law, another provision must . . . clearly permit the conduct.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>There is a difference between (1) not making
an activity unlawful, and (2) making that activity lawful.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid. [instructing that “a statute that does
not ‘affirmatively permit[ ] [a type of conduct] . . . does not preclude a
court from deeming [such] conduct unfair under the unfair competition law’”].)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(54)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Stated
another way, “the Legislature's mere failure to prohibit an activity does not
prevent a court from finding it unfair.”<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(<i>BBBB Bonding Corp. v. Caldwell</i> (2021) 73 Cal.App.5th 349,
377.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“[T]o ‘qualify for the “safe
harbor” rule, the defendant must show that a statute “explicitly prohibit[s]
liability for the defendant's acts or omissions” [citation] or “expressly precludes
an action based on the conduct.”’”<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(Ibid.) “If a statute does not ‘explicitly prohibit liability’ for a
defendant's specific acts or omissions, the court may not create an ‘implied
safe harbor.’”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Ibid</i>.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(55)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer
Defendants raise the safe harbor defense in relation to the Attorney General’s
unfair-prong UCL claim; however, several courts have assumed that it also
applies to UCL claims brought pursuant to the unlawful and fraud prongs.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See, e.g., <i>The People v. Johnson &amp;
Johnson</i> (2022) 77 Cal.App.5th 295, 345 [“We also assume, without deciding,
that the safe harbor concept applies to UCL claims based on FAL violations and
fraudulent or unlawful business practices, not merely claims based on unfair
business practices.”]; see also <i>Olszewski v. Scripps Health</i> (2003) 30
Cal.4th 798, 827-828 [“In <i>Cel-Tech</i>, we considered a UCL claim for unfair
– but not unlawful – business practices and recognized a safe harbor from such
claims for acts expressly allowed by the Legislature.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>[¶] “<a style="mso-comment-reference:DC_2;
mso-comment-date:20240616T1716">We</a></span><span class="MsoCommentReference fontChange"><span style="font-size:8.0pt" class="fontChange"><!--[if !supportAnnotations]--><a class="msocomanchor" id="_anchor_2" href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/Lilly%20DF%20SOD.docx#_msocom_2" language="JavaScript" name="_msoanchor_2">[DC2]</a><!--[endif]--><span style="mso-special-character:comment" class="fontChange">&nbsp;</span></span></span><span style="font-size:14.0pt" class="fontChange">, however, need not determine whether the safe harbor
applies to unlawful business practices, because plaintiff cannot establish that
defendant violated federal law.”]; <i>De La Torre v. CashCall, Inc.</i> (2018)
5 Cal.5th 966, 986-987 [assuming the safe harbor can apply in an unlawful-prong
case].)<span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(56)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Manufacturer Defendants argue that their actions, including offering rebates
and setting list prices, are protected by the safe harbor provisions because
both federal and state laws allow for those activities. (Demurrer, p. 14.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>In support, Manufacturer Defendants cite 42
U.S.C. sections 1320b-23(b), 1395w-3a(c)(6)(B), and 1396r-8(a)(1) and Health
and Safety Code section 127676(b)(2).<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(See <i>id</i>. at p. 15; see also Reply, pp. 6-7.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(57)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Section
1320b-23(b) sets certain reporting requirements for PBMs:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">“(b) Information described<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">The information described in
this subsection is the following with respect to services provided by a health
benefits plan or PBM for a contract year:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">(1) The percentage of all
prescriptions that were provided through retail pharmacies compared to mail
order pharmacies, and the percentage of prescriptions for which a generic drug
was available and dispensed (generic dispensing rate), by pharmacy type (which
includes an independent pharmacy, chain pharmacy, supermarket pharmacy, or mass
merchandiser pharmacy that is licensed as a pharmacy by the State and that
dispenses medication to the general public), that is paid by the health
benefits plan or PBM under the contract.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">(2) The aggregate amount, and
the type of rebates, discounts, or price concessions (excluding bona fide
service fees, which include but are not limited to distribution service fees,
inventory management fees, product stocking allowances, and fees associated
with administrative services agreements and patient care programs (such as
medication compliance programs and patient education programs)) that the PBM
negotiates that are attributable to patient utilization under the plan, and the
aggregate amount of the rebates, discounts, or price concessions that are
passed through to the plan sponsor, and the total number of prescriptions that
were dispensed.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">(3) The aggregate amount of
the difference between the amount the health benefits plan pays the PBM and the
amount that the PBM pays retail pharmacies, and mail order pharmacies, and the
total number of prescriptions that were dispensed.”<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange">(42
U.S.C. § 1320b-23, subd. (b), emphasis in original.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(58)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Section
1395w-3a(c)(6)(B) provides a definition for “wholesale acquisition cost”:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">“(B) Wholesale acquisition
cost<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.7in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">The term “wholesale
acquisition cost” means, with respect to a drug or biological, the
manufacturer's list price for the drug or biological to wholesalers or direct
purchasers in the United States, not including prompt pay or other discounts,
rebates or reductions in price, for the most recent month for which the
information is available, as reported in wholesale price guides or other
publications of drug or biological pricing data.”<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange">(Id.
at § 1395w-3a, subd. (c)(6)(B), emphasis in original.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(59)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Section
1396r-8(a)(1) requires manufacturers to enter into rebate agreements with
states:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">“(a) Requirement for rebate
agreement<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">(1) In general<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.7in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">In order for payment to be
available under section 1396b(a) of this title or under part B of subchapter
XVIII for covered outpatient drugs of a manufacturer, the manufacturer must
have entered into and have in effect a rebate agreement described in subsection
(b) with the Secretary, on behalf of States (except that, the Secretary may
authorize a State to enter directly into agreements with a manufacturer), and
must meet the requirements of paragraph (5) (with respect to drugs purchased by
a covered entity on or after the first day of the first month that begins after
November 4, 1992) and paragraph (6). Any agreement between a State and a
manufacturer prior to April 1, 1991, shall be deemed to have been entered into
on January 1, 1991, and payment to such manufacturer shall be retroactively
calculated as if the agreement between the manufacturer and the State had been
entered into on January 1, 1991. If a manufacturer has not entered into such an
agreement before March 1, 1991, such an agreement, subsequently entered into,
shall become effective as of the date on which the agreement is entered into
or, at State option, on any date thereafter on or before the first day of the
calendar quarter that begins more than 60 days after the date the agreement is
entered into.”<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange">(Id.
at § 1396r-8, subd. (a)(1), emphasis in original.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(60)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Section
127676(b)(2) gives manufacturers discretion to make pricing decisions:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.7in;margin-bottom:10.0pt;
margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">“(2) It is further the intent
of the Legislature to permit a manufacturer of a prescription drug to
voluntarily make pricing decisions regarding a prescription drug, including any
price increases. It is further the intent of the Legislature to permit purchasers,
both public and private, as well as pharmacy benefit managers, to negotiate
discounts and rebates consistent with existing state and federal law.”<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange">(Health
&amp; Saf. Code § 127676, subd. (b)(2).)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(61)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>However,
the Attorney General argues that the Manufacturer Defendants’ interpretation of
the safe harbor is too narrow. The Attorney General contends that although the
statutes mentioned might acknowledge the existence of rebates and pricing
practices, they do not shield the Manufacturer Defendants from liability for
the alleged artificial inflation of insulin prices through a conspiracy
involving both price increases and concealed rebates.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(62)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>In
<i>Cel-Tech Communications, Inc. v. Los Angeles Cellular Telephone Co. </i>(1999)
20 Cal.4th 163, the California Supreme Court ruled that L.A. Cellular's
practice of selling cellular phones below cost did not violate the Unfair
Practices Act (UPA), as the plaintiffs did not prove the company acted with the
intent of injuring competitors or destroying competition. The Supreme Court
determined that a business must act with the <b><i>desire</i></b>, not just the
knowledge, of harming competition to violate the UPA. (<i>Cel-Tech
Communications, Inc.</i>, 20 Cal.4th at 169.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(63)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Supreme Court also addressed whether L.A. Cellular's conduct violated the
unfair competition law, which prohibits “any unlawful, unfair or fraudulent”
business act or practice. (<i>Cel-Tech Communications, Inc., </i>20 Cal.4th
163.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>While acknowledging that the
unfair competition law can apply to practices not explicitly prohibited by
other laws, the Court established a test for determining "unfairness"
in this context. To be considered "unfair" under Section 17200, the
conduct must meet one of the following criteria: (1) threaten an incipient
violation of an antitrust law; (2) violate the policy or spirit of an antitrust
law because its effects are comparable to or the same as a violation of the law;
or, (3)otherwise significantly threaten or harm competition. (<i>Ibid</i>.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(64)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Court noted that low prices generally benefit consumers and are a fundamental
aspect of competition. (<i>Cel-Tech Communications, Inc., </i>20 Cal.4th at
188-190.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>However, in the <i>Cel-Tech</i>
case, the Supreme Court found that L.A. Cellular's actions, while not violating
the UPA, could be considered unfair under the unfair competition law because
L.A. Cellular, as a duopolist, held a privileged position in the market due to
its government-issued duopoly license. (<i>Ibid</i>. at 188-192.) The
privileged position allowed the company to subsidize losses from below-cost
phone sales with profits from its cellular service, a strategy not legally
available to its competitors. (<i>Ibid</i>.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(65)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Attorney General cites additional federal court rulings that support his
stance, rejecting the argument that those specific federal laws provide blanket
immunity to the Manufacturer Defendants. The Attorney General further emphasizes
that the California law cited, while permitting manufacturers to set different prices
for a hospital’s uninsured patients, the law does not condone artificially
inflated or excessively high prices for such financially vulnerable individuals.
He cites a relevant California case, <i>Moran v. Prime Healthcare Management,
Inc. </i>(2016)</span> <span style="font-size:14.0pt" class="fontChange">3 Cal.App.5th 1131,</span>
<span style="font-size:14.0pt" class="fontChange">208 Cal. Rptr. 3d 303, which held that a statute
allowing a hospital to establish its own billing rates for emergency services for
the uninsured did not protect the hospital from accusations of setting
"artificial" and "grossly excessive" prices. (<i>Ibid</i>.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp; </span>In <i>Moran</i>, the hospital billed the
self-pay patient $10,000 for emergency room visits. (<i>Id.</i>)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(66)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>In
the <i>Moran v. Prime Healthcare Management, Inc</i>. case, the court
determined that a statute permitting “a hospital to bill for treatment and
services based on its own schedule of fees” for emergency services did not
establish a safe harbor against claims of “exorbitant” prices because the
statute lacked explicit language barring an action under the UCL or granting
hospitals the authority to charge “artificial and grossly excessive
rates." (<i>Supra., </i>3 Cal. App.5th 1141.) <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(67)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>In
contrast, in <i>Schnall v. Hertz Corp.</i>, the contested surcharge was deemed
avoidable and thus not unconscionable. (<i>Schnall v. Hertz Corp.</i> (2000) 78
Cal. App.4th 1144.) Because the surcharge in <i>Schnall</i> was not
unconscionable, the court found that a statute authorizing the surcharge
established a safe harbor against claims that the surcharge was unreasonable.
Unlike in <i>Schnall</i>, the defendants in <i>Moran</i> did not dispute the
issue of unconscionable fee setting based on financial vulnerability. Moreover,
the plaintiffs in <i>Moran</i> successfully argued that the emergency room
charges were artificially inflated, unavoidable, and resulted in significant
harm to individuals particularly vulnerable because of the immediate need for
medical services. (<i>Moran v. Prime Healthcare Management, Inc</i>., 3 Cal. App.5th
at 1147-1149.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(68)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Court is inclined to overrule this portion of the demurrer.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Manufacturer Defendants’ argument appears to
be based on a limited reading of the Complaint.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>They characterize the Attorney General’s liability theory as being about
deceptive list prices. Namely, the list prices are inflated and unlawful
because they do not account for/disclose the rebate payments that Manufacturer
Defendants pay to PBM Defendants.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See
Demurrer, p. 1.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>However, the Complaint
alleges “two main components” to the alleged scheme.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Complaint, ¶ 6.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The first component concerns a
price-inflation conspiracy among Manufacturer Defendants – they purportedly
agree to “raise the list price . . . in lockstep with each other to artificial
levels.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The second component concerns a rebate
conspiracy between Manufacturer Defendants and PBM Defendants – “PBM Defendants
obtain significant secret rebates, which are a percentage of the inflated and
artificial list price, from the Manufacturer Defendants in exchange for
favorable placement on the PBM’s standard formularies.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Id. at ¶ 7.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(69)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>As
alleged, neither component indicates that the list prices would be reasonable
and lawful if they simply reflected or disclosed the rebate payments.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>In fact, given the alleged price collusion, a
reasonable reading of the components – whether considered separately or
conjoined – is that the list prices would remain inflated and unlawful even if
the rebate payments were reflected or disclosed.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Court agrees with the Attorney General that
the statutes do not bar liability under these allegations at this stage.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See, e.g., Opposition, pp. 18-21 [noting, in
part, that section 127676(b)(2) is a general statement of legislative intent as
opposed to an express grant of immunity against pricing claims].)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(70)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>To
the extent Manufacturer Defendants assert that the allegations are conclusive
and lack detail, the Court disagrees.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>As
already noted, the conspiracy/price-collusion allegations show enough to put
Manufacturer Defendants on notice.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See,
e.g., Complaint, ¶¶ 4-9, 62, 133-143, 147-176.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>The efficient way to obtain further details is through discovery.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(71)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer
Defendants’ citation to <i>In re Insulin Pricing Litigation</i> (D.N.J. Feb. 5,
2024, No. 2:17-cv-00699 (BRM) (RLS)) 2024 WL 416500 is unavailing for now.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The district judge ruled at the certification
stage on a factual record.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>He did not
rule as a matter of law that the plaintiffs could never prove a basis for
injunctive relief, only that they had not explained a basis at that point.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See <i>In re Insulin Pricing Litig</i>.,
supra, 2024 WL 416500, at *28.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>Additionally, the two separate components alleged here, especially the
alleged price collusion, make this case distinguishable at the pleading
stage.<span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(72)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Court also finds it noteworthy that other federal courts have rejected
Manufacturer Defendants’ argument.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See <i>City
of Miami v. Eli Lilly and Co.</i> (S.D. Fla. Jan. 21, 2022, No.
21-22636-Civ-Scola) 2022 WL 198028, at * 8 n.8 [“The Defendants argue that
federal law prohibits including rebates in a list price for pharmaceutical
products. [Citation omitted.] However, the City’s claim is that the
Manufacturer Defendants’ inflated the price of insulin and other medications using
fraudulent rebates that served as kickbacks to the PBM Defendants. The
Manufacturer Defendants cannot use Section 1395w-3a(c)(6)(B) to avoid the
City’s allegations of wrongdoing.”]; see also <i>Minnesota v. Sanofi-Aventis
U.S. LLC</i> (D.N.J. Mar. 31, 2020, No. 3:18-cv-14999 (BRM) (LHG) 2020 WL
2394155, at * 14 [similar].)<o:p></o:p></span></p>

<p class="MsoListParagraphCxSpFirst fontChange" style="margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:1.0in;mso-add-space:auto;text-indent:-.5in;
mso-list:l23 level1 lfo31"><!--[if !supportLists]--><b><i><span style="font-size:
14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:
&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">2.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b><i><span style="font-size:14.0pt;
line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Unfair-Prong of the
UCL<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></i></b></p>

<p class="MsoListParagraphCxSpLast fontChange" style="margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:1.25in;mso-add-space:auto;text-indent:-.25in;
mso-list:l23 level2 lfo31"><!--[if !supportLists]--><b><i><span style="font-size:
14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:
&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">a.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b><i><span style="font-size:14.0pt;
line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">Price inflation, alleged
collusion, the harm to diabetics and the balancing test<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(73)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
UCL’s unfair prong prohibits unfair business practices.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Because the UCL is written in the
disjunctive, “a business practice can be ‘unfair’ . . . even if it is not
‘deceptive’ and even if it is ‘lawful.’”<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(See Stern, Business and Professions Code Section 17200 Practice (The
Rutter Group March 2023 Update) at ¶ 3:112.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>“The ‘unfair’ standard is intentionally broad, allowing courts maximum
discretion to prohibit new schemes to defraud.”<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(Id. at ¶ 3:113.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(74)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>In
contrast to its limited remedies, the unfair competition law's scope is broad. As
the Supreme Court noted in <i>Cel-Tech</i>, it does not proscribe specific
practices. “Rather, . . . it defines “unfair competition” to include “any
unlawful, unfair or fraudulent business act or practice.” (§ 17200.)(<i>Cel-Tech</i>,
supra, 20 Cal.4th at p. 180-181.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Its
coverage is “sweeping, embracing ‘ “anything that can properly be called a
business practice and that at the same time is forbidden by law.” ’ ” (<i>Rubin
v. Green</i> (1993) 4 Cal.4th 1187, 1200, 17 Cal.Rptr.2d 828, 847 P.2d 1044,
quoting <i>Barquis v. Merchants Collection Assn.</i> (1972) 7 Cal.3d 94, 113,
101 Cal.Rptr. 745, 496 P.2d 817.) It governs “anti-competitive business
practices” as well as injuries to consumers and has as a major purpose “the
preservation of fair business competition.” (<i>Barquis v. Merchants Collection
Assn</i>., supra, 7 Cal.3d at p. 110, 101 Cal.Rptr. 745, 496 P.2d 817; see also
<i>People v. McKale</i> (1979) 25 Cal.3d 626, 631–632, 159 Cal.Rptr. 811, 602
P.2d 731; <i>People ex rel. Mosk v. National Research Co. of Cal.</i> (1962)
201 Cal.App.2d 765, 771, 20 Cal.Rptr. 516.)</span> <span style="font-size:14.0pt" class="fontChange">The
<i>Cel-Tech</i> court also held that “to guide courts and the business
community adequately and to promote consumer protection, we must require that
any finding of unfairness to competitors under section 17200 be tethered to
some legislatively declared policy or proof of some actual or threatened impact
on competition.” (<i>Cel-Tech</i>. supra, 20 Cal.4th at pp. 186–187, 83 Cal. Rptr.2d
548, 973 P.2d 527.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(75)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>According
to Manufacturer Defendants, “[t]he People’s unfairness claim boils down to the
notion that the amount the Manufacturers charge for insulin is too high, and
thus unfair.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Demurrer, p. 16.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Manufacturer Defendants contend the claim is
“misguided because the UCL is not a vehicle for judicial price controls.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Ibid</i>.)</span> <span style="font-size:
14.0pt" class="fontChange">They argue that simply raising prices, without more, does not
constitute an unfair business practice under the UCL. The Manufacturer
Defendants further assert that the People's reliance on cases like <i>Saunders
v. Superior Court</i> (1994) 27 Cal.App.4th 832, 33 Cal. Rptr. 2d 438 and <i>Moran
v. Prime Healthcare Management, Inc</i>. is misplaced, as those cases involved
additional factors beyond simple price increases.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(76)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Court disagrees that reliance on <i>Saunders v. Superior Court</i>, and <i>Moran
v. Prime Healthcare Management, Inc</i>. is misplaced.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“[A]n ‘unfair’ business practice occurs when
that practice ‘offends an established public policy or when the practice is
immoral, unethical, oppressive, unscrupulous or substantially injurious to
consumers.’”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Bardin v.
DaimlerChrysler Corp.</i> (2006) 136 Cal. App.4th 1255, 1268.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Attorney General argues the Manufacturer
Defendants' conduct is unfair under the UCL because the Manufacturers and PBMs
operate in an oligopoly that has allowed them to inflate insulin prices, with
the manufacturers engaging in price collusion and paying secret rebates to PBMs.
The Attorney General’s argument goes beyond a request to order Manufacturer
Defendants to sell at cost, sell at the same price, or receive a meager
profit.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Cf. <i>Kunert v. Mission
Financial Services Corp.</i> (2003) 110 Cal. App.4th 242, 265; cf. also <i>Boris
v. Wal-Mart Stores, Inc.</i> (C.D. Cal. 2014) 35 F.Supp.3d 1163,
1171-1172.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The UCL can be used to
challenge price collusion and similar types of anticompetitive behavior. <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(77)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Attorney General contends that the balancing test used to assess the unfair
prong of the UCL, weighs the gravity of harm to the consumer against the
utility of the business practice, and favors the State’s argument in the
instant case. The balancing test “involves an examination of [that practice’s]
impact on its alleged victim, balanced against the reasons, justifications and
motives of the alleged wrongdoer.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Bardin</i>,
supra, 136 Cal.App.4<sup>th</sup> at 1268-1269.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Complaint alleges that access to insulin
to regulate their blood sugar levels is a matter of life and death for
diabetics relying on insulin. (See Complaint, ¶ 1.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Plaintiff cites <i>Saunders v. Superior Court</i>,
and <i>Moran v. Prime Healthcare Management, Inc</i> to demonstrate that
similar allegations have satisfied this test in previous cases. “In brief, the
court must weigh the utility of the defendant’s conduct against the gravity of
the harm to the alleged victim.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Bardin</i>,
supra, 136 Cal.App.4<sup>th</sup> at 1269.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>Oligopolies and price collusion burden competition.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>There is little to no utility to anyone but
the colluders, so the alleged harm to consumers outweighs the minimal utility
at this stage and passes the balancing test.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(See Complaint, ¶¶ 206-224; see also Opposition, pp. 13-14.)<o:p></o:p></span></p>

<p class="MsoListParagraph fontChange" style="margin-top:0in;margin-right:0in;margin-bottom:
10.0pt;margin-left:1.25in;mso-add-space:auto;text-indent:-.25in;mso-list:l23 level2 lfo31"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">b.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></i></b><!--[endif]--><b><i><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">FTC
Act Test<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(78)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
second test is the Federal Trade Commission (“FTC”) post-1980 test.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The FTC test comes from section 5 of the FTC
Act.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>It has three factors: “(1) the
consumer injury must be substantial; (2) the injury must not be outweighed by
any countervailing benefits to consumers or competition; and (3) it must be an
injury that consumers themselves could not reasonably have avoided.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Nationwide Biweekly Administration, Inc.
v. Superior Court</i> (2020) 9 Cal.5th 279, 303 n.10 (“<i>Nationwide</i>”).)</span>
<span style="font-size:14.0pt" class="fontChange">The Court agrees with Plaintiff that the FTC
test is satisfied for the same reasons that the balancing test is
satisfied.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Opposition, p. 14.)<o:p></o:p></span></p>

<p class="MsoListParagraph fontChange" style="margin-top:0in;margin-right:0in;margin-bottom:
10.0pt;margin-left:1.25in;mso-add-space:auto;text-indent:-.25in;mso-list:l23 level2 lfo31"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">c.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></i></b><!--[endif]--><b><i><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The
Tethering Test<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(79)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
third test is the tethering test.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>It
requires that “the public policy which is a predicate to” an unfair-prong claim
“‘must be “tethered” to specific constitutional, statutory or regulatory
provisions’ in a manner similar to which [<i>Cel-Tech Communications, Inc. v.
Los Angeles Cellular Telephone Co.</i> (1999) 20 Cal.4th 163] requires a
competitor’s cause of action to be tethered to the antitrust laws.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Nationwide</i>, supra, 9 Cal.5th at 303
n.10.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Of course, the parties disagree
about whether Plaintiff states a claim under the tethering test.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Opposition, pp. 14-16; see also Reply,
pp. 9-10.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(80)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Court tends to agree with the Attorney General’s arguments, at least with
respect to the price-collusion allegations.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>The alleged conduct either “violates the policy or spirit of the
antitrust laws” or “otherwise significantly threatens or harms competition.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>People’s Choice Wireless, Inc. v. Verizon
Wireless </i>(2005) 131 Cal.App.4th 656, 662.) Regardless, the demurrer should
be overruled.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Case law is split on “the
proper test for determining whether a business practice is unfair under the UCL
in consumer cases” (<i>Nationwide</i>, supra, 9 Cal.5th at 303), yet the trend
favors the FTC test.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See, e.g., Stern,
supra, at ¶ 3:121.1.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>It is appropriate
to overrule the demurrer since the Complaint satisfies the FTC test.<o:p></o:p></span></p>

<p class="MsoListParagraph fontChange" style="margin-top:0in;margin-right:0in;margin-bottom:
10.0pt;margin-left:1.0in;mso-add-space:auto;text-indent:-.5in;mso-list:l23 level1 lfo31"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">3.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b><i><span style="font-size:14.0pt;
line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Unlawful-Prong of the
UCL<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(81)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>“[T]he
UCL permits a cause of action to be brought if a practice violates some other
law.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>In effect, the ‘unlawful’ prong . .
. makes a violation of the underlying law a per se violation of [section]
17200.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Stern, supra, at ¶ 3:53.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“Virtually any law or regulation – federal or
state, statutory or common law – can serve as predicate for” an unlawful claim.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Id. at ¶ 3:56.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“Thus, if a ‘business practice’ violates any
law – literally – it also violates [section] 17200 and may be redressed under
that section. [Citation.]”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.) <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(82)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
underlying statute highlighted in the complaint is Civil Code section
1770(a)(13), the Consumer Legal Remedies Act (“CLRA”).<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Complaint, ¶ 229 [alleging that
“Defendants’ acts or practices are unlawful, as that term is used in the UCL,
and include, but are not limited to, violating the [CLRA], Civil Code section
1770, subdivision (a), subpart (13), by making false or misleading statements
of fact concerning reasons for, existence of, or amounts of, price reductions
to analog insulin”].)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(83)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Attorney General points out three alleged misstatements that they contend
subsection (a)(13) covers:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange">*
“Manufacturer Defendants have publicly represented that the prices for their
analog insulins are justified because . . . insulin’s net price is decreasing”
(Complaint, ¶ 186; see also Opposition, p. 22);<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange">*
“[e]ach of the Manufacturer Defendants claims to offer support programs,
including coupons, to help consumers afford their insulin” (Complaint, ¶ 190;
see also Opposition, p. 22); and<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange">*
“[i]n March 2019, Defendant Eli Lilly announced that it would produce an
authorized generic version of Humalog, ‘Insulin Lispro,’ and promised that it
would ‘work quickly with supply chain partners to make [the authorized generic]
available in pharmacies as quickly as possible.’”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Complaint, ¶ 191; see also Opposition, p.
22.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(84)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer
Defendants contend the statements are true and are not about price
reductions.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Demurrer, p. 22
[arguing that the case is about purported price increases]; see also Reply, pp.
12-13.)</span> <span style="font-size:14.0pt" class="fontChange">The alleged misstatements do have
some truth to them.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>For instance, the
complaint admits that “net prices have shrunk in recent years” (Complaint, ¶
171), Manufacturer Defendants do offer support programs (see id. at ¶ 193), and
Eli Lilly does produce Insulin Lispro.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(See id. at ¶ 196.) Also, the Court is inclined to agree with
Manufacturer Defendants that the first and third statements do not address
price reductions.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See Reply, p. 13.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:10.0pt"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(85)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
second statement is a close call.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Complaint
says the second statement is misleading because “not all consumers are
eligible” for the support programs, and “Manufacturer Defendants do not
sufficiently advertise such support programs, resulting in limited awareness by
consumers.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Complaint, ¶¶ 193,
194.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Per the complaint, “[s]tudies []
suggest that consumers have been turned away from” the programs “due to their
strict eligibility requirements.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Id.
at ¶ 194.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>A broad reading of the
statement is that it is about price reductions as it indicates to many
consumers that they can receive cheaper prices via coupons and other programs
that, in many cases, they do not qualify for.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>A narrower reading is that it merely notes the general availability of
coupons without guaranteeing eligibility or a cheaper price.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Since this is the demurrer stage, the Court
leans toward the broad interpretation and overruling the demurrer.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Indeed, how a reasonable consumer would
interpret the second statement is a factual question.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(86)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>However,
the Court is willing to grant leave to amend to give the Attorney General an
opportunity to add details to all three statements – or include new statements
– to render them actionable under subsection (a)(13) and the UCL.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraph fontChange" style="margin-top:0in;margin-right:0in;margin-bottom:
10.0pt;margin-left:1.0in;mso-add-space:auto;text-indent:-.5in;mso-list:l23 level1 lfo31"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">4.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b><i><span style="font-size:14.0pt;
line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Fraud-Prong of the
UCL<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(87)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>“The
third type of conduct proscribed by § 17200 is ‘fraudulent’ business
practices.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Stern, supra, at<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>¶ 3:153.)<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>“A business practice is ‘fraudulent’ within the meaning of § 17200 if
‘members of the public are likely to be deceived.’”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Id. at ¶ 3:154.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“An advertisement's potentially deceptive
effect is measured by the audience to which it is addressed.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Under the UCL and False Advertising statute,
this will usually be the ‘reasonable person’ standard.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(Ibid.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(88)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
demurrer is overruled.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Paragraph 231
alleges:<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange">“231.
Defendants’ acts or practices are fraudulent, as that term is used in the UCL,
and include, but are not limited to: <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange">a.
artificially inflating the list prices of analog insulin; or <br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange">b.
making material misrepresentations regarding or failing to disclose the
existence, amount, and/or purpose(s) of discounts, rebates, and/or other
payments offered by the Manufacturer Defendants to PBM Defendants.”<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt"><span style="font-size:14.0pt" class="fontChange">(Complaint,
¶ 231.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><br style="mso-special-character:
line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(89)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Manufacturer Defendants argue that the Attorney General fails to demonstrate
any specific misrepresentation connected to insulin list prices or rebates
within the complaint. They assert that:<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoListParagraphCxSpFirst fontChange" style="text-indent:-.25in;mso-list:l2 level1 lfo37"><!--[if !supportLists]--><span style="font-size:14.0pt;line-height:107%;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol" class="fontChange"><span style="mso-list:Ignore" class="fontChange">·<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><!--[endif]--><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Complaint lacks allegations of a duty
to disclose that would support a fraudulent-omission claim.<o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="text-indent:-.25in;mso-list:l2 level1 lfo37"><!--[if !supportLists]--><span style="font-size:14.0pt;line-height:107%;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol" class="fontChange"><span style="mso-list:Ignore" class="fontChange">·<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><!--[endif]--><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Attorney General 's characterization
of list prices as "artificially inflated" does not equate to
fraudulent conduct, as federal law requires Manufacturers to publish list
prices without including rebates.<o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="text-indent:-.25in;mso-list:l2 level1 lfo37"><!--[if !supportLists]--><span style="font-size:14.0pt;line-height:107%;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol" class="fontChange"><span style="mso-list:Ignore" class="fontChange">·<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><!--[endif]--><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Complaint lacks any factual
allegations of misrepresentations by the Manufacturers regarding the existence,
amount, or purpose of rebates offered to PBMs.</span><span style="font-size:
14.0pt;line-height:107%" class="fontChange"><o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="text-indent:-.25in;mso-list:l2 level1 lfo37"><!--[if !supportLists]--><span style="font-size:14.0pt;line-height:107%;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol" class="fontChange"><span style="mso-list:Ignore" class="fontChange">·<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><!--[endif]--><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif" class="fontChange">There is no "secrecy" or
collusion surrounding pharmaceutical rebates, as Manufacturers have openly
disclosed their payment of rebates, acknowledging their increasing prevalence
over time.<o:p></o:p></span></p>

<p class="MsoListParagraphCxSpLast fontChange" style="text-indent:-.25in;mso-list:l2 level1 lfo37"><!--[if !supportLists]--><span style="font-size:14.0pt;line-height:107%;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol" class="fontChange"><span style="mso-list:Ignore" class="fontChange">·<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><!--[endif]--><span style="font-size:14.0pt;line-height:107%;
font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The Attorney General 's reliance on an
omissions theory is flawed, as there was no duty for Manufacturers to disclose
the existence, amount, or purpose of rebates.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(90)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
artificial-inflation allegation is founded on the alleged price-collusion
conspiracy.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See, e.g., Complaint, ¶¶
4-9, 62, 133-143, 147-176.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The People's
argument centers on three key examples of alleged misrepresentations:<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">•
The Manufacturer Defendants claimed that net prices for insulin were
decreasing, which the Attorney General suggested was misleading because the
Manufacturers knew that net prices had already shrunk. The Attorney General
asserts that a reasonable consumer could have been misled by this statement,
especially as PBMs allegedly make it difficult to determine the amount of
rebates they secure, thus obscuring the true net price.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-left:.5in"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">• The
Manufacturer Defendants promoted insulin affordability programs, which the Attorney
General suggests created a false impression that the Manufacturers were taking
meaningful steps to address high insulin prices. The Attorney General does not
specify what aspects of these programs are misleading but argue that the
existence of such programs, in conjunction with other alleged conduct,
contributes to an overall deceptive picture of insulin pricing.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-left:.5in"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="margin-left:.5in"><span style="font-size:14.0pt" class="fontChange">• Eli
Lilly, one of the Manufacturer Defendants, represented in 2019 that it would
offer a cheaper, generic version of its insulin. The Attorney General claim
this was misleading because the generic insulin was largely unavailable in
pharmacies. The Attorney General asserts that this misrepresentation, coupled
with the Manufacturers’ other alleged conduct, forms part of a pattern of
misleading statements about insulin pricing.<br style="mso-special-character:
line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(91)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
discounts/rebates allegation is founded, at least partly, on the alleged
violations of the CLRA, subsection (a)(13).<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>As misrepresentations and/or omissions, the allegations state claims
under the fraud prong for the reasons stated in the unfair-prong and
unlawful-prong sections.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraph fontChange" style="margin-bottom:10.0pt;mso-add-space:auto;
text-indent:-18.75pt;line-height:normal;mso-list:l14 level1 lfo15"><!--[if !supportLists]--><b><i><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:
&quot;Times New Roman&quot;" class="fontChange"><span style="mso-list:Ignore" class="fontChange">D.<span style="font:7.0pt &quot;Times New Roman&quot;" class="fontChange">&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><!--[endif]--><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span style="font-size:14.0pt;font-family:
&quot;Times New Roman&quot;,serif" class="fontChange">The Unjust Enrichment Claim</span></i></b><span style="font-size:14.0pt" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(92)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Unjust
enrichment is an equitable doctrine.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>It
“is based on the idea that ‘one person should not be permitted unjustly to
enrich himself at the expense of another, but should be required to make
restitution of or for property or benefits received, retained, or appropriated,
where it is just and equitable that such restitution be made, and where such
action involves no violation or frustration of law or opposition to public
policy, either directly or indirectly.’”<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(<i>City of Oakland v. Oakland Raiders</i> (2022) 83 Cal.App.5th 458,
478.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“The elements . . . are the
‘receipt of a benefit and [the] unjust retention of the benefit at the expense
of another.’”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Peterson v. Cellco
Partnership</i> (2008) 164 Cal.App.4th 1583, 1593.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(93)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer
Defendants contend “unjust enrichment is not a distinct cause of action”
(Demurrer, p. 23; see also Reply, p. 14), the Attorney General “have an
adequate remedy at law” (Demurrer, p. 23; see also Reply, pp. 14-15), the Attorney
General fails to show that “[He has] a ‘better right’ to the [insulin] revenue”
(Demurrer, p. 24; see also Reply, p. 15), and “an express contract governs the
subject matter of this action[.]”<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(Reply, p. 15; see also Demurrer, p. 24.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(94)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
demurrer is sustained.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Case law is split
about whether unjust enrichment can be a standalone cause of action.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See <i>O’Grady v. Merchant Exchange
Productions, Inc.</i> (2019) 41 Cal.App.5th 771, 791 [acknowledging the
split].)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Apparently, the Second District
falls on the side of it not being a cause of action.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(See <i>Jogani v. Superior Court</i> (2008)
165 Cal.App.4th 901, 911; see also <i>Bank of New York Mellon v. Citibank, N.A.</i>
(2017) 8 Cal.App.5th 935, 955; <i>Melchior v. New Line Productions, Inc.</i>
(2003) 106 Cal.App.4th 779, 793.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The
Court intends to follow the Second District.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(95)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Attorney General’s cases do not change the outcome.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>Except for <i>O’Grady</i>, a First District
decision, none of them takes up the issue.<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(See <i>Professional Tax Appeal v. Kennedy-Wilson Holdings, Inc.</i>
(2018) 29 Cal.App.5th 230, 238; see also <i>Prakashpalan v. Engstrom, Lipscomb
&amp; Lack</i> (2014) 223 Cal.App.4th 1105, 1132; <i>Ghirardo v. Antonioli</i>
(1996) 14 Cal.4th 39, 50.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(96)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
question is whether leave to amend should be granted.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“The phrase ‘Unjust Enrichment’ <a name="_Hlk169447875">does not describe a theory of recovery</a>, but an effect:
the result of a failure to make restitution under circumstances where it is
equitable to do so.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Melchior</i>,
supra, 106 Cal.App.4th at 793.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“Unjust
enrichment is ‘“a general principle, underlying various legal doctrines and
remedies,”’ rather than a remedy itself.”<span style="mso-spacerun:yes" class="fontChange">&nbsp;
</span>(<i>Ibid</i>.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>“It is synonymous
with restitution.”<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>(<i>Ibid</i>.)<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><a name="_Hlk169447945">The Court’s
inclination is to grant the Attorney General leave to assert a common count for
restitution based on unjust enrichment as an alternative in case the UCL cause
of action gets dismissed down the road.<o:p></o:p></a></span></p>

<span style="mso-bookmark:_Hlk169447945"></span>

<p class="MsoNormal fontChange" style="mso-layout-grid-align:none;text-autospace:none"><span style="font-size:16.0pt;mso-bidi-font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="line-height:15.75pt"><b style="mso-bidi-font-weight:
normal"><span style="font-size:14.0pt" class="fontChange">THEREFORE, THE COURT RULES AS FOLLOWS:<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--></span></b><span style="font-size:14.0pt" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(97)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Manufacturer
Defendants’ Request for Judicial Notice (“RJN”) is denied.<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange" style="margin-right:.5in"><span style="font-size:14.0pt" class="fontChange"><span style="mso-spacerun:yes" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>(98)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
Court further finds that:<o:p></o:p></span></p>

<p class="MsoListParagraphCxSpFirst fontChange" style="margin-top:0in;margin-right:.5in;
margin-bottom:8.0pt;margin-left:1.0in;mso-add-space:auto"><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange"><br>
(a)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>A four-year limitations period
applies to the UCL and either a three-year limitations period or a four-year
limitations period applies to unjust enrichment.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span><br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-top:0in;margin-right:.5in;
margin-bottom:8.0pt;margin-left:1.0in;mso-add-space:auto"><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">(b)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>The equitable exceptions may overcome any
applicable statute of limitations defense to the UCL at the pleading stage.</span>
<span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">The
Complaint states the alleged conspiracy and misconduct, including inflated
prices and overcharging, are ongoing. However, the Court observes that the
Complaint lacks explicit allegations identifying a specific overcharge within
the past four years. Therefore, the Court believes an alternative option is
available. The Court sustains the demurrer with leave to amend allowing the
Attorney General to provide more detailed allegations demonstrating specific
overcharges within the past four years. The Court favors this option due to a
discrepancy between the Plaintiff's statements and a chart in paragraph 130 of
the Complaint regarding the flattening of price increases. The Court leans
toward overruling the demurrer on the grounds of the continuing violation
doctrine and continuous accrual doctrine. The Court believes that the Attorney
General should be allowed to pursue discovery to develop the facts related to
the alleged conspiracy.<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-top:0in;margin-right:.5in;
margin-bottom:8.0pt;margin-left:1.0in;mso-add-space:auto"><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">(c)
<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>UCL's safe harbor provisions do not
bar liability against the Manufacturer Defendants as a matter of law.<o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-top:0in;margin-right:.5in;
margin-bottom:8.0pt;margin-left:1.0in;mso-add-space:auto"><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-top:0in;margin-right:.5in;
margin-bottom:8.0pt;margin-left:1.0in;mso-add-space:auto"><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">(d)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>The allegations of price inflation, coupled
with allegations of collusion and significant harm to insulin consumers in
California, as alleged in the Complaint state a claim of an unfair business
practice and unlawful conduct under the UCL.<br style="mso-special-character:
line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoListParagraphCxSpMiddle fontChange" style="margin-top:0in;margin-right:.5in;
margin-bottom:8.0pt;margin-left:1.0in;mso-add-space:auto"><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">(e)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The allegations of "secret
rebates" and inflated list prices as alleged in the Complaint state a
claim of unfair and unlawful conduct under the UCL.<br>
<br>
(f)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The discounts/rebates allegation
is founded, at least partly, on the alleged violations of the CLRA, subsection
(a)(13).<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>As misrepresentations and/or
omissions, the allegations state claims under the fraud prong of the UCL for
the reasons stated in the unfair-prong and unlawful-prong sections.<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoListParagraphCxSpLast fontChange" style="margin-top:0in;margin-right:.5in;
margin-bottom:8.0pt;margin-left:1.0in;mso-add-space:auto"><span style="font-size:14.0pt;line-height:107%;font-family:&quot;Times New Roman&quot;,serif" class="fontChange">(g)<span style="mso-tab-count:1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp; </span>The unjust enrichment claim does not
describe a theory of recovery; thus, the Court sustains the demurrer to this
cause of action.<span style="mso-spacerun:yes" class="fontChange">&nbsp; </span>The Court’s inclination
is to grant the Attorney General leave to assert a common count for restitution
based on unjust enrichment as an alternative in case.<span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><span style="mso-tab-count:
1" class="fontChange">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><b style="mso-bidi-font-weight:normal"><span style="font-size:14.0pt" class="fontChange">IT IS SO ORDERED:<o:p></o:p></span></b></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange">Dated:<br>
<br style="mso-special-character:line-break">
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
<!--[endif]--><o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange"><br>
Hon. David S. Cunningham III, Judge<o:p></o:p></span></p>

<p class="MsoNormal fontChange"><span style="font-size:14.0pt" class="fontChange">Los Angeles Superior Court<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-bottom:12.0pt"><span style="font-size:14.0pt" class="fontChange"><o:p>&nbsp;</o:p></span></p>

<div style="mso-element:comment-list"><!--[if !supportAnnotations]-->

<hr class="msocomoff" align="left" size="1" width="33%">

<!--[endif]-->

<div style="mso-element:comment"><!--[if !supportAnnotations]-->

<div id="_com_1" class="msocomtxt" language="JavaScript"><!--[endif]--><span style="mso-comment-author:
&quot;Judge David Cunningham&quot;;mso-comment-providerid:AD;mso-comment-userid:&quot;S\:\:DCunningham\@lacourt\.org\:\:dd43d58d-f8a4-4d57-a234-5be322b352d2&quot;"><!--[if !supportAnnotations]--><a name="_msocom_1"></a><!--[endif]--></span>

<p class="MsoCommentText fontChange"><span class="MsoCommentReference fontChange"><span style="font-size:
8.0pt" class="fontChange"><span style="mso-special-character:comment" class="fontChange">&nbsp;<!--[if !supportAnnotations]--><a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/Lilly%20DF%20SOD.docx#_msoanchor_1" class="msocomoff">[DC1]</a><!--[endif]--></span></span></span>citation<o:p></o:p></p>

<!--[if !supportAnnotations]--></div>

<!--[endif]--></div>

<div style="mso-element:comment"><!--[if !supportAnnotations]-->

<div id="_com_2" class="msocomtxt" language="JavaScript"><!--[endif]--><span style="mso-comment-author:
&quot;Judge David Cunningham&quot;;mso-comment-providerid:AD;mso-comment-userid:&quot;S\:\:DCunningham\@lacourt\.org\:\:dd43d58d-f8a4-4d57-a234-5be322b352d2&quot;"><!--[if !supportAnnotations]--><a name="_msocom_2"></a><!--[endif]--></span>

<p class="MsoCommentText fontChange"><span class="MsoCommentReference fontChange"><span style="font-size:
8.0pt" class="fontChange"><span style="mso-special-character:comment" class="fontChange">&nbsp;<!--[if !supportAnnotations]--><a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/Lilly%20DF%20SOD.docx#_msoanchor_2" class="msocomoff">[DC2]</a><!--[endif]--></span></span></span>Paragraph
sign?<o:p></o:p></p>

<!--[if !supportAnnotations]--></div>

<!--[endif]--></div>

</div>***********************************************************************************************************************************************<br><br><br><p class="MsoNormal fontChange" align="center" style="text-align:center"><b><u>People of the State of California</u> (23STCV00719)<o:p></o:p></b></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center"><b>Tentative Ruling Re: Motion to Quash Re: Personal Jurisdiction<o:p></o:p></b></p>

<p class="MsoNormal fontChange"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6/18/24</b><o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Time:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9:00
am<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>Moving Party:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CVS Health Corp. (“CVS Health”)<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>Opposing Party:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The People of the State of California
(the “People”)<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Department:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Judge:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; David
S. Cunningham III<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>________________________________________________________________________<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>TENTATIVE RULING<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify">The hearing on CVS Health’s motion to quash is continued to give the
People an opportunity to conduct discovery regarding purposeful availment.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>BACKGROUND<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify">The People filed this case against three manufacturers of insulin, three
pharmacies, and a holding company.&nbsp;
According to the complaint, the manufacturers provide rebates to the
pharmacies for filling insulin prescriptions.&nbsp;
The People claim the publicly reported list prices for insulin are
inflated and misleading because the manufacturers fail to take the rebate
payments into account when they list the prices.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">Here, the holding company, CVS Health, moves to quash service of the
summons.&nbsp; CVS Health contends the Court
lacks personal jurisdiction.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>LAW<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify">There are “two types of personal
jurisdiction[,]” general and specific.&nbsp; (<u>Bristol-Myers
Squibb Co. v. Superior Court</u> (2017) 582 U.S. 255, 262 (“<u>BMS</u>”).)
Plaintiff only relies on specific jurisdiction. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">“When
determining whether specific jurisdiction exists, courts consider the
‘relationship among the defendant, the forum, and the litigation.’” (<u>Halyard Health, Inc. v. Kimberly-Clark Corp.</u><i> </i>(2019) 43 Cal.App.5<sup>th</sup> 1062,
1070.)&nbsp; “[C]ourts focus on the nature and
quality (not the quantity) of defendant’s activity in the forum state.”&nbsp; (Edmond &amp; Karnow, Cal. Practice Guide:
Civ. Procedure Before Trial (The Rutter Group June 2023 Update) ¶ 3:240.) “[S]ingle
or occasional acts of the corporate agent in a state” may be adequate as long
as the lawsuit relates to the “in-state activity.”&nbsp; (<u>Daimler AG v. Bauman</u> (2014) 571 U.S. 117,
127; see also<i> </i>Edmond &amp; Karnow, supra, at ¶ 3:240.1 [“Provided a ‘substantial
connection’ with the forum is created thereby, even a single act may support
specific personal jurisdiction over a nonresident.”].)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">To exercise
specific jurisdiction, a court must find purposeful availment (the defendant made
purposeful contacts with the forum), relatedness (the litigation arises out of
or relates to the defendant’s forum contacts), and reasonableness (the forum’s “assertion”
of specific jurisdiction “comport[s] with ‘fair play and substantial justice’”).
(<u>Halyard Health</u>, supra,
43 Cal.App.4<sup>th</sup> at 1070.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">Plaintiff bears the initial burden to
establish specific jurisdiction. (See <u>Vons Companies, Inc. v. Seabest Foods,
Inc.</u> (1996) 14 Cal.4<sup>th</sup> 434, 449.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b>DISCUSSION<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b><i>Purposeful Availment<o:p></o:p></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“‘The purposeful availment inquiry . . .
focuses on the defendant's intentionality. &nbsp;[Citation.] &nbsp;This prong is only satisfied when the
defendant purposefully and voluntarily directs his activities toward the forum
so that he should expect, by virtue of the benefit he receives, to be subject
to the court's jurisdiction based on’ his contacts with the forum.”&nbsp; (<u>Pavlovich v. Superior Court</u> (2002) 29
Cal.4<sup>th</sup> 262, 269.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">CVS Health<o:p></o:p></span></b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">CVS Health claims: <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">* CVS Health “has no regular business
operations or employees” in California</span> (Motion, p. 3; see also Reply,
pp. 1-2 [discussing <u>Corcoran v. CVS Health Corp.</u> (N.D. Cal. 2016) 169
F.Supp.3d 970, asserting that CVS Health “is a holding company that performs no
functions unrelated to that status[,]” and criticizing the People’s evidence]);
<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">* the People
cannot use allegations to meet their evidentiary burden (Motion, pp. 3-4
[arguing that allegations treating subsidiary CaremarkPCS Health, LLC (“CVS
Caremark”) and parent CVS Health “as one and the same” are inadequate to show
purposeful availment]; <o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">* CVS Health
“has ‘no direct involvement in directing, managing, or supervising the
operations or employees of’” CVS Caremark (id. at pp. 4-5; see also Reply, pp.
3-4); and<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">* “CVS
Caremark is not an agent or alter ego of CVS Health.” &nbsp;(Motion pp. 5-6; see also Reply, pp. 3-4.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b>The People<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">The People
disagree.&nbsp; They contend “CVS deliberately
and purposefully availed itself of California’s benefits” by:<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">* having “a
corporate mandate to increase drug rebates” (Opposition, p. 10);<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">* involving
CVS Health employees in (1) “insulin rebate negotiation and contracting”
(ibid.), and (2) “the [Formulary Review Committee (“FRC”)] and [Pharmacy and
Therapeutics] Committee [(“PTC”)] that set the standard (template) formularies”
(ibid.); and <o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">* using the
formularies “nationwide, including in California” (id. at pp. 10-11
[analogizing <u>SK Trading International Co. Ltd. v. Superior Court</u> (2022)
77 Cal.App.5<sup>th</sup> 378 (“<u>SK Trading</u>”)]).<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">In addition,
the People say they are not arguing:<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">* “for
personal jurisdiction based solely on CVS Health’s status as the parent of” CVS
Caremark (ibid.); <o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">* “that they
can satisfy the purposeful availment only based on” allegations (id. at pp.
11-12); or<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">* “for
personal jurisdiction based on an agency or alter ego theory” (id. at p. 12). <o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b>Analysis<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">The Court
starts with CVS Health’s evidence.&nbsp; CVS
Health cites the declaration of Thomas Moffat, the vice president and senior
legal counsel of CVS Pharmacy, Inc.&nbsp;
Moffatt declares:<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">4.
CVS Health Corporation is a holding company, and its primary functions are to
issue stock that is traded on the New York Stock Exchange and to file reports
with the U.S. Securities and Exchange Commission. CVS Health Corporation also
performs certain other functions related to those primary functions. However,
CVS Health Corporation has no operations unrelated to its status as a holding
company. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">5.
CVS Health Corporation is organized under the laws of the State of Delaware,
and its principal place of business is located in the State of Rhode Island. It
has no offices or facilities in California, and none of its limited business
functions regularly occur there. CVS Health Corporation has no assets, income,
employees, or operations in California. CVS Health Corporation is not qualified
as a foreign corporation under the laws of California, it does not have a
registered agent for service of process there, and it is not regulated by any
California state agency. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">6.
CVS Health Corporation has agreements with a limited number of senior
executives who are officers of CVS Health Corporation and who are employed by
and provide services to various subsidiaries of CVS Health Corporation. None of
these officers is located in California. CVS Health Corporation has no direct
involvement in directing, managing, or supervising the operations or the
employees of any of its direct or indirect subsidiary companies, including
CaremarkPCS Health, L.L.C. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">7.
CVS Health Corporation is a separate and distinct company from CaremarkPCS
Health, L.L.C. Both of these companies observe and enforce corporate
formalities. CaremarkPCS Health, L.L.C. is not a reporting division of CVS
Health Corporation. Rather, it is a separate entity. It has its own governing
documents; maintains its own corporate records, bank accounts, and financial
records; for jurisdictions where required to file separately, files its own tax
returns; funds its own operations, if any; bears responsibility for its own
debts, if any; and has its own managers, who meet separately from the board of
directors of CVS Health Corporation.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">(Moffatt
Decl., ¶¶ 4-7.)&nbsp; These facts support CVS
Health’s position, but they do not end the analysis.&nbsp; <o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">“[C]ourts ‘begin[ ] with “the firm
proposition that neither ownership nor control of a subsidiary corporation by a
foreign parent corporation, without more, subjects the parent to the
jurisdiction of the state where the subsidiary does business.”’”&nbsp; (<u>SK Trading</u>, supra, 77 Cal.App.5<sup>th</sup>
at 388.)&nbsp; The result changes, however, if
the parent’s contacts “reflect more than passive investment or ownership of a
subsidiary.”&nbsp; (Ibid.)&nbsp; </span>The necessary “<span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">question is . . . whether the defendant has
purposefully directed its activities at the forum state by causing a separate
person or entity to engage in forum contacts.”&nbsp;
(Ibid.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">In <u>SK Trading</u>, which the People
cite, the plaintiff alleged that “several oil and gas firms” “participat[ed] in
a multiyear conspiracy to manipulate the California gasoline market[.]”&nbsp; (Id. at 382.)&nbsp;
One of the companies – SK Trading, a South Korean corporation – moved to
quash.&nbsp; The trial court denied the
motion, finding that “SK Trading purposefully directed its activities at
California residents by and through” a subsidiary, “SK Energy, whose employees
made trades on the California spot market and engaged in business in California
on behalf of SK Trading.”&nbsp; (Id. at
387.)&nbsp; The Court of Appeal considered the
following evidence and affirmed:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">. . . In January 2014, SK
Trading conducted its “1st Half 2014 Strategic Meeting” at which it set forth a
plan to improve SK Energy's profits from trading on the spot market in
California. The plan encouraged SK Energy to hire a new trader with California
gasoline trading experience and expertise and called for the promotion of
“alliances” or “joint ventures” between SK Energy and other gas firms.
Thereafter, a business plan was drafted for SK Energy incorporating the
strategies previously discussed.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">SK Trading subsequently
supported and approved the hiring of former Vitol trader David Niemann as SK
Energy's new west coast gasoline trader. SK Trading received background
information on potential hires, including their trading history and likelihood
of being recruited. SK Trading organized the information that SK Energy
provided to its personnel committee in support of its decision to hire Niemann.
A SK Trading executive interviewed Niemann at SK Energy's headquarters in
Houston and provided final approval for his hire. The SK Trading executive then
reported to the SK Trading CEO that he supported hiring Niemann “given his
focus on teamwork, clear views based on more than 20 years of experience in the
[United States West Coast] market, and decent attitudes.” Niemann thought of SK
Trading as his “management” and accused SK Trading of “micromanaging every
little aspect of the finances.”<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">Executives of both SK
Trading and SK Energy met regularly with Vitol executives throughout 2014 and
2015. In early 2015, SK Trading's CEO reported on a meeting with Vitol's CEO
and Global Distillates Bookleader, among others, at which they “exchanged opinions
on the overall issues of the oil industry such as oil prices” and “Vitol agreed
to make mutual efforts to develop cooperative projects with SK.” In July 2016,
a SK Trading executive visited Houston to meet with, among others, Vitol's west
coast gasoline trader. Vitol's trader informed him that Vitol “has been
achieving good performance record last year and this year through JV [joint
venture] with SK ... in the USWC market” and that their “JV with Niemann is
more effective and creates higher net profits than any other Regional Book.”
The Vitol trader also advised that “[d]ue to [his] lack of experience, he had
quite a tough time in his first year of trading (year 2014), but along with the
super strong trend of USWC market in 2015, he has continued collaboration with
Niemann through Storage, cargo JV, etc.”<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span class="costarpage fontChange"><b><span style="mso-fareast-font-family:
&quot;Times New Roman&quot;;mso-fareast-theme-font:major-fareast;color:#3C6848;
border:solid #86B392 1.5pt;padding:0in" class="fontChange"><o:p>&nbsp;</o:p></span></b></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">Throughout the relevant
time period, SK Energy submitted a weekly report to SK Trading. The report
included position and valuation information as well as information on CARBOB
trading and the ongoing coordination with Vitol related to the California market.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">* * *<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">The record establishes that SK Trading
actively adopted and implemented a plan designed to increase SK Energy's
profits derived from trading on the California spot markets. SK Trading
actively participated in the hiring and management of SK Energy's California
trader and facilitated agreements between SK Energy and Vitol regarding
gasoline sales in California. These are not, as SK Trading suggests, “general
management activities common to parent-subsidiary relationships.” In <u>Sonora
Diamond Corp. v. Superior Court</u> (2000) 83 Cal.App.4<sup>th</sup> 523, 552,
99 Cal.Rptr.2d 824, the court emphasized that “[t]he critical acts may be taken
directly by the parent or indirectly through the subsidiary, but in all events
must be attributable to the parent corporation itself. Thus, the theory does
not rest on a finding that the subsidiary is a sham corporation or an agent or
representative of the parent. Rather, the focus is on the acts of the parent
itself.” Here, the record establishes that SK Trading officers personally and
directly participated in making the decisions affecting the California gasoline
market that the People allege violated California law.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify;mso-pagination:
none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify;mso-pagination:
none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">(Id. at 385-386, 388,
underlining of case name added.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify;mso-pagination:
none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">The Court turns to the People’s
evidence.&nbsp; The People cite eight
exhibits.&nbsp; The Court will discuss them
individually.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Exhibit H is testimony from Dr. Alan
Lotvin, CVS Health’s executive vice president and chief transformation officer,
during a motion hearing in a federal case called <u>United States v. CVS Health
Corp.</u>&nbsp; Dr. Lotvin testified that,
“across the entire” CVS corporate family, “the mandate . . . is to grow the
business[,]” which necessitates “winning new clients.”&nbsp; (The People’s Exhibit List, Ex. H, p.
305.)&nbsp; The testimony says nothing about
California contacts by either CVS Health or CVS Caremark.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Exhibit M is a July 2013 rebate contract
between CVS Caremark and Sanofi-Aventis U.S. LLC (“Sanofi”).&nbsp; The People pinpoint page </span>CVSCM_SFC_0003995,
the signature page of the contract.&nbsp; (See
Opposition, p. 10 [misnumbering the page as CVSCV_SFC_0003995.)&nbsp; It contains signatures from CVS Caremark’s
senior vice president of trade relations and two Sanofi vice presidents.&nbsp; (See the People’s Exhibit List, Ex. M, p.
CVSCM_SFC_0003995.)&nbsp; There is no mention
of CVS Health.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">Exhibit N is
a printout of Gary Loeber’s LinkedIn profile.&nbsp;
No specific page is pinpointed.&nbsp;
(See Opposition, p. 10.)&nbsp; Loeber
is the person who signed the exhibit M rebate contract on behalf of CVS
Caremark.&nbsp; The LinkedIn profile suggests
that he also worked for CVS Health at that time; however, the page does not
establish that signed the contract in his capacity as a CVS Health
employee.&nbsp; (See the People’s Exhibit
List, Ex. N, p. 003.)&nbsp; Moreover, the
website is unauthenticated and unverified.<a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/people%20v%20eli%20lilly%206-18-24%20tentative%20ruling%20re%20mtn%20to%20quash%20re%20personal%20jurisdiction%20(23stcv00719).docx#_ftn1" name="_ftnref1" title=""><span class="MsoFootnoteReference fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[1]</span></span><!--[endif]--></span></a><o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">Exhibit O is
a testimony from Joseph Anderson in a federal case called <u>In re EpiPen
(Epinephrine Injection, USP) Marketing, Sales Practices &amp; Antitrust
Litigation</u>.&nbsp; The People do not
explain who Anderson is.&nbsp; The pinpoint is
page 51 (see Opposition, p. 10), which states:<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">THE
WITNESS: So if I -- I recall, the statement I made was that one of the -- one
of the roles that FRC plays is ensuring that the -- that the recommendations,
you know, focus on those that must align with the priorities and strategies of
CVS Caremark and its clients. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">In
general, that -- that is, you know, based on the, you know, the formulary that
a particular client has chosen, you know, trying to deliver the -- the lowest
net cost, manage a clinically appropriate formulary, provide, you know, you
know, formulary, you know, services to those clients that, you know, that we
believe are, you know, competitive in the market.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify;mso-pagination:
none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify;mso-pagination:
none">(The People’s Exhibit List, Ex. O, p. 51.)&nbsp; CVS Health is not discussed.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify;mso-pagination:
none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">Exhibit Q is
a list of CVS Health’s PTC participants.&nbsp;
Most of the participants are unnamed.&nbsp;
The extent of the California connection shown on the face of the list is
that a couple of the unnamed participants are licensed to practice medicine in
California.&nbsp; (See id. at Ex. Q, pp. 001,
004.)&nbsp; Purposeful availment requires
more.&nbsp;&nbsp; <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify;mso-pagination:
none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">Exhibit R is
an August 2019 letter from CVS Health’s counsel to United States Senators
Charles Grassley and Ron Wyden.&nbsp; The
People highlight pages three through five.&nbsp;
While the pages do address the FRC and PTC, they do not address
California, let alone targeted contacts.&nbsp;
(See the People’s Exhibit List, Ex. R, pp. 3-5).&nbsp; Indeed, at most, the letter shows contacts
targeted at Washington, DC. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">Exhibit T is
a July 2015 declaration from Brian McCarthy in a federal case called <u>Pharmaceutical
Care Management Association v. Rutledge</u>.&nbsp;
McCarthy is the chief operating officer of the Pharmaceutical Care
Management Association.&nbsp; The pinpointed
paragraphs are paragraphs two through 4 and 6:&nbsp;
<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">2.
Pharmacy Benefit Managers ("PBM" or ''PBMs") administer
prescription drug plans for more than 236 million Americans covered by
self-funded and insured ERISA-governed employee health benefit plans, health
plans offered by non-profit hospital or medical services corporations, health
insurers, health maintenance organizations, and union-sponsored plans. PBMs
also administer pharmaceutical benefit plans for state governments, as well as
Federal programs including Medicare Part D, Medicaid, and the Federal Employee
Health Benefits Program (FEHBP). Each Member PBM conducts business nationwide.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify;mso-pagination:
none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">3.
Plaintiff PCMA is a non-profit 50l(c)(6) corporation organized in 2002 under
the laws of laws of the State of Delaware. It is the national trade association
representing PBMs. PCMA currently comprises the following eleven member
companies: Aetna, Cigna, Catamaran, CVSHealth, Express Scripts, Humana Pharmacy
Solutions, LDI, Medlmpact Healthcare System, Optum Rx, Prime Therapuetics, and
USScript (collectively, Member PBMs"). The Member PBMs comprise the
largest PBMs in the country and account for approximately 75% of annual
prescription volume nationwide, as of the latest figures available, from the
third quarter of 2012. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">4.
As reflected in PCMA's certificate of incorporation, a true copy of which is
attached hereto as Exhibit A, PCMA's purpose is as follows: <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:1.0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">(a)
to advance the common interests of these companies engaged in the business of
pharmaceutical care management; (b) to improve the safety and affordability of
prescription drug services; ( c) to advance pharmaceutical care management as
the most effective means of delivering prescription drug care; ( d) to lead,
educate and advocate on behalf of those companies engaged in pharmaceutical
care management; and ( e) to do everything necessary, proper, advisable, or
convenient for the accomplishment of PCMA's purposes . . . .<o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify;mso-pagination:none">6.
PCMA fulfills this purpose in part by leading industry initiatives on
legislation and regulation. As part of its legal strategy, PCMA also initiates
litigation on behalf of Member PBMs to challenge those laws and regulations
that cause the Member PBMs undue harm. On information and belief, PCMA has
brought four such challenges since its founding, including the present
litigation regarding Act 900.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">(Id. at Ex.
T, ¶¶ 2-4, 6; see also Opposition, pp. 10, 11.)&nbsp;
The declaration is unauthenticated, the statements are unverified, and
the statements fail to establish contacts targeted at California as opposed to
generic targeting of the nation.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">Exhibit W is
a January 2021 SAG-AFTRA summary plan description.&nbsp; The People cite page 57.&nbsp; (See Opposition, p. 10.)&nbsp; Among other things, it states that “[t]he
Plan uses Caremark’s Advanced Control Formulary, which is a list of covered
brand-name and generic medications.”&nbsp;
(The People’s Exhibit List, Ex. W, p. 57 [also numbered as page 002].)&nbsp; CVS Health is not named, nor do the
statements show direction and participation.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">On the
current record, the People’s showing is insufficient to satisfy their burden,
and <u><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">SK Trading</span></u><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange"> is distinguishable.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">T</span>he Court finds that a discovery
continuance should be granted.&nbsp; (See
Opposition, pp. 14-15 [requesting a discovery continuance]; see also <u>In re
Automobile Antitrust Cases I &amp; II</u> (2005) 135 Cal.App.4<sup>th</sup>
100, 127 [“A plaintiff attempting to assert personal jurisdiction over a
nonresident defendant is entitled to an opportunity to conduct discovery of the
jurisdictional facts necessary to sustain its burden of proof.”].)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b><i><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Relatedness<o:p></o:p></span></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b><i><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">For the relatedness prong, “‘the suit’
must ‘aris[e] out of or relat[e] to the defendant’s contacts with the
forum.’”&nbsp; (<u>BMS</u>, supra, 582 U.S. at
262.)&nbsp; “In other words, there must be ‘an
affiliation between the forum and the underlying controversy, principally, [an]
activity or occurrence that takes place in the forum State and is therefore
subject to the State’s regulation.’”&nbsp;
(Id.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">This prong appears to be
uncontested.&nbsp; CVS Health does not address
it in the moving brief.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b><i>Reasonableness<o:p></o:p></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b><i>&nbsp;</i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none">“<span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Finally, it must appear that the
exercise of jurisdiction by local courts in the particular case would ‘comport
with fair play and substantial justice.’”&nbsp;
(Edmond &amp; Karnow, supra, at ¶ 3:244.)&nbsp; “The burdens on the nonresident must clearly
outweigh the plaintiff’s and forum’s interests.”&nbsp; (Id. at ¶ 3:247.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">This prong also appears to be
uncontested.&nbsp; The moving brief is
silent.&nbsp; <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify;mso-pagination:none"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange"><o:p>&nbsp;</o:p></p>

<div><!--[if !supportFootnotes]--><br clear="all">

<hr align="left" size="1" width="33%">

<!--[endif]-->

<div id="ftn1">

<p class="MsoFootnoteText fontChange" style="text-align:justify"><a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/people%20v%20eli%20lilly%206-18-24%20tentative%20ruling%20re%20mtn%20to%20quash%20re%20personal%20jurisdiction%20(23stcv00719).docx#_ftnref1" name="_ftn1" title=""><span class="MsoFootnoteReference fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[1]</span></span><!--[endif]--></span></a>
Almost all of the exhibits lack authentication and verification.&nbsp; The People’s counsel lacks personal knowledge
to render the exhibits admissible.<o:p></o:p></p>

</div>

</div><br>***********************************************************************************************************************************************<br><p class="MsoNormal fontChange" align="center" style="text-align:center"><b><u>People of the State of California</u> (23STCV00719)<o:p></o:p></b></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" align="center" style="text-align:center"><b><span style="background:yellow;mso-highlight:yellow" class="fontChange">Tentative Ruling
Re: Demurrer</span><o:p></o:p></b></p>

<p class="MsoNormal fontChange"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6/18/24</b><o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Time:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9:00
am<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>Moving Party:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CaremarkPCS Health, LLC (“CVS
Caremark”), CVS Health Corp. (“CVS Health”), Express Scripts, Inc. (“Express
Scripts”), and OptumRX, Inc. (“OptumRX”) (collectively “PBM Defendants”)<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="margin-left:1.5in;text-align:justify;text-indent:
-1.5in"><b>Opposing Party:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The People of the State of California
(the “People”)<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Department:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Judge:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; David
S. Cunningham III<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>________________________________________________________________________<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>TENTATIVE RULING<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>PBM Defendants’ Request for Judicial Notice (“RJN”)<o:p></o:p></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>&nbsp;</i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify">PBM Defendants’ RJN is denied.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>PBM Defendants’ Demurrer<o:p></o:p></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>&nbsp;</i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Statutes of Limitations<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify">PBM Defendants’ demurrer is sustained with leave to amend.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Unfair Competition Law (“UCL”)<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify">PBM Defendants’ demurrer is overruled as to the safe-harbor issue,
unfair-prong issue, unlawful-prong issue, and fraud-prong issue.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Unjust Enrichment<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify">PBM Defendants’ demurrer is sustained with leave to amend to assert a
common count for restitution.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>CVS Health’s Demurrer<o:p></o:p></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify">CVS Health’s demurrer is sustained with leave to amend.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>BACKGROUND<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify">The People filed this case against three manufacturers of insulin
(Manufacturer Defendants), three pharmacy-benefit managers (“PBM Defendants” or
“PBMs”), and a holding company (CVS Health).&nbsp;
<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">At its core, this is a price-gouging case.&nbsp; The complaint alleges:<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">1. Millions of
Californians suffer from diabetes. For many diagnosed with this condition,
access to insulin to regulate their blood sugar levels is a matter of life and
death. Yet, the excessive price of insulin undermines their access to this
century-old, life-sustaining drug. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">2. Inexplicably,
list prices for insulin have risen several hundred percent over the last two
decades. Today, California diabetics who require insulin to survive and who are
exposed to insulin’s full price, such as uninsured consumers and consumers with
high deductible insurance plans, pay thousands of dollars per year for insulin.
<o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">3. The excessive
price of insulin disproportionately harms low-income communities who must
choose between paying for insulin or everyday necessities, such as housing and
food. To stretch dollars and insulin supplies, many Californians have turned to
the dangerous practice of rationing insulin or skipping doses despite the
severe risks of loss of sight, limbs, or death. These harms are further
compounded for Black, Hispanic, and low-income communities in California as
they are more likely to be diagnosed with diabetes and to be uninsured or
underinsured. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">4. The United States
insulin market is an oligopoly. The defendants include three insulin
manufacturers (Manufacturer Defendants)—Eli Lilly, Novo Nordisk, and Sanofi—who
make nearly all of the insulin sold in the United States. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">5. Also named as
defendants are the three pharmacy benefit managers (PBM Defendants) that
dominate the PBM market—CVS Caremark, Express Scripts, and OptumRx. PBMs are
entities that administer prescription drug programs, which are a part of the
essential benefits that health insurance plans must cover. One aspect of the
PBM’s role is determining the prescription drugs a given health insurance plan
covers (known as a formulary). Another aspect of the PBM’s role is negotiating
confidential contracts that provide for post-sale discounts (rebates) that a
drug manufacturer will provide to the PBM, not the consumer, if a consumer
fills a prescription for the manufacturer’s drug.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">6. The conduct at
issue in this Complaint has two main components. First, the Manufacturer
Defendants aggressively raise the list price of insulin in lockstep with each
other to artificial levels. The inflated and artificial insulin price increases
have significantly exceeded inflation and are not justified by advances in the
efficacy of the drugs or the cost of manufacturing. Insulin costs less than $10
a month to manufacture and its development costs have long been recouped. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">7. Second, PBM
Defendants obtain significant secret rebates, which are a percentage of the
inflated and artificial list price, from the Manufacturer Defendants in
exchange for favorable placement on the PBM’s standard formularies. This
rebating strategy incentivizes the Manufacturer Defendants to raise their list
prices high and higher. The result is that the PBM Defendants’ standard
formularies promote the Manufacturer Defendants’ high list-price insulin
products over lower list-price insulins in California and nationwide. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">8. The Manufacturer
Defendants participate in this conduct because being listed on a PBM
Defendant’s standard national formulary is a financial boon. Like the insulin
market in the United States, the PBM market in the United States is also
oligopolistic. The PBM Defendants capture over 75% of the market. Being
included on a PBM Defendant’s standard national formulary drives higher sales
volume and revenue. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">9. The PBM
Defendants participate in this conduct because their revenue is related to the
size of the secret rebates they negotiate. Larger list prices support larger
secret rebates because rebates are calculated as a percentage of the list
price. Also, the PBM Defendants have a perverse incentive for ever-growing list
prices. The PBM Defendants claim they can extract higher rebates due to their
market power. If drug list prices grow, demand for their rebate negotiation
services increases. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">10. In addition to
participating in conduct raising list prices, Defendants made
misrepresentations about insulin prices and their actions in relation to
insulin prices. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">11. By increasing
the list price of insulin, Defendants harm diabetic Californians who require
insulin. They are exposed to insulin’s unaffordable list price and do not
benefit from the secret rebates.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">12. Defendants are
liable for the harms caused by their conduct under theories that protect
consumers and competition. Defendants’ conduct harms diabetic Californians who
require insulin without a sufficient counterweighing benefit to them.
Additionally, Defendants’ conduct runs against several principles of honesty
and fair dealing with competitors and consumers, including (a) prohibition on
false discounts and prohibition on misleading statements made in furtherance of
the false discounts, (b) prohibition on members of oligopolies abusing their
market power in order to raise their product prices to unconscionable levels,
(c) prohibition on middlemen in product distribution chains with large market
share leveraging their market power to obtain secret rebates from manufacturers
that are not granted to their smaller middlemen competitors, and (d)
prohibition on members of oligopolies adopting practices that facilitate the
coordination of price increases. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-right:.5in;text-align:justify">(Complaint, ¶¶
1-12.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">The complaint contains two causes of action: (1) violation of the UCL;
and (2) unjust enrichment.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">Here, PBM Defendants and CVS Health demur to both causes of action.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>LAW<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>&nbsp;</i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify">When considering demurrers,
courts read the allegations liberally and in context, and “treat the demurrer
as admitting all material facts properly pleaded, but not contentions,
deductions or conclusions of fact or law.” (<u>Serrano v. Priest</u> (1971) 5
Cal.3d 584, 591.)&nbsp; “<span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">A demurrer
tests the pleadings alone and not the evidence or other extrinsic matters.
Therefore, it lies only where the defects appear on the face of the pleading or
are judicially noticed.”&nbsp; (</span><u><span style="border: 1pt none windowtext; padding: 0in;" class="fontChange">Hahn v. Mirda</span></u>&nbsp;(2007) 147 Cal.App.4th 740, 747.)&nbsp; It is error “<span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">to sustain a demurrer without leave to amend if the
plaintiff shows there is a reasonable possibility any defect identified by the
defendant can be cured by amendment.”&nbsp; (</span><u><span style="border:
none windowtext 1.0pt;mso-border-alt:none windowtext 0in;padding:0in" class="fontChange">Aubry v.
Tri-City Hospital Dist.</span></u>&nbsp;(1992) 2 Cal.4th 962, 967.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>DISCUSSION<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>PBM
Defendants’ RJN<o:p></o:p></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">PBM
Defendants <span style="color:#3D3D3D" class="fontChange">seek judicial notice of
legislative reports and hearings (exhibits A through E) and rules published in
the Federal Register (exhibits F through I).<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
Court finds that the</span> RJN should be denied because PBM Defendants failed
to submit evidence authenticating the documents.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">Alternatively, if defense counsel
makes a successful offer of proof at the hearing, the Court’s inclination would
be to grant the RJN since the documents constitute legislative official acts.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>Tentative Ruling Re:
Manufacturer Defendants’ Demurrer<o:p></o:p></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>&nbsp;</i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify">The Court incorporates <span style="color:#3D3D3D" class="fontChange">the tentative ruling on Manufacturer Defendants’
demurrer.&nbsp; For the most part, the
analysis there applies equally here.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>PBM Defendants’ Demurrer<o:p></o:p></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>&nbsp;</i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>Statutes of Limitations<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify">A four-year limitations period
applies to the UCL (see <span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Stern,
Business and Professions Code Section 17200 Practice (The Rutter Group March
2023 Update) </span><span style="color:#3D3D3D" class="fontChange">¶ 5:290), and either a
three-year limitations period or a four-year limitations period applies to
unjust enrichment.&nbsp; (See <u>Federal
Deposit Ins. Corp. v. Dintino</u> (2008) 167 Cal.App.4<sup>th</sup> 333, 347
[finding a three-year limitations period applicable to fraud-based unjust
enrichment]; see also Opposition, p. 33 [arguing that Code of Civil Procedure
section 343’s four-limitations period should apply because the People’s claim
is equity-based].)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">PBM
Defendants contend the demurrer should be sustained because both causes of
action accrued prior to 2019, more than four years before the People filed
their complaint.&nbsp; (See Demurrer, pp.
4-6.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
People claim the allegations satisfy equitable exceptions, namely, the
last-overt-act rule, the continuing-violation doctrine, and the
continuous-accrual doctrine.&nbsp; (See
Opposition, pp. 29-33.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">Manufacturer
Defendants assert that the equitable exceptions do not apply.&nbsp; (See Demurrer, pp. 5-6; see also Reply, pp.
1-3.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
demurrer is sustained with leave to amend.&nbsp;
The complaint alleges a two-part conspiracy between two oligopolies –
Manufacturer Defendants and PBM Defendants.&nbsp;
In short, the People claim Manufacturer Defendants agree to artificially
inflate list prices in order to fund large rebates to PBM Defendants “in
exchange for favorable placement on” PBM Defendants’ “standard
formularies.”&nbsp; (Complaint, ¶¶ 6, 7; see
also id. at ¶¶ 4-5, 8-</span>9, 62, 133-143, 147-176<span style="color:#3D3D3D" class="fontChange">.)&nbsp; Allegedly, the large rebates </span>“are a
percentage of the inflated and artificial list price[s.]”&nbsp; (Id. at ¶ 7.)&nbsp;
The problem is that the People’s own chart shows <span style="color:
#3D3D3D" class="fontChange">prices flatlining since 2018 (see id. at ¶ 130), which, seemingly, if
true, could have curtailed, if not ended, the purported rebate scheme.&nbsp; The People need to provide amended
allegations to address this discrepancy and to show price increases and
actionable conduct during the limitations period.&nbsp; (See Tentative Ruling Re: Manufacturer
Defendants’ Demurrer, pp. 4-7.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify">This ruling applies to all three
equitable exceptions.&nbsp; (See ibid.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>UCL<o:p></o:p></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b>&nbsp;</b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><i><u>Safe
Harbor<o:p></o:p></u></i></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i>&nbsp;</i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify">“If t<span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">he Legislature has permitted certain
conduct or considered a situation and concluded no action should lie, courts
may not override that determination.”&nbsp; (<u>Klein
v. Chevron U.S.A., Inc.</u> (2012) 202 Cal.App.4<sup>th</sup> 1342, 1379
[quoting <u>Cel-Tech Communications, Inc. v. Los Angeles Cellular Telephone Co.</u>
(1999) 20 Cal.4<sup>th</sup> 163, 182].) &nbsp;“When specific legislation provides a ‘safe
harbor,’ plaintiffs may not use the general unfair competition law to assault
that harbor.”&nbsp; (Ibid.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">This rule “does not . . . prohibit an action under the unfair
competition law merely because some other statute on the subject does not . . .
prohibit the challenged conduct.”&nbsp;
(Ibid.) &nbsp;“To forestall an action
under the unfair competition law, another provision must . . . clearly permit
the conduct.&nbsp; There is a difference
between (1) not making an activity unlawful, and (2) making that activity
lawful.”&nbsp; (Ibid. [instructing that “a statute
that does not ‘affirmatively permit[ ] [a type of conduct] . . . does not
preclude a court from deeming [such] conduct unfair under the unfair
competition law’”].)&nbsp; Stated another way,
“the Legislature's mere failure to prohibit an activity does not prevent a
court from finding it unfair.”&nbsp; (<u>BBBB
Bonding Corp. v. Caldwell</u> (2021) 73 Cal.App.5<sup>th</sup> 349, 377.)&nbsp; “[T]o ‘qualify for the “safe harbor” rule,
the defendant must show that a statute “explicitly prohibit[s] liability for
the defendant's acts or omissions” [citation] or “expressly precludes an action
based on the conduct.”’”&nbsp; (Ibid.)&nbsp; “If a statute does not ‘explicitly prohibit
liability’ for a defendant's specific acts or omissions, the court may not
create an ‘implied safe harbor.’”&nbsp;
(Ibid.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">PBM Defendants claim the safe harbor applies because federal
and state law “protect[] manufacturers’ ability to ‘voluntarily make pricing
decisions’ and PBMs’ right ‘to negotiate discounts and rebates.’”&nbsp; (Demurrer, p. 8.)&nbsp; In support, PBM Defendants cite 42 U.S.C.
sections 1320b-23(b), 1395w-3a(c)(6)(B), and 1396r-8(k)(1)(B)(i)(IV), Health
and Safety Code section 127676(b)(2), and Business and Professions Code section
4441(e).&nbsp; (See Demurrer, pp. 7-9; see
also Reply, pp. 4-5.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Sections 1320b-23(b), 1395w-3a(c)(6)(B), and 127676(b)(2) do
not help PBM Defendants.&nbsp; (See Tentative
Ruling Re: Manufacturer Defendants’ Demurrer, pp. 7-11.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Section 1396r-8(k)(1)(B)(i)(IV) defines “average manufacturer
price” and excludes “rebates or discounts” from the definition:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><span class="num fontChange"><b><span style="color: rgb(51, 51, 51); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">(k)</span></b></span><span class="heading fontChange"><b><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; color: rgb(51, 51, 51); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Definitions<a name="k_1"></a><o:p></o:p></span></b></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><span class="heading fontChange"><b><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; color: rgb(51, 51, 51); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></b></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><span class="heading fontChange"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; color: rgb(51, 51, 51); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">* * *<o:p></o:p></span></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><span class="heading fontChange"><b><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; color: rgb(51, 51, 51); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></b></span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><span class="num fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:major-fareast;
color:#333333" class="fontChange">(1) </span></b></span><span class="heading fontChange"><b><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; color: rgb(51, 51, 51);" class="fontChange">Average manufacturer price</span></b></span><b><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; color: rgb(51, 51, 51); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange"><o:p></o:p></span></b></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><a name="k_1_A"></a><a name="k_1_B"></a><span class="num fontChange"><b><span style="mso-fareast-font-family:
&quot;Times New Roman&quot;;mso-fareast-theme-font:major-fareast;color:#333333" class="fontChange">&nbsp;</span></b></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="num fontChange"><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:
major-fareast;color:#333333" class="fontChange">* * *<o:p></o:p></span></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="num fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:
major-fareast;color:#333333" class="fontChange">&nbsp;</span></b></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="num fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:
major-fareast;color:#333333" class="fontChange">(B) </span></b></span><span class="heading fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:major-fareast;
color:#333333" class="fontChange">Exclusion of customary prompt pay discounts and other payments</span></b></span><span style="color:#333333" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><a name="k_1_B_i"></a><span class="num fontChange"><b><span style="mso-fareast-font-family:
&quot;Times New Roman&quot;;mso-fareast-theme-font:major-fareast;color:#333333" class="fontChange">&nbsp;</span></b></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="heading fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;
mso-fareast-theme-font:major-fareast;color:#333333" class="fontChange">(i) In general<o:p></o:p></span></b></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="heading fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;
mso-fareast-theme-font:major-fareast;color:#333333" class="fontChange">&nbsp;</span></b></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="chapeau fontChange"><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;
mso-fareast-theme-font:major-fareast;color:#333333" class="fontChange">The average manufacturer
price&nbsp;for a covered outpatient drug shall exclude – </span></span><span style="color:#333333" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><a name="k_1_B_i_I"></a><a name="k_1_B_i_IV"></a><span class="num fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:major-fareast;
color:#333333" class="fontChange">&nbsp;</span></b></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="num fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:
major-fareast;color:#333333" class="fontChange">* * *<o:p></o:p></span></b></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="num fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:
major-fareast;color:#333333" class="fontChange">&nbsp;</span></b></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="num fontChange"><b><span style="mso-fareast-font-family:&quot;Times New Roman&quot;;mso-fareast-theme-font:
major-fareast;color:#333333" class="fontChange">(IV)</span></b></span><span style="color:#333333" class="fontChange">
payments received from, and rebates or discounts provided to, pharmacy benefit
managers, managed care organizations, health maintenance organizations,
insurers, hospitals, clinics, mail order pharmacies, long term care providers,
manufacturers, or any other entity that does not conduct business as a
wholesaler or a retail community pharmacy, unless the drug is an inhalation,
infusion, instilled, implanted, or injectable drug that is not generally
dispensed through a retail community pharmacy<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="color:#333333" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="color:#333333" class="fontChange">(42 U.S.C. § </span><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">1396r-8, subd. (k)(1)(B)(i)(IV), emphasis in original.)</span><span style="color:#333333" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><a name="k_1_B_i_V"></a><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Section 4441(e) sets certain reporting requirements for PBMs:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(e) The pharmacy benefit
manager shall, on a quarterly basis, disclose, upon the request of the
purchaser, the following information with respect to prescription product
benefits specific to the purchaser:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(1) The aggregate
wholesale acquisition costs from a pharmaceutical manufacturer or labeler for
each therapeutic category of drugs containing three or more drugs, as outlined
in the state's essential health benefits benchmark plan pursuant to Section
1367.005 of the Health and Safety Code.&nbsp; <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(2) The aggregate amount
of rebates received by the pharmacy benefit manager by therapeutic category of
drugs containing three or more drugs, as outlined in the state's essential
health benefits benchmark plan pursuant to Section 1367.005 of the Health and
Safety Code. The aggregate amount of rebates shall include any utilization
discounts the pharmacy benefit manager receives from a pharmaceutical
manufacturer or labeler.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(3) Any administrative
fees received from the pharmaceutical manufacturer or labeler.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(4) Whether the pharmacy
benefit manager has a contract, agreement, or other arrangement with a
pharmaceutical manufacturer to exclusively dispense or provide a drug to a
purchaser's employees, insureds, or enrollees, and the application of all
consideration or economic benefits collected or received pursuant to that
arrangement.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(5) Prescription drug
utilization information for the purchaser's enrollees or insureds that is not
specific to any individual enrollee or insured.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(6) The aggregate of
payments, or the equivalent economic benefit, made by the pharmacy benefit
manager to pharmacies owned or controlled by the pharmacy benefit manager.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(7) The aggregate of
payments made by the pharmacy benefit manager to pharmacies not owned or
collected by the pharmacy benefit manager.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin: 0in 0.5in 0.0001pt; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(8) The aggregate amount
of the fees imposed on, or collected from, network pharmacies or other
assessments against network pharmacies, and the application of those amounts
collected pursuant to the contract with the purchaser.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-right: 0.5in; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin-right: 0.5in; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">(Cal. Bus. &amp; Prof.
Code § 4441, subd. (e).)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="margin-right: 0.5in; text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
Court agrees with the People that neither of these statutes </span>provides a
safe harbor as to the price-inflation/rebates conspiracy alleged in the
complaint.&nbsp; (See Opposition, pp. 23-26;
see also <span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Tentative Ruling Re:
Manufacturer Defendants’ Demurrer, pp. 7-11 [analyzing safe-harbor issue and
conspiracy allegations].)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;">The demurrer is
overruled.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><i><u><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Unfair Prong</span></u></i><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
UCL’s unfair prong prohibits unfair business practices. &nbsp;Because the UCL is written in the disjunctive,
“a business practice can be ‘unfair’ . . . even if it is not ‘deceptive’ and
even if it is ‘lawful.’”&nbsp; (Stern, supra,
at ¶ 3:112.)&nbsp; “The ‘unfair’ standard is
intentionally broad, allowing courts maximum discretion to prohibit new schemes
to defraud.”&nbsp; (Id. at ¶ 3:113.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">PBM
Defendants contend the People’s allegations </span>fail under the UCL’s
balancing test, <span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Federal Trade
Commission post-1980 test, and tethering test.&nbsp;
(See Demurrer, pp. 16-19; see also Reply, pp. 8-12.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">The Court disagrees.&nbsp;
The allegations tend to show a price-collusion/rebate conspiracy between
oligopolies.&nbsp; (</span>See, e.g.,
Complaint, ¶¶ 4-9, 62, 133-143, 147-176.)&nbsp;
<span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">They pass the tests
(assuming, of course, that the People are able to amend to allege misconduct
within the limitations period); thus, the demurrer is overruled.&nbsp; (See Tentative Ruling Re: Manufacturer
Defendants’ Demurrer, pp. 11-12.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">As a result of the People alleging a violation of the unfair
prong, the Court does not need to reach the unlawful and fraud prongs.&nbsp; (See <u>Durell v. Sharp Healthcare</u> (2010)
183 Cal.App.4<sup>th</sup> 1350, 1359 [stating that, “[b]ecause the statute is
framed in the disjunctive, a business practice need only meet one of the three
criteria to be considered unfair competition”]; see also Stern, supra, at ¶¶
3:15-3:16.)&nbsp; The partial-demurrer rule
prevents the Court from striking portions of the cause of action.&nbsp;&nbsp; <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">Nevertheless, the Court offers the following analysis.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><i><u><span style="color:#3D3D3D" class="fontChange">Unlawful
Prong<o:p></o:p></span></u></i></p>

<p class="MsoNormal fontChange" style="text-align:justify"><i><u><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></u></i></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">“[T]he
UCL permits a cause of action to be brought if a practice violates some other
law. &nbsp;In effect, the ‘unlawful’ prong . .
. makes a violation of the underlying law a per se violation of [section]
17200.”&nbsp; <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">(Stern,
supra, at ¶ </span>3:53.)&nbsp; “Virtually any
law or regulation – federal or state, statutory or common law – can serve as
predicate for” an unlawful claim.&nbsp; (Id.
at ¶ 3:56.) &nbsp;“Thus, if a ‘business
practice’ violates any law – literally – it also violates [section] 17200 and
may be redressed under that section. [Citation.]”&nbsp; (Ibid.) <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
underlying statute highlighted in the complaint is Civil Code section
1770(a)(13), the Consumer Legal Remedies Act (“CLRA”).&nbsp; (See Complaint, ¶ 229 [alleging that “</span>Defendants’
acts or practices are unlawful, as that term is used in the UCL, and include,
but are not limited to, violating the [CLRA], Civil Code section 1770,
subdivision (a), subpart (13), by making false or misleading statements of fact
concerning reasons for, existence of, or amounts of, price reductions to analog
insulin”].)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
People point out three alleged misstatements that they contend subsection
(a)(13) covers:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">* in
2017, “CVS Caremark stated that it ‘[m]anage[s] </span>formulary and leverage
competition to negotiate for lowest-net cost’ and its ‘formulary and
utilization management options helped reduce cost for antidiabetic drugs for
clients’” (Complaint, ¶ 198; see also Opposition, p. 19);<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">* in 2017, an Express Scripts
executive told CBS News that “PBMs work to ‘negotiate with drug companies to
get the prices down’” and that Express Scripts’s “mission [is] to make the use
of prescription drugs safer and more affordable” (Complaint, ¶¶ 200, 201; see
also Opposition, p. 19); and<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">* “OptumRX’s website” contains “a
company video stating that PBMs like OptumRX ‘negotiate with drug companies for
the best medication prices[.]’”&nbsp;
(Complaint, ¶ 202; see also Opposition, p. 19.)<span style="color:#3D3D3D" class="fontChange"><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">PBM
Defendants respond with three arguments.&nbsp;
One, “the CLRA </span>has its own safe harbor doctrine that
independently bars the State’s ‘unlawful’ claims.”&nbsp; (Demurrer, p. 10.)&nbsp; Two, “PBMs engage in financial transactions
with sophisticated health-plan clients; they do not transact with consumers or
provide ‘goods’ or ‘services’ at all.”&nbsp;
(Ibid.; see also id. at pp. 11-13; Reply, pp. 6-7.)&nbsp; Three, the three alleged misstatements do not
include “false or misleading statements about price decreases.”&nbsp; (Demurrer, p. 10; see also id. at pp. 13-16;
Reply, pp. 7-8.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">The first argument is
unavailing.&nbsp; The CLRA safe harbor is
inapplicable for the same reasons that the UCL safe harbor is inapplicable.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">The second argument is
persuasive.&nbsp; “The CLRA broadly applies to
any transaction involving the sale or lease of goods or services to a
‘consumer.’”&nbsp; (Stern, supra, at ¶ 10:16.)&nbsp; “The CLRA’s substantive section . . .
prohibits various unfair or deceptive acts . . . ‘in a transaction intended to
result or which results in the sale or lease of goods or services to any
consumer.’”&nbsp; (Ibid.)&nbsp; “The Act broadly defines ‘transaction’ as ‘an
agreement <span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">between a consumer and
any other person, whether or not the agreement is a contract enforceable by
action, and includes the making of, and the performance pursuant to, that
agreement.’”&nbsp; (Id. at ¶ 10:18.)&nbsp; “Broad as it is,” though, “the CLRA only
permits ‘consumers’ to sue.”&nbsp; (Id. at ¶
10:25.)&nbsp; A “consumer” is “an individual
who seeks or acquires, by purchase or lease, any goods or services for
personal, family, or household purposes.”&nbsp;
(Id. at ¶ 10:26.)&nbsp; The Court’s
understanding is that PBM Defendants transact with “pharmaceutical
manufacturers, health-plan payors, and retail pharmacies[,]” not with
individual “consumers.”&nbsp; (Demurrer, p.
11.)&nbsp; Given this distinction, the current
allegations fail to render the CLRA applicable.<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">The third argument is also persuasive.&nbsp; The first and second alleged misstatements
occurred in 2017; they are time-barred.&nbsp;
The third alleged misstatement only concerns OptumRX and is merely a
general statement about prescription drugs as opposed to a specific statement
about reducing insulin prices.&nbsp; These
allegations do not establish a violation of subsection (a)(13).<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">However, the Court is inclined to overrule the demurrer.&nbsp; The UCL cause of action incorporates all
preceding allegations.&nbsp; (See Complaint, ¶
225.)&nbsp; This means it incorporates the
conspiracy allegations.&nbsp; (</span>See,
e.g., Complaint, ¶¶ 4-9, 62, 133-143, 147-176.)&nbsp;
At the pleading stage, the Court believes a civil conspiracy – the
purported price-collusion/rebate scheme – can serve as the predicate.&nbsp; (See Stern, supra, at ¶ 3:56.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">That
said, the Court favors granting leave to amend to give the People an
opportunity (if they want) to include new statements under subsection (a)(13)
and/or facts showing violations of a different underlying statute, common law,
etc.&nbsp; (</span>See Tentative Ruling Re:
Manufacturer Defendants’ Demurrer, p. 14.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><i><u><span style="color:#3D3D3D" class="fontChange">Fraud
Prong<o:p></o:p></span></u></i></p>

<p class="MsoNormal fontChange" style="text-align:justify"><i><u><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></u></i></p>

<p class="MsoNormal fontChange" style="text-align:justify">“<span style="color:#3D3D3D" class="fontChange">The third type of conduct proscribed by [section] 17200
is ‘fraudulent’ business practices.”&nbsp;
(Id. at ¶ 3:153.)&nbsp; “A business
practice is ‘fraudulent’ within the meaning of [section] 17200 if ‘members of
the public are likely to be deceived.’”&nbsp;
(Id. at ¶ 3:154.)&nbsp; Indeed, “a
plaintiff can prove a prima facie case t<span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">hat a
business practice is ‘fraudulent’ without having to prove intent, scienter,
actual reliance, or damage.”&nbsp; (Id. at ¶
3:157.) &nbsp;“Even actual deception is not
required.”&nbsp; (Ibid.)&nbsp; “If anything, the prohibition against
‘fraudulent’ business is broad[]” in that “it reaches practices that do not
involve advertising [citation] and that involve no untrue statement.&nbsp; [Citation.]”&nbsp;
(Id. at ¶ 3:158.)</span><o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">Paragraph
231 alleges:<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">231. Defendants’
acts or practices are fraudulent, as that term is used in the UCL, and include,
but are not limited to: <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">a. artificially
inflating the list prices of analog insulin; or <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">b. making material
misrepresentations regarding or failing to disclose the existence, amount,
and/or purpose(s) of discounts, rebates, and/or other payments offered by the
Manufacturer Defendants to PBM Defendants.<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">(Complaint, ¶ 231.)&nbsp; <o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">PBM Defendants contend the
artificial-inflation claim cannot be asserted against PBM Defendants because
the list prices “are set unilaterally and exclusively by” Manufacturer
Defendants, “and there is no allegation that” Manufacturer Defendants “misreported
them.”&nbsp; (Demurrer, p. 20; see also Reply,
p. 13.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">PBM Defendants claim the
failure-to-disclose-rebating-practices claim fails because the complaint lacks
facts showing materiality and a duty to disclose.&nbsp; (See Demurrer, pp. 21-22; see also Reply, pp.
13-14.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">On balance, the demurrer should
be overruled.&nbsp; The artificial-inflation
and failure-to-disclose-rebating-practices claims are both founded on PBM
Defendants’ purported civil conspiracy with Manufacturer Defendants – the
alleged price-collusion/rebates plot.&nbsp;
(See, e.g., Complaint, ¶¶ 4-9, 62, 133-143, 147-176.)&nbsp; According to the complaint, PBM Defendants’
own conspiratorial conduct contributed to the inflated insulin pricing.&nbsp; (See id. at ¶¶ 149-162.)&nbsp; The Court agrees with the People that, at
this stage, at minimum, the allegations give rise to a duty to disclose and
state an omissions-based fraud-prong claim.&nbsp;
(See Opposition, pp. 21-22.)<a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/people%20v%20eli%20lilly%206-18-24%20tentative%20ruling%20re%20pharmacies'%20demurrer%20(23stcv00719).docx#_ftn1" name="_ftnref1" title=""><span class="MsoFootnoteReference fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[1]</span></span><!--[endif]--></span></a><o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><span style="color:#3D3D3D" class="fontChange">Unjust
Enrichment<o:p></o:p></span></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><i><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></i></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">Unjust
enrichment is an equitable doctrine.&nbsp; It
“<span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">is based on the idea that ‘one person should
not be permitted unjustly to enrich himself at the expense of another, but
should be required to make restitution of or for property or benefits received,
retained, or appropriated, where it is just and equitable that such restitution
be made, and where such action involves no violation or frustration of law or
opposition to public policy, either directly or indirectly.’”&nbsp; (<u>City of Oakland v. Oakland Raiders</u>
(2022) 83 Cal.App.5<sup>th</sup> 458, 478.)</span>&nbsp; “The elements . . . are the ‘receipt of a
benefit and [the] unjust retention of the benefit at the expense of
another.’”&nbsp; (<u>Peterson v. Cellco
Partnership</u> (2008) 164 Cal.App.4<sup>th</sup> 1583, 1593.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
demurrer is sustained.&nbsp; Unjust enrichment
is not a standalone cause of action in the Second District.&nbsp; (See Tentative Ruling Re: Manufacturer
Defendants’ Demurrer, pp. 14-15.)&nbsp; <o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">The
Court grants the People leave to assert a common count for restitution based on
unjust enrichment as an alternative in case the UCL cause of action gets
dismissed down the road.&nbsp; (See ibid.)<o:p></o:p></span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><span style="color:#3D3D3D" class="fontChange">CVS
Health<o:p></o:p></span></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><b><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></b></p>

<p class="MsoNormal fontChange" style="text-align:justify">CVS Health claims it “is not
liable for the acts of its subsidiary[y,]” and the People fail to allege facts
sufficient to pierce the corporate veil.&nbsp;
(Demurrer, p. 24; see also Reply, p. 15.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">The People disagree.&nbsp; They contend the claims against CVS Health
are “based on [CVS Health’s] own conduct.”&nbsp;
(Opposition, p. 34.)<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">The demurrer is sustained with
leave to amend.&nbsp; The People focus on paragraphs
48 and 181.&nbsp; (See ibid.)&nbsp; Paragraph 48 states:<o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">48. CVS Health holds
itself out as deliberately directing, and is therefore responsible for,
CaremarkPCS Health, LLC’s forum-related activities. Among other things: <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">a. Prior to 2014,
CVS Health bore the name CVS Caremark Corporation. When announcing its name
change in 2014, CVS Health stated that its PBM services would continue to be
known as “CVS/Caremark.” <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">b. CVS Health
continues to use CVS Caremark to refer to its PBM services on its website and
in other locations. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">c. The website
located at www.caremark.com bears the name CVS Caremark. The website is
interactive. Among other things, it allows customers to enter personal
information, such as addresses. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">d. CVS Health states
in its filings with the U.S. Securities and Exchange Commission that its
“Pharmacy Services segment provides a full range of PBM solutions, including
plan design offerings and administration, formulary management, retail pharmacy
network management services and mail order pharmacy.” <o:p></o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="margin-top:0in;margin-right:.5in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-align:justify">e. Likewise, CVS
Health has stated that as part of its PBM services CVS Health: (a) designs
pharmacy benefit plans; and (b) negotiates with pharmaceutical companies to
obtain discounted acquisition costs for many of the products on CVS Health’s
drug lists. <o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify">(Complaint, ¶ 48.)&nbsp; Paragraph 181 states: “Thomas Moriarty, Chief
Policy and External Affairs Officer and General Counsel for CVS Health
testified to similar concerns. He stated, ‘A real barrier in our country to achieving
good health is cost, including the price of insulin products which are too
expensive for too many Americans.’”&nbsp; (Id.
at ¶ 181.)&nbsp; These allegations do not show
direct misconduct by CVS Health or that “CVS Health performs the challenged PBM
services.”&nbsp; (Reply, p. 15.)&nbsp; Additional facts need to be added.<a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/people%20v%20eli%20lilly%206-18-24%20tentative%20ruling%20re%20pharmacies'%20demurrer%20(23stcv00719).docx#_ftn2" name="_ftnref2" title=""><span class="MsoFootnoteReference fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[2]</span></span><!--[endif]--></span></a><o:p></o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align:justify"><span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">&nbsp;</span></p>

<p class="MsoNormal fontChange" style="text-align: justify; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; vertical-align: baseline;"><b><span style="color:#3D3D3D" class="fontChange">&nbsp;</span></b></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange" style="text-align:justify"><o:p>&nbsp;</o:p></p>

<p class="MsoNormal fontChange"><o:p>&nbsp;</o:p></p>

<div><!--[if !supportFootnotes]--><br clear="all">

<hr align="left" size="1" width="33%">

<!--[endif]-->

<div id="ftn1">

<p class="MsoNormal fontChange" style="text-align:justify"><a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/people%20v%20eli%20lilly%206-18-24%20tentative%20ruling%20re%20pharmacies'%20demurrer%20(23stcv00719).docx#_ftnref1" name="_ftn1" title=""><span class="MsoFootnoteReference fontChange"><span style="font-size:10.0pt" class="fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[1]</span></span><!--[endif]--></span></span></a><span style="font-size:10.0pt" class="fontChange"> To the extent the People intend to rely on the three
alleged CLRA misstatements to allege a fraud-prong claim, the Court
disagrees.&nbsp; Again, to the alleged
misstatements are time-barred, and the third alleged misstatement does not
specifically regard insulin prices.<o:p></o:p></span></p>

</div>

<div id="ftn2">

<p class="MsoNormal fontChange" style="text-align:justify"><a href="file:///C:/Users/arosas/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/KEY8N9QU/people%20v%20eli%20lilly%206-18-24%20tentative%20ruling%20re%20pharmacies'%20demurrer%20(23stcv00719).docx#_ftnref2" name="_ftn2" title=""><span class="MsoFootnoteReference fontChange"><span style="font-size:10.0pt" class="fontChange"><!--[if !supportFootnotes]--><span class="MsoFootnoteReference fontChange"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;,serif;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-font-kerning:0pt;mso-ligatures:
none;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" class="fontChange">[2]</span></span><!--[endif]--></span></span></a><span style="font-size:10.0pt" class="fontChange"> <u>Mississippi ex rel. Fitch v. Eli Lilly and Co.</u>
(S.D.Miss. Aug. 29, 2022, No. 3:21-CV-674-KHJ-MTP) 2022 WL 18401603 (“<u>Fitch</u>”)
is distinguishable.&nbsp; (See Opposition, p.
34 [claiming the <u>Fitch</u> court found that similar allegations stated a
claim against CVS Health under Mississippi law].)&nbsp; The <u>Fitch</u> complaint “alleged that CVS
Health . . . publicly <span style="color: rgb(61, 61, 61); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;" class="fontChange">represented
that it constructs programs to lower the cost of the <i>at-issue diabetes
medications</i>.”&nbsp; (<u>Fitch</u>, supra,
2022 WL 18401603, at *5, emphasis added.)&nbsp;
Paragraph 48 is broader and vaguer.&nbsp;
It has a general reference to “many of the products on CVS Health’s drug
lists” but does not have a specific reference to insulin.&nbsp; (Complaint, ¶ 48.)</span><o:p></o:p></span></p>

<p class="MsoFootnoteText fontChange"><o:p>&nbsp;</o:p></p>

</div>

</div><br><br><br><br><span name="wp"><hr></span></span></div>
						</td>
					</tr>
                        
                        
                        <script>
                            $("p font").addClass("fontChange");
                            $("h1 font").addClass("fontChange");
                            $("li u span ").addClass("fontChange");
                            $("p b span").addClass("fontChange");
                            $("p span").addClass("fontChange");
                            $("span p").addClass("fontChange");
                            $("p MsoNormal").addClass("fontChange");
                            
                        </script>

					</tbody></table>



            </div>
        </div>
        <script>var contentArea = "#divMainContent";</script>
    </div>
    <div class="moreContentWrap">
        <div class="moreLeftWrap">
            
            
        </div>
        <div class="moreMidWrap">
            
            
        </div>
        <div class="moreRightWrap">
            
                <!--<div id="siteMasterHolder_rightMoreHolder_returnLink_returnLinkContainer" style="text-align:right; display:none">
    <a href="../commonv4/source/uc/x" id="siteMasterHolder_rightMoreHolder_returnLink_homeButtonLink" type="button" class="btn btn-default btn-sm" onclick="return processLink(this);">
        <span class="glyphicon glyphicon-screenshot"></span>  Home
    </a>

</div>
-->
            
        </div>
    </div>

    <div class="lastContentWrap">
        <div class="lastLeftWrap">
            

        </div>
        <div class="lastRightWrap">

            

        </div>
    </div>
    

            </div>
        </form>
        <div id="footerWrap">
                <!-- Start MainMenu -->
                <div id="footerWrap">
    <script type="text/javascript">
        var d = new Date();
        var copyrightYear = d.getFullYear();
            </script>
    <!-- Start Right Footer -->
    <div class="footerRight">
        Copyright © 
        <script type="text/javascript">
            document.write(copyrightYear); // add the current year
        </script>2024 Superior Court of California, County of Los Angeles
    </div>
    <!-- End Right Footer -->
    <!-- Start Left Footer -->
    <div class="footerLeft">
        <a href="/page/HO0050" onclick="return processLink(this);">Privacy Statement</a> | <a href="/page/HO0051" onclick="return processLink(this);">Disclaimer</a> | <a href="/page/GI_EM001" onclick="return processLink(this);">Employment</a> | <a href="/page/HO0015" onclick="return processLink(this);">ADA</a> | <a href="/page/HO0009" onclick="return processLink(this);">Holidays</a> | <a href="/page/HO0052" onclick="return processLink(this);">Comment on our Website</a>
    </div>
    <!-- End Left Footer -->
</div>
                <!-- End MainMenu -->
        </div>
    </div>

    <!-- Scripts Loaded at End -->
    <!-- Provides performance benefit. Also fix for Asp.Net error, "The Controls collection cannot be modified because the control contains code blocks (i.e. < % ... % >)" -->
    <!-- See http://www.aspdotnet-suresh.com/2011/12/aspnet-controls-collection-cannot-be.html -->

    <!--JQuery-->
    
    <script src="/tentativerulingnet/commonv4/scripts/jquery-ui.min.js" type="text/javascript"></script>
    <script src="/tentativerulingnet/commonv4/scripts/jquery.cookie.js" type="text/javascript"></script>

    <!--Google Analytics-->
    <script src="/tentativerulingnet/commonv4/scripts/analytics.js" type="text/javascript"></script>

    <!-- lascweb -->   
    <script src="/tentativerulingnet/commonv4/scripts/config.js" type="text/javascript"></script>
    <script src="/tentativerulingnet/commonv4/scripts/common.js" type="text/javascript"></script>
    <script src="/tentativerulingnet/commonv4/scripts/tooltip.js" type="text/javascript"></script>
    <script src="/tentativerulingnet/commonv4/scripts/linkredirect.js" type="text/javascript"></script>
    <script src="/tentativerulingnet/commonv4/scripts/globaljs.js" type="text/javascript"></script>  <!-- Nav Menu -->

    <!-- text-2-speech -->
    <!--script src="/tentativerulingnet/commonv4/scripts/text2speech.js" type="text/javascript" ></!--script-->

    <!-- ajax control toolkit extension -->
    <script src="/tentativerulingnet/commonv4/scripts/ajaxcontroltoolkit.js" type="text/javascript"></script>

    <script type="text/javascript">
        <!-- Executes OnFocus. Highlights the text in the search box. -->
        function selectSearchText() {
            $("#searchfield").select();
        }
        function doSearch() {
            $("#searchLink").attr("href", "/page/ho0100/" + escape($("#searchfield").val().trim()));
            return processLink($("#searchLink"));
        }
    </script>
    <!-- End Lascweb -->

    
    
    
            



</div><div role="log" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>
